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11 Introduction and outline of the thesis
Survival of children with cancer has increased to almost 80%, as a result of advances in treatment. 
[1,2]. Currently, in the Netherlands, about 1 of every 250 young adults is a long-term survivor of 
childhood cancer [3]. Unfortunately, improved survival is accompanied by the occurrence of late 
effects of treatment. It has become clear that damage to the organ systems of children, caused 
by chemotherapy and radiation therapy may not be clinically evident for many years.  One of the 
serious late effects of treatment is cardiotoxicity. Treatment-related cardiac dysfunction is mainly 
attributed to the use of anthracyclines and mediastinal irradiation. It leads to an important 
increase in morbidity and mortality; the relative risk of severe and life threatening cardiac 
dysfunction is 10-15 times higher than in siblings [2]. And, being a survivor of childhood cancer, 
the risk to die of cardiac disease is eight times higher than in the normal population [1]. In this 
thesis, we focus on the cardiotoxic effect of anthracyclines. We aim to investigate new strategies 
for the early detection of anthracycline-induced cardiotoxicity. 
1 Anthracyclines
Anthracyclines are key components of many cytotoxic regimens since their 
introduction in the 1960´s and remain important in the treatment of many 
adult and pediatric malignancies. They are effective anticancer drugs and are 
incorporated in more than 50% of the pediatric treatment protocols [4]. The first 
anthracyclines were isolated from the pigment producing bacterium Streptomyces 
peucetius and were named doxorubicin and daunorubicin. Doxorubicin and 
daunorubicin have similar chemical structures and share aglyconic and sugare 
moieties. The only difference between doxorubicin and daunorubicin is that the 
side chain of doxorubicin terminates with a primary alcohol, whereas daunorubicin 
terminates with a methyl. This minor difference has important consequences on 
the spectrum of activities of both anthracyclines. Doxorubicin is the essential 
component of solid tumours and aggressive lymphomas. Daunorubicin shows 
activity in acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia 
(AML) [5]. After the introduction of doxorubicin and daunorubicin, a lot of work 
has been done to identify novel anthracyclines. This work has resulted in some 
2000 analogs. However, only epirubicin and idarubicin have reached the stage of 
clinical development and approval and are useful alternatives of doxorubicin and 
daunorubicin, respectively. Epirubicin is a semi-synthetic derivate of doxorubicin. 
The difference is a positional change of the hydroxyl group at C-4’ in daunosamine. 
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This positional change enhanced total body clearance and shorter half-life. 
Therefore, epirubicin is used at cumulative doses almost double of doxorubicin. 
Idarubicin is an analog obtained from daunorubicin after removal of the 4-methoxy 
group in ring D. Idarubicin has a broader spectrum of use than daunorubicin due to 
its increased lipophilicity and cellular uptake. Other anthracyclines are pirarubicin, 
aclacinomycin and mitoxantrone (a substituted aglyconic anthraquinone) [4,5]. In 
this thesis, we considered the sum of daunorubicin and doxorubicin as cumulative 
anthracycline dose. Figure 1 shows the structures of doxorubicin, daunorubicin, 
epirubicin and idarubicin.
Figure 1.1 Structures of doxorubicin, daunorubicin , epirubicin and idarubicin
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1.1 Anti-tumour activity of anthracyclines
Although anthracyclines are widely used, the mechanism of the anti-tumour 
activity of anthracyclines remains a topic of debate [5-7]. An extensive review on 
the anti-tumour activity of anthracyclines is written by Minotti and colleagues [5]. 
Several mechanisms have been suggested: (1) intercalation into DNA, leading to 
inhibition of synthesis of macromolecules, (2) generation of free reactive oxygen 
species (ROS), leading to DNA damage or lipid peroxidation, (3) DNA binding 
and alkylation, (4) DNA cross-linking, (5) interference with DNA unwinding 
or DNA strand separation and helicase activity, (6) direct membrane effects, (7) 
initiation of DNA damage via inhibition of topoisomerase II and (8) induction of 
apoptosis in response to topoisomerase II inhibition [7]. The generation of ROS 
was one of the early suggestions of the anti-tumour activity of anthracyclines. When 
free oxygen radicals are formed close to DNA strands, they can damage the DNA 
and can cause strand breaks [8]. However, relatively high in vitro concentrations 
of anthracyclines were necessary to demonstrate free ROS-induced DNA damage, 
higher than the peak or steady-state plasma concentrations observed in patients [7]. 
Topoisomerases can cause transient DNA breaks that are resealed after changing 
the twisting status of the DNA double helix. Inhibition of topoisomerase II, caused 
by anthracyclines, prevents this DNA sealing [9]. Anthracyclines activate p53-
DNA binding and might therefore be involved in the execution of apoptosis [10]. 
Another mechanism of apoptosis is caused by the direct effect of anthracyclines on 
the release of cytochrome c from mitochondria [11]. 
 
2 Anthracycline-induced cardiotoxicity
Shortly after the introduction of anthracyclines in the treatment of patients with 
cancer, it became clear that a major limitation of the use of anthracyclines is 
cardiotoxicity [12-15].
2.1 Mechanisms of anthracyline-induced cardiotoxicity
Multiple mechanisms responsible for anthracycline-induced cardiotoxicity have 
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been proposed based on studies in animals and cell culture systems. The mechanisms 
responsible for anthracycline-induced cardiotoxicity seem to be different from the 
anti-tumour activity [6]. This concept raises hope for development of treatment 
protocols that protect the myocardium without diminishing the anti-tumour 
activity [6,14-17].
Anthracycline-induced myocyte cell death
One of the most valid hypotheses is that myocyte death occurs with each 
exposure to anthracyclines. Endomyocardial biopsies, obtained from human 
patients within hours after anthracycline exposure show electron microscopical 
evidence of mitochondrial swelling and chromatin contraction, hallmarks of 
apoptosis [17]. Anthracyclines induce cell death of cultured cardiac myocytes 
in a concentration dependent manner. The mechanism of cell death varies with 
anthracycline concentration, with apoptosis occurring at lower and necrosis at 
higher concentrations [18,19].
Anthracycline-induced oxidative stress
Anthracyclines generate cellular oxidative stress which might be the most 
important step leading to myocyte cell death. Anthracylines accumulate in the 
mitochondria and the interaction with the mitochondrial membrane generates 
ROS. The formation of superoxide and superhydroxide free radicals increases 
the permeability of the mitochondrial membrane. Because the myocardium has 
low catalytic enzymes that break down these free radicals, they accumulate and 
eventually destroy the mitochondria. Free radical formation can be inhibited by 
superoxide dismutase (SOD), catalase and the iron chelator dexrazoxane which 
have shown to decrease markers of myocyte cell death in several studies [19-
21]. Interestingly, the necrosis of myocytes that occurs at high concentrations 
of anthracyclines is not suppressed by antioxidants [14]. Another mechanism 
which induced increased oxidative stress is the iron-dependent mechanism. The 
anthracycline-iron complexes can produce free oxygen radicals in the myocardium 
which is thought to be the primary pathway of anthracycline-induced oxidative 
stress and cardiotoxicity [22].
Cellular stress, and specifically oxidative stress, activates a host of kinase 
pathways that appear important in determining cell fate, and these pathways 
modulate the response of the myocytes to anthracycline exposure. The stress-
activated protein kinase c-Jun N-terminal kinase and P38 correlate with cardiac 
myocyte apoptosis [23, 24]. Recent findings suggest that ROS production can 
Chapter 1  -  Introduction and outline of the thesis
16
activate these pathways, in particular JNK and p38, supporting the association of 
anthracyclines and stress activated protein kinase mediated apoptosis [24].
Anthracycline-induced apoptosis
Anthracycline-induced ROS production induces cytochrome complex (c) release. 
Cyto chrome c interacts with Apaf-1 and procaspase- 9, generating caspase-9. 
Caspase-9 activates caspase-3, inducing DNA fragmentation en apoptosis. Recent 
studies have demonstrated release of cytochrome c after anthracycline treatment in 
rat myocyte cell line (H9C2) and in vivo [24]. It was also observed that increased 
Bax levels can lead to formation of multimers, destabilizing the mitochondria and 
inducing cytochrome c release [25]. 
Anthracycline-induced DNA damage
Anthracyclines can intercalate between base pairs in DNA, which leads to 
inhibition of DNA and RNA synthesis and leads to oxidant damage [26]. 
Anthracycline-induced GATA4 down regulation
GATA4 is a transcription factor that regulates myocyte differentiation, sarcomere 
synthesis, and survival. Anthracyclines down-regulates GATA4 expression 
in cardiac myocytes. Increasing GATA4 expression by α-adrenergic agonists 
suppresses anthracycline-induced cardiotoxicity [27].
Anthracycline-induced sarcomere disruption
Since the integrity of the myocyte sarcomere is important for the myocyte function, 
its disorganization can lead to impaired cardiac function and cardiomyopathy. 
Ultrastructural changes of myocyte sarcomeres seen in endomyocardial biopsies of 
anthracycline treated patients as well as rodents include loss of myofibrils, disarray 
of myofibrils of the sarcomere, dilation of the sarcomere reticulum, swelling of the 
mitochondria and cytoplasmatic vacuolization [28,29].
The above mentioned mechanisms of cardiotoxicity, the apoptotic mechanism 
and the free radical injury lead to damage and destruction of myocytes. Loss 
of myocytes leads to decreased cardiac muscle mass. This leads to reduced left 
ventricular performance and a significant morbidity  and mortality[5,12,30]. The 
accumulation of myocardial damage is particularly concerning in pediatric patients 
because the myocardium is thought to be especially sensitive during cardiovascular 
development. By 6 months of age, the heart of humans has the adult number of 
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myocytes, and subsequent myocardial growth occurs primarily by hypertrophy 
of individual myocytes. The myocardial growth failure, loss of myocardial cells or 
both, may contribute to the striking decrease in left ventricular mass [31,32].
2.2 Types and presentation of anthracycline-induced cardiotoxicity
Anthracycline-induced cardiotoxicity can, by clinical presentation, be classified 
into three categories: (1) acute cardiotoxicity, (2) early-onset cardiotoxicity and (3) 
late-onset cardiotoxicity. They do not only differ in time of presentation, but also in 
clinical characteristics and their association with risk factors known to predispose 
to anthracycline-induced cardiotoxicity [15, 32,33].
The cardiotoxic effects of anthracyclines are variable and include asymptomatic 
electrocardiographic abnormalities, mild hypotension, arrhythmias, myocarditis, 
pericarditis, acute myocardial infarction and long-term cardiomyopathy [32,33].
Acute cardiotoxicity
Acute anthracycline-induced cardiotoxicity is defined as cardiotoxicity during or 
immediately after anthracycline treatment. It is often reversible and discontinuation 
of the anthracycline usually results in significant improvement. The incidence of 
acute cardiotoxicity is less than 1%. Even less frequent are the life-threatening 
arrhythmias, myocardial infarction and myocarditis-pericarditis syndrome [34]. 
Also, nonspecific ECG changes, such as ST-T wave changes, decreased QRS 
amplitude and prolongation of QT interval have been described but these rarely 
cause clinical significant problems [35]. 
Early-onset cardiotoxicity
Early-onset cardiotoxicity is defined as cardiotoxicity occurring within the first 
year after completion of anthracycline treatment. Electrophysiological changes, 
left ventricular dysfunction, decreased exercise capacity and clinical heart failure 
may develop. Early-onset cardiotoxicity may persist or progress even after 
discontinuation of anthracycline therapy. The majority of adults who develop 
significant cardiotoxicity present with dilated cardiomyopathy. In the pediatric 
patient, the clinical picture can also present itself as restrictive cardiomyopathy 
[36]. Early anthracycline-induced cardiotoxicity occurs in <5% of all children 
[31,37].
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Late-onset cardiotoxicity
Late-onset cardiotoxicity occurs more than one year after anthracycline treatment. 
With this type of cardiotoxicity, there is a period during which no left ventricular 
dysfunction is observed, cardiac function appears normal and the patient is 
asymptomatic. After a latent period, cardiac function may begin to deteriorate 
and is associated with myocyte loss, which leads to left ventricular wall thinning 
and in some cases progressive left ventricular dilation and increased afterload. 
Echocardiographic abnormalities include decreased left ventricular fractional 
shortening (FS), decreased left ventricular mass (LVM), decreased wall thickness 
and decreased contractility [15,31,36,38]. Late-onset cardiotoxicity is reported in 
1-5% as clinical heart failure and in up to 65% as subclinical heart failure [15,31,36-
38,42].
2.3 Clinical versus subclinical cardiotoxicity
Clinical anthracycline-induced cardiotoxicity is defined by the New York Heart 
Association (NYHA) classification for heart failure (table 1.1) [36]. The definition 
of subclinical heart failure is less clear, and is most often based on echocardiographic 
abnormalities without clinical symptoms. Usually, deterioration of conventional 
echocardiographic parameters is used to determine how often subclinical heart 
failure occurs in anthracycline treated patients. Subclinical cardiotoxicity is 
thought to be progressive, and might develop into clinical heart failure with time. 
However, anticipating those patients that will develop clinical heart failure is 
extremely difficult. Many studies show that cardiac damage occurs in some patients 
with low cumulative anthracycline doses, while other patients are able to tolerate 
doses larger than 1000 mg/m2 [43, 44]. The wide variation between individuals in 
anthracycline-induced cardiotoxicity suggests a genetic predisposition.
Table 1.1
NYHA class Symptoms
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, 
palpitation, or dyspnea (shortness of breath).
II Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity 
results in fatigue, palpitation, or dyspnea.
III Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity 
causes fatigue, palpitation, or dyspnea.
IV Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
Anthracycline-induced cardiotoxicity
19
2.4 Anthracycline-induced cardiotoxicity and mortality risk
Several studies have reported an increase in mortality risk in childhood cancer 
survivors compared to the general population (Figure 1.2)[1,2,45]. Cardiovascular 
events are the leading non-malignant cause of mortality and morbidity among 
survivors of childhood cancer. Mertens and colleagues reported in a large cohort 
study of more than 10.000 survivors of childhood cancer, that the risk of death 
from cardiac-related events was eight times higher for long-term survivors than 
for the normal population [1]. Oeffinger and colleagues showed in their study of 
more than 10.000 survivors of childhood cancer that the relative risk of severe 
and life-threatening congestive heart failure and coronary artery disease is 15 
and 10 respectively as compared to healthy siblings [2]. Clinical heart failure is 
associated with significant mortality. The 1-year mortality rate for patients with 
NYHA class IV is approximately 50%, for patients with NYHA class III 20-25%. 
Anthracycline-induced clinical heart failure has been shown to have a mortality 
rate of more than 50% within two years of treatment cessation [46].
Figure 1.2 Survival function estimate of long-term survivors of childhood cancer
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2.5 Risk factors of anthracycline-induced cardiotoxicity
Several risk factors for anthracycline-induced cardiotoxicity have been identified 
over the last 20 years. These risk factors relate to early and late anthracycline-induced 
cardiotoxicity, not to acute cardiotoxicity. Some are modifiable; some are not [33]. 
Cumulative anthracycline dose
The total cumulative anthracycline dose is the most well known risk factor of 
anthracycline-induced cardiotoxicity and remains the best predictor of eventual 
cardiac dysfunction [12,15,31,47-51]. Several studies have reported the relation 
of increased cumulative anthracycline doses and the risk of clinical heart failure 
[33,36,37]. Van Dalen and colleagues reported an eight times higher risk of 
anthracycline-induced heart failure in patients treated with 300 mg/m2 or more 
compared to patients treated with less than 300 mg/m2. The estimated risk of 
anthracycline-induced clinical heart failure increased with time to 5.5% at twenty 
years after start of treatment and to almost 10% if treated with a cumulative 
anthracycline dose of 300 mg/m2 or more [51]. 
However, as stated before, there is no absolutely safe dose of anthracyclines, 
even the lowest clinically relevant dose may cause subsequent cardiac dysfunction 
[33,36]. Although anthracyclines have proven to be really effective, the question 
raises whether we can cure patients without anthracyclines to avoid anthracycline-
induced cardiotoxicity. Van Dalen and colleagues showed in their review that 
randomized clinical trials (RCTs) are lacking to answer the question whether 
anthracyclines are really necessary in the treatment of various types of (childhood) 
cancer [49].
Age at treatment
Patients treated with anthracyclines at a younger age are more vulnerable to 
anthracycline-induced cardiotoxicity [31,36,38]. This difference could be due to 
the inhibition of myocardial growth by anthracyclines, which would be accentuated 
in younger children, whose left ventricular mass is smaller. Another explanation 
could be that higher levels of doxorubicin in tissue and blood occurred in younger 
patients because of their higher percentage of body fat [33]. 
Length of follow-up
With longer follow-up duration after completion of anthracycline therapy, the 
prevalence and severity of cardiac abnormalities do also increase [38,54]. This 
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increase may relate to the emergence of new cases of late-onset cardiotoxicity and 
to worsening of previously early-onset cardiotoxicity. The importance of long-term 
follow-up of has become clearer, with the increasing numbers of asymptomatic 
survivors of childhood cancer at risk for cardiac dysfunction [15].
Gender
Girls appear to be at greater risk for anthracycline-induced cardiotoxicity than boys 
(relative risk: 1.9) [36-38,41]. Although the mechanism for this is not completely 
understood, differences in body composition might play a role by altering the 
distribution and metabolism of anthracyclines. Anthracyclines are poorly absorbed 
by fat tissue. Since girls have more body fat than boys compared to body surface 
area and doxorubicin clearance is reduced with increased body fat, equivalent doses 
of anthracyclines in girls will lead to higher concentrations, for a longer time [36].
Genetic factors
The wide variation between individuals in anthracycline-induced cardiotoxicity 
suggests a genetic predisposition. Recognition of genetic and proteomic markers 
of individual patient susceptibility to the cardiotoxic effects of anthracyclines could 
improve the safety of anthracycline treatment. This topic has not been extensively 
studied. However, cardioprotective measures tailored to carriers of predisposing 
polymorphisms should not markedly interfere with anthracycline’s antitumour 
activity [55].
Rate of anthracycline administration
High peak anthracycline serum concentrations are considered to be related to 
cardiotoxicity [36]. Peak serum concentrations can be altered by altering the rate 
of anthracycline administration. Prolonged infusion has been recommended in 
reducing anthracycline-induced cardiotoxicity. On the other hand, there is also 
concern about the potential risk of longer infusion rate, such as longer exposure of 
the myocyte to anthracycline which may lead to myocardial damage. Van Dalen and 
colleagues concluded from their study, that infusion duration of more than six hours 
might reduce cardiotoxicity, without evidence of it compromising the anti-tumour 
effectiveness [50]. Other studies have not reported decrease in cardiotoxicity when 
comparing infusion rates [56-58]. In conclusion, there is a need for randomized 
controlled trials (RCTs) with respect to longer duration infusions in children for 
both cardiotoxicity and anti-tumour effect.
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Concomitant radiation and other chemotherapy agents
Radiation therapy is often used in combination with multidrug chemotherapy 
regimens in the treatment of children with cancer. Mediastinal irradiation may 
worsen the cardiotoxic effects of anthracyclines, but whether this effect is additive or 
synergistic is unclear [15,42,59-63]. The radiation-induced cardiotoxicity appears 
to be related to progressive fibrosis of cardiovascular structures, which seems to be 
a different mechanism than the myocyte loss caused by anthracyclines [32]. There 
are also reports that concomitant high dose cyclophosphamide, bleomycin, and 
vincristine may also increase anthracycline-induced cardiotoxicity [48,50,62,63].
Other factors
Black race (relative risk: 1.7) and Trisomy 21 (relative risk: 3.4) have also been 
described as being risk factors for the development of anthracycline-induced 
cardiotoxicity [37,64].
These risk factors might help to identifying patients at risk for the development of 
anthracycline-induced cardiotoxicity. 
2.6 Detection and monitoring of anthracycline-induced cardiotoxicity
Cardiomyocytes that have been damaged cannot be repaired and, consequently, 
anthracycline-induced cardiac damage is irreversible. Early detection of 
cardiomyopathy is therefore extremely important in order to find preventive 
measures or treatment. Different techniques are being used to determine clinically 
apparent cardiac injury. Subclinical cardiotoxicity, detected by cardiac function 
abnormalities, is often evident in anthracycline-treated patients, long before they 
develop clinical heart failure [33]. Long-term cardiac monitoring of any patient 
after exposure to anthracyclines is needed [15]. The Dutch Childhood Oncology 
Group, organized as “Projectgroep Later” (Later is acronym for late effects of 
treatment) published guidelines for long-term follow-up of survivors of childhood 
cancer, including cardiac evaluation [3]. There is no real “golden standard” to 
detect anthracycline-induced cardiotoxicity, although endomyocardial biopsies 
are sometimes considered as the “golden standard” [16]. In addition, none of the 
methods of detection of anthracycline-induced cardiotoxicity has proven to be an 
adequate predictor of early or late cardiac outcomes. Nevertheless, the standard 
methods of monitoring cardiotoxicity in children, i.e. echocardiography and 
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electrocardiography (ECG), are being used to determine further management of 
patients with cardiac dysfunction. In addition to this, the majority of the published 
evidence describing the incidence of late-onset asymptomatic cardiotoxicity has 
been based on data derived from echocardiographic and Doppler studies [65]. 
The most often used methods as well as the new promising methods for cardiac 
monitoring will be discussed below.
2.7 Current standard methods
Electrocardiography
ECG represents the traditional support and completion to the physical examination 
for patients receiving cardiotoxic chemotherapy. However, ECG abnormalities 
are often non specific in the setting of anthracycline-induced cardiotoxicity. In 
acute anthracycline-induced cardiotoxicity, non specific ST-segment and T-wave 
changes are seen as well as decreased QRS voltage and QT-interval prolongation. 
In late-onset anthracycline-induced cardiotoxicity, life-threatening arrhythmias can 
develop, even many years after completion of anthracycline therapy [43,66-68]. Von 
Hoff and colleagues showed in more than 5000 patients that electrocardiographic 
changes in children and adults did not show a dose-dependent relationship (as 
echocardiographic changes did) and did not predict for subsequent development of 
cardiomyopathy [12]. Horacek and colleagues found in 26 adult leukemia patients 
a statistically significant correlation between decreased QRS voltage, QTc interval 
prolongation and left ventricular (LV) dysfunction on echocardiography [68]. 
Twenty-for-hour Holter monitoring can be helpful in detecting arrhythmias [69].
Echocardiography
Two dimensional B-mode, M-mode and Doppler echocardiography is the most often 
used non-invasive method of monitoring anthracycline-induced cardiotoxicity. It is 
a solid method to identify the main forms of cardiac complications in anthracycline-
treated patients, namely, left ventricular systolic and diastolic dysfunction, valvular 
disease, pericarditis and pericardial effusion and carotid artery lesions [65]. 
Left ventricular dysfunction
Left ventricular (LV) dysfunction is the main interest and concern in anthracycline-
induced cardiotoxicity. LV dysfunction may progress to overt clinical heart failure 
[65,69]. Many studies have reported decreased left ventricular systolic and diastolic 
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function in relation to treatment with anthracyclines in both adult and pediatric 
cancer patients [28,33-35,37,38,46,70-75]. 
LV fractional shortening (FS) and ejection fraction (EF) are the most commonly 
used echocardiographic parameters of LV systolic function. However, they are not 
very sensitive in the early detection of heart failure. Besides this, these parameters 
are load dependent. End-systolic wall stress (ESWS) and contractility, expressed 
as velocity of circumferential fiber shortening (Vcfc), are thought to be more 
specific [76]. Left ventricular diastolic function is often assessed by mitral valve 
early (E) and late (A, after atrial contraction) diastolic blood flow velocities, E/A 
ratio, velocity of early rapid filling (E’) and by isovolumic relaxation time. Diastolic 
function seems to be equally important as systolic function in the assessment 
of anthracycline-induced cardiotoxicity. Karakurt and colleagues showed in 32 
survivors of childhood cancer that peak velocity of the early rapid filling on tissue 
Doppler (E’) was significantly lower and the ratio of early peak velocity of rapid 
filling on pulse Doppler to tissue Doppler (E/E’) values were higher in patients 
compared to healthy controls [77]. Diastolic filling can be impaired during and 
after anthracycline therapy [78,79]. Other echocardiographic parameters to assess 
myocardial damage by anthracyclines are left ventricular dimension parameters 
such as intraventricular septum thickness (IVS), LV posterior wall thickness 
(LVPW), LV internal diastolic and systolic diameter (LVIDd and LVIDs). With 
these parameters LV mass can be calculated with the Devereux formula [80]. In 
anthracycline-induced cardiotoxicity, loss of myocytes can lead to decreased IVS, 
LVPW and LVM en increased LVIDd and LVIDs [81-83]. LV systolic and 
diastolic dysfunction can be seen as clinical heart failure in up to 5% and subclinical 
heart failure in up to 65% of the survivors [42].
Valvular disease
Valvular disease can occur after anthracycline treatment as well as after radiation 
therapy, mainly as left sided valvular regurgitation. A study of Mulrooney 
and colleagues [84] showed a nearly fivefold higher relative hazard of valvular 
abnormalities in survivors of cancer than in the sibling control group, as well as 
an association between valvular disease and higher doses of anthracyclines. The 
cumulative incidence of valvular disease, thirty years after diagnosis was reported 
as 4%, and was increasing over time [84]. Another study of Hodgkin’s lymphoma 
survivors younger than 41 years of age at treatment found a sevenfold increased risk 
of valvular abnormalities associated with mantle radiation and a twofold increased 
risk associated with anthracycline therapy [85]. Valvular dysfunction was reported 
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mainly left sided with the aortic and mitral valve equally involved [86].
A limitation of echocardiography is that LVEF assessment is dependent on 
the quality of the images obtained and subject to variability. The strength of 
echocardiography is that it is noninvasive and that it gives information on all the 
above mentioned aspects of the heart. 
Tissue Doppler Imaging
Tissue Doppler Imaging (TDI), a more recently developed echocardiographic 
technique, enables quantitative assessment of the transmyocardial tissue velocities 
throughout the cardiac cycle [87]. This echocardiographic technique allowes the 
analysis of regional ventricular function, which is important in the early detection 
of local abnormalities (i.e. before any change is apparent in global function 
measurements). TDI was also introduced in the assessment of anthracycline-
induced cardiotoxicity. In previous work of our group, we observed decreased 
transmyocardial velocity gradients years after anthracycline treatment.  Abnormal 
left ventricular wall movements were seen in 60% of children shortly after 
anthracycline treatment and in 20% with a follow-up of approximately ten years 
[88-90].  One of the limitations of this TDI technique is the dependency of the 
velocity measurements on the adjacent myocardial segments and global heart 
movements. This limitation can be overcome by a newer technique, namely strain 
and strain rate imaging, which will be discussed in due course.
99mTc-multigated radionuclide angiography
The standard method to detect cardiotoxicity in the management of adult patients 
treated with cardiotoxic agents is serial ejection fraction measurement with 
multigated acquisition radionuclide angiography (MUGA) [91]. MUGA is a 
semi-invasive technique that makes use of an intravenously injected radionuclide 
(99mTechnetium) that binds to erythrocytes. This technique enables the cardiac 
pool to be visualized with a γ-camera. Due to the ionizing radiation with MUGA, 
echocardiography has been favoured in pediatric patients. The radiation exposure, 
especially with repeated examinations, may be significant and may hinder its use for 
long-term cardiac surveillance in patients. In anthracycline-induced cardiotoxicity, 
the LVEF measured with MUGA correlates with the severity of pathologic 
changes seen on endomyocardial biopsy [92]. MUGA has a very good specificity 
for detection patients at risk for developing clinical heart failure. In a small study, 
Corapçioglu and colleagues showed that MUGA was more sensitive in detecting 
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anthracycline-induced cardiotoxicity than echocardiopraphy [93]. The sensitivity 
for the detection of subclinical early cardiomyopathy is generally reported low. This 
is because no significant change of LVEF occurs until a critical degree of myocardial 
damage has been occurred. The sensitivity becomes higher when the procedures 
are combined with exercise stress testing, but this also increases the incidence of 
false positive findings, which reduces its specificity [94].
2.8 Alternative and new methods
Myocardial strain (rate) imaging
Myocardial strain imaging with 2D echocardiography is a relatively new non-
invasive method to assess myocardial deformation [95]. Strain is the change in size 
relative to its original size, i.e. the relative deformation. Myocardial strain imaging 
is now increasingly used in clinical studies [96-99]. This method is described in 
chapter 4.
Cardiac biomarkers
The assessment of biomarkers for the detection of anthracycline-induced 
cardiotoxicity seems to be promising [100-104]. Release of cardiac troponins 
reflects damage of cardiomyocytes and is indicative for myocardial necrosis. 
Natriuretic peptides are released by the myocardium in response to volume and 
pressure overload. These biomarkers have shown to be sensitive in the detection 
of left ventricular dysfunction [105,106]. Several studies in adult patients treated 
with anthracyclines have reported a correlation between the levels of various 
biomarkers, e.g. brain natriuretic peptide (BNP), N-terminal pro-brain natriuretic 
peptide (NT-pro-BNP) cardiac troponin T (cTnT) and cardiac troponin I (cTnI) 
and abnormalities documented by echocardiography [100-103].
The role of biomarkers in the early detection of anthracycline-induced 
cardiotoxicity in children is further discussed in chapter 2.
Stress echocardiography
Dobutamine stress echocardiography (DSE) is another method recommended 
for long- term follow-up of subclinical cardiotoxicity. Stress echocardiography can 
be useful for detecting cardiac dysfunctions that were not significant at rest [107-
109]. Dobutamine stress echocardiography allows assessment of cardiac reserve 
and function in asymptomatic patients who received anthracycline treatment. It 
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has been reported to be more sensitive than echocardiographic examination at 
rest; therefore, it has been recommended for long-term follow-up of these patients 
[108,109]. Results of several studies using stress echocardiography showed that 
preexisting abnormalities in patients who received anthracycline treatment are 
either amplified after stress with dobutamine infusion or exercise, or observed only 
during dobutamine infusion [107-112].
123I-labeled metaiodobenzylguanidine (123I-MIBG) scintigraphy
MIBG is a guanethidine analogue that shares the same uptake, storage, and 
release pathway as norepinephrine. When labeled with 123Iodine, this analogue 
can be used to generate a scintigraphic image of the efferent sympathetic nervous 
innervations of the heart. Myocardial sympathetic dysinnervation seems to 
appear early and before deterioration of LVEF [113]. 123I-MIBG uptake is often 
expressed semi-quantitatively by drawing regions of interest over the myocardium 
and mediastinum for calculation of a heart-to-mediastinum count ratio. Several 
studies showed that MIBG uptake in the heart is lower in patients treated with 
anthracyclines compared to patients who are not treated with anthracyclines, and 
that the MIBG uptake decreased in a dose dependent way. This phenomenon 
appeared earlier than morphologic changes and alterations in LVEF [114, 115]. 
Two mechanisms have been suggested to explain decreased MIBG uptake in a 
heart with doxorubicin cardiomyopathy: (1) decreased MIBG uptake due to 
destruction of adrenergic nerve tissue and (2) functional alteration of adrenergic 
nerves, such as hyperexcitation of nerve endings as a compensatory mechanism for 
impaired cardiac pump function [116, 117].
MRI
Cardiac magnetic resonance imaging (MRI) is considered the gold standard for 
the non-invasive assessment of LVEF in myocardial disorders. MRI combined 
with late gadolinium contrast enhancement can detect subtle areas of irreversibly 
damaged myocardium [118,119]. It has been frequently used to assess cardiac 
morphologic, functional and metabolic changes. Cardiac MRI has been successfully 
used in visualizing the site and extensiveness of myocardial infarction and acute 
myocarditis. Cardiac MRI in anthracycline treated patients has not been studied 
extensively. One study in asymptomatic patients showed a small decrease in LVEF 
together with changes in contrast enhancement pattern of the myocardium, 
reflecting early myocardial changes after anthracycline therapy [120]. Another 
study showed similar findings in ten symptomatic breast cancer patients treated 
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with trastuzumab [121]. However, in the clinical setting, the high costs of repeated 
examinations and the limited availability reduce MRI to a second line option which 
is of great value in particular circumstances [122].
2.9 No longer used method
 
Endomyocardial biopsy
Endomyocardial biopsy has traditionally been viewed as the gold standard for the 
evaluation of anthracycline-induced cardiotoxicity and is reported to be very sensitive 
[119]. However its invasive nature, together with the associated risks, makes this 
method less attractive for monitoring the occurrence of cardiotoxicity [122].
3 Prevention of anthracycline-induced cardiotoxicity
Extensive research has been done to identify methods or agents capable of ameliorating 
anthracycline-induced cardiotoxicity. This has been summarized by Cochrane and 
other reviews. It covers evidence on (1) the use of cardioprotective agents, (2) the use 
of less cardiotoxic anthracyline analogues, and (3) the use of different anthracycline 
dosage schedules [47,48,124,125]. Some of the above mentioned aspects have been 
mentioned earlier. This section focuses on the cardioprotective agent dexrazoxane.
Dexrazoxane
Dexrazoxane is a bisdioxopiperazine compound and was introduced in the 1970s 
as an anticancer agent. As doxorubicin, dexrazoxane is a topoisomerase inhibitor. Its 
cardioprotective activity is thought to be due to the conversion into an iron chelator 
that can remove iron from the doxorubicine-iron complex. As a result, formation 
of free radicals is prevented, the free iron pool is reduced and cellular damage will 
decrease [126]. The cardioprotective effect of dexrazoxane has been confirmed in 
several studies, first in adults, later in children. Dexrazoxane significantly reduces the 
occurrence of heart damage caused by anthracyclines [48,49,128]. The concern about 
dexrazoxane is whether, besides reducing the cardiotoxic effect of anthracyclines, it 
also reduces its anti tumour activity. The effect on tumour activity has been suggested 
by studies in adults, however it could not be confirmed, nor ruled out in studies in 
children [47]. Another concern about dexrazoxane is its association of dexrazoxane 
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with an increased risk of secondary malignant neoplasms (SMNs), as reported by 
the Children’s Oncology Group (COG) [128]. In a recent study by Lipshultz in 
children with Acute Lymphoblastic Leukemia (ALL), dexrazoxane reduced early 
myocardial injury during doxorubicin treatment as measured by increased serum 
cTnT concentrations [129], did not cause an increased risk for SMNs with a median 
follow-up of six years [130] and provided long-term cardioprotection without 
compromising oncological efficacy [130]. Dexrazoxane showed greater long-term 
cardioprotective effects in girls than in boys [131]. 
Recently, the European Medicines Agency has recommended restricting the 
use of dexrazoxane to adult patients with advanced or metastatic breast cancer 
who have already received a certain amount of the anthracyclines doxorubicin and 
epirubicin to treat their cancer. The Agency’s Committee for Medicinal Products 
for Human Use (CHMP) also recommended contraindicating the use of this 
medicine in children, based on the above mentioned concerns [132].
4 Treatment of anthracycline-induced cardiotoxicity
The optimal management of a patient with asymptomatic cardiac dysfunction after 
anthracycline treatment for childhood cancer is not clear. The use of angiotensin-
converting enzyme (ACE)-inhibitors and beta-blockers has been subject to several 
human and animal studies [133-144].
ACE-inhibitors
Afterload reduction is useful for treating and preventing adult congestive heart 
failure outside the scope of anthracycline-induced cardiotoxicity [143,144]. 
However, the use of afterload reduction for the prevention of anthracycline-
induced cardiomyopathy remains controversial. Lipshultz and colleagues showed 
that the effect of enalapril treatment in survivors of childhood cancer treated 
with anthracyclines is transient and produces a 6-10 years improvement followed 
by a return to the initial cardiac situation and a 2-6 years benefit before medical 
management fails for patients with congestive heart failure. In addition to this, 
enalapril does not prevent progressive left ventricular wall thinning [135]. The 
goal of the Ace-inhibitor After Anthracycline (AAA) study was to determine if an 
ACE-inhibitor, enalapril, could slow progression of cardiac dysfunction by lowering 
left ventricular end-diastolic wall stress in patients exposed to anthracyclines who 
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had developed specific abnormalities on cardiac screening tests (i.e. FS ≤ 29%, 
EF≤55%, >10% drop of FS or EF, QTc ≥ 440 ms) any time after anthracycline 
exposure. The AAA trial demonstrated that survivors of pediatric cancer exposed 
to anthracyclines can tolerate long-term administration of an ACE-inhibitors and 
can experience reductions in end-systolic wall stress that may last for a moderate 
period of time (between 3 and 7 years). The study failed to show a significant and 
important improvement of exercise function [133,134]. Cardinale and colleagues 
showed that early treatment with enalapril in patients with myocardial cell injury 
(as measured by a cTnI increase) seemed to prevent the further development of 
cardiotoxicity and the occurrence of associated adverse clinical events [136].
Beta blockers
Beta blockers are often used in the treatment of chronic heart failure due to 
ischemic, congenital or acquired heart disease. The use of beta blockers in the 
treatment of anthracycline-induced cardiotoxicity has only been evaluated in 
small studies. Georgakopoulos and colleagues studied the effect of metoprolol in 
doxorubicin-treated adult lymphoma patients. No decreased risk of cardiotoxicity 
was seen. However, they reported a trend in lower incidence of heart failure in the 
metoprolol group compared to the placebo group [137].
In order to make an evidence-based decision regarding lifelong treatment with either 
ACE-inhibitors or beta blockers, randomized controlled trials should be undertaken.
5 The need for early detection of anthracycline-induced 
 cardiotoxicity
Early detection of anthracycline-induced cardiotoxicity may prevent morbidity and 
mortality when preventive measures or treatment are effective. Efforts to prevent 
further complications include intensified monitoring, initiation of preventive 
measures, or changes to cancer treatment. 
In this thesis, we report the use of cardiac biomarkers cTnT and NT-pro-BNP 
and 2D myocardial strain imaging in the early detection of anthracycline-induced 
cardiotoxicity in a group of long-term survivors of childhood cancer and a group of 
newly diagnosed patients with ALL.
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6 Outline of the thesis
Chapter 2 covers a review of the available literature about the use of cardiac 
biomarkers cTnT, cTnI, NT-pro-BNP and BNP in the early detection of 
anthracycline-induced cardiotoxicity in children. The aim of this study was to 
analyze the available evidence for the role of biomarkers in the early detection of 
anthracycline-induced cardiotoxicity in childhood and adolescence.
In chapter 3, the study of the use of cTnT and NT-pro-BNP in a cohort of long-
term survivors of childhood cancer is reported. The aims of this study were 1) 
to document plasma concentrations of NT-pro-BNP and Troponin T in a large 
group of asymptomatic survivors of childhood cancer treated with anthracyclines, 
2) to study the relation of the abnormal biomarker levels with different risk factors 
for anthracycline-induced cardiotoxicity based on conventional echocardiographic 
parameters.
In chapter 4, the interobserver, intraobserver and intrapatient reliability scores of 
myocardial strain imaging with 2-dimensional echocardiography in patients treated 
with anthracyclines are reported. We evaluated myocardial strain measurements of 
ten asymptomatic survivors of childhood cancer.
Chapter 5 describes the study where we aimed to evaluate left ventricular 
myocardial strain in all three directions (longitudinal, circumferential and radial) 
assessed by 2D echocardiography in a large, healthy pediatric and young adult 
cohort to establish reference values and to determine the influence of age and 
growth on these values.
In chapter 6, the study is covered where we aimed to determine the role of global 
myocardial strain and strain rate in monitoring subclinical heart failure in a large 
group of asymptomatic long-term survivors of childhood cancer. Myocardial global 
strain and strain rate parameters of survivors are compared to healthy controls and 
related to conventional echocardiographic parameters, N-terminal-pro-natriuretic 
peptide (NT-pro-BNP) levels and clinical parameters in the survivors.
Chapter 7 covers a prospective study, where we aimed to document conventional 
and myocardial 2D strain echocardiographic parameters and cTnT and NT-pro-
BNP levels during and shortly after treatment with anthracyclines in children with 
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newly diagnosed ALL. In addition to this, we wanted to compare cardiac function 
of children with ALL after one year of anthracycline treatment to cardiac function 
of healthy controls.
Chapter 8 is a summary and future perspectives of the research described in this 
thesis. Chapter 9 covers the Dutch summary of the research presented in this thesis, 
as well as the future perspectives. Chapter 10 presents the acknowledgements, 
curriculum vitae and list of publications. Chapter 11 shows the illustrations in 
full colour.
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 Abstract
Background
Anthracycline-induced cardiotoxicity can cause serious health problems for an 
increasing number of children surviving childhood malignancies. Early detection 
of cardiac failure is critically important for the prevention and management of 
anthracycline-induced cardiotoxicity.
Aim
To determine the role of biomarkers in the early detection of anthracycline-induced 
cardiotoxicity in children.
Study Design
A literature review of studies regarding the use of the biomarkers B-type natriuretic 
peptide (BNP), N-terminal pro-BNP (NT-pro-BNP), cardiac Troponin T 
(cTnT) and cardiac Troponin I (cTnI) in relation with anthracycline-induced 
cardiotoxicity in children.
Results
Six of fourteen studies in children showed a significant relation between elevated 
biomarkers BNP, NT-pro-BNP and cTnT and cardiac dysfunction.
Conclusion
Six studies, although small, suggest that BNP, NT-pro-BNP and cTnT might be 
useful markers in the early detection of anthracycline-induced cardiotoxicity.
Anthracycline-induced cardiotoxicity
44
Chapter 2  -  The role of biomarkers in the early detection of 
anthracycline-induced cardiotoxicity in children. A review of the literature.
45
1 Introduction
Anthracycline-induced cardiotoxicity can cause serious health problems for an 
increasing number of children surviving childhood malignancies. Acute changes 
can progress to early-onset and late-onset chronic progressive cardiomyopathy. 
It can manifest itself in patients as clinical or subclinical heart failure with an 
increased risk for sudden death. The incidence of severe cardiotoxicity is dose-
related, but even low cumulative doses of anthracyclines can lead to permanent 
myocardial injury [1-4]. 
Noninvasive techniques for identification of patients who are at high risk 
of developing anthracycline cardiomyopathy are critically important for the 
prevention and management of anthracycline-induced cardiotoxicity. Methods 
currently available are conventional echocardiography, ECG and radionuclide 
ventriculography. Unfortunately, they lack the sensitivity required to detect 
the early stages of cardiomyopathy [5,6]. The role of newer echocardiographic 
methods, such as tissue Doppler imaging (TDI) and strain rate imaging (SRI) is 
encouraging [7-10]. 
There is a growing interest in the use of biomarkers for the detection of cardiac 
injury. BNP and NT-pro-BNP and cardiac troponin T and I are currently widely 
used for the detection of cardiac injury (primary ischemic cardiac injury, secondary 
ischemic cardiac injury and non-ischemic cardiac injury) in both adults and 
children [11-24]. Several studies have reported a correlation between the levels 
of the various biomarkers and abnormalities seen by echocardiography in adult 
patients treated with anthracyclines [25-29].
The objective of this review was to analyze pediatric studies to determine the 
available evidence for the role of biomarkers in the early detection of anthracycline-
induced cardiotoxicity in childhood and adolescence.
2 Methods
We searched the literature for studies regarding the use of the biomarkers BNP, NT-
pro-BNP, cTnT and cTnI in the relation with anthracycline-induced cardiotoxicity 
in children. Medline was searched for relevant articles from 1966 till May 2007 by 
using the terms cardiotoxicity, BNP, NT-pro-BNP, (cardiac) troponin I, (cardiac) 
46
troponin T, anthracycline, children and pediatric as search criteria. The search was 
focused on original studies and abstracts from the annual meeting of the American 
Heart Association (AHA), the European Association of Pediatric Cardiology 
(AEPC) and the European Society of Cardiology (ESC) in the years 2001 till 
2006. Cardiac dysfunction was defined as abnormalities on echocardiography.
3 Results
Fourteen studies, evaluating anthracycline-induced cardiotoxicity in relation to 
biomarkers in children, were published from 1995 till May 2007 (table 2.1) [5,30-
42]. Two studies [5,34] evaluated both NT-pro-BNP or BNP and cTnI in the same 
study. The number of patients varied from 15 to 63 per study. The time from the 
last dose of anthracycline and the evaluation point by measurement of biomarker 
levels and/or echocardiography varied from immediately after the anthracycline 
dose till 17.5 years later. Cumulative doses of anthracyclines ranged from 22 to 
1200 mg/m2. The specific abnormalities on echocardiography found in relation to 
elevated biomarker levels are shown in table 2.2. A significant correlation of cardiac 
dysfunction with elevated BNP, NT-pro-BNP and cTnT levels was found in six 
studies [5,30,33,34,36,39].
BNP and cardiac dysfunction
Five studies evaluated BNP levels in children who had received anthracycline 
therapy. In the study of Hayakawa and colleagues [30] 34 patients were evaluated 
after anthracycline therapy. Eight of the 34 patients showed cardiac dysfunction. 
This group had significantly higher levels of BNP (p<0.05) and received a 
significantly higher cumulative anthracycline dose (p<0.01) compared to the 
group with normal results on echocardiography. In the study of Pinarli, reduced 
shortening fraction (SF), increased wall stress and abnormalities in diastolic filling 
patterns were seen significantly more in the patient group compared to controls 
[31]. They also showed that the BNP-levels in the patient group were significantly 
higher than in the control group. There was no correlation between BNP levels and 
the total cumulative dose of anthracyclines, or the mean time interval after the last 
dose of anthracycline. No data are reported on the relation of cardiac dysfunction 
and BNP-levels. Poutanen and colleagues [32] could not show a significant 
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correlation between BNP and cardiac dysfunction and cumulative anthracycline 
dose. No significant elevation of BNP level was observed in the patient group with 
decreased left ventricle muscle mass. Both Aggarwal and colleagues and Erkus and 
colleagues showed a significant relation between BNP level and late respectively 
early cardiac dysfunction, even in low cumulative anthracycline doses [33,34].
NT-pro-BNP and cardiac dysfunction
Three studies evaluated NT-pro BNP levels in children after or during 
anthracycline therapy. Ekstein and colleagues assessed levels of NT-pro BNP 
during treatment with anthracyclines [35]. Significant higher levels of NT-pro-
BNP were measured after the first dose of anthracyclines in patients receiving 
more than 25 mg/m2 doxorubicin in the first dose compared to controls. All 
patients had normal echocardiographic findings. Soker and Germanakis [5,36] 
assessed levels of NT-pro BNP after completion of anthracycline therapy. In four 
of the 31 patients in the study of Soker, left ventricular dysfunction was observed. 
Plasma NT-pro BNP levels in these four patients were significantly elevated 
compared to patients with normal cardiac function (p<0.008) and compared to 
the control group (p<0.001). Germanakis and colleagues studied the prevalence 
of left ventricular mass reduction and its possible association with NT-pro BNP 
levels in 19 asymptomatic patients. Fourteen of the 19 patients showed a significant 
reduction of left ventricular myocardial mass (LVM). NT-pro-BNP levels in 
these patients were significantly higher compared to patients with normal LVM 
(p=0.003) [36].
Troponin T and cardiac dysfunction
Four studies evaluated cardiac Troponin T levels in children in relation to 
anthracycline therapy [37-40]. Kremer reported cardiac dysfunction in 7 of 38 
patients. The patients were in different stages of their treatment. Three of the 
seven patients had elevated cTnT levels (>0.01 ng/ml), two did not develop 
cardiac dysfunction 2 and 8 months after their treatment, one developed clinical 
heart failure [37]. Fink and colleagues studied cTnT levels during anthracycline 
treatment. They did not observe elevated cTnT or signs of cardiac dysfunction [38]. 
Only Lipshultz and colleagues reported a significant correlation between cTnT 
levels and cardiac dysfunction [39]. They found cTnT levels significantly related 
to increased left ventricle end-diastolic dimension and decreased posterior wall 
thickness at late follow-up. The cut-off for defining abnormality used was >0.03 
ng/ml. Kismet reported on 24 patients after their anthracycline therapy, with a 
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cumulative dose of 400 mg/m2 or more. In only one patient an elevated cTnT level 
(>0.01 ng/ml) was found. In nine patients cardiac dysfunction was observed, of 
which only one showed an elevated cTnT level [40].
Troponin I and cardiac dysfunction
Four studies evaluated cardiac Troponin I levels in children who had received 
anthracycline therapy [5,34,41,42]. Mathew reported fifteen patients during their 
anthracycline treatment of which only one patient showed an elevated cTnI level, 
without signs of cardiac dysfunction [41]. Soker could not observe elevated cTnI 
levels in 31 patients after anthracycline therapy [5]. Koseoglu reported on 22 
patients, all without elevation of cTnI after anthracycline therapy [42]. In the study 
of Erkus and colleagues only two patients had elevated TnI levels, but without 
cardiac dysfunction [34]. 
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Table 2.1 Studies evaluating the use of biomarkers in relation with 
 anthracycline-induced cardiotoxicity in children 
First author,
year (ref.)
Number of 
patients
Time to last dose 
of anthracycline 
(range)
Mean cumulative 
dose of 
anthracycline mg/
m2 (range)
Echocardiographic 
abnormalities in 
study group
Elevated 
biomarkers in 
study group
Elevated 
biomarker and 
echocardiographic 
abnormalities
Significant relation 
of biomarker with 
cumulative 
anthracycline dose
BNP
Hayakawa
2001 (30)
34 > 1 month 274
SD ± 174
yes, 8/34 yes yes, p<0.05 no
Pinarli
2005 (31)
34 46 months
(3-122)
260
(90-490)
yes yes no data no
Poutanen
2003 (32)
39 8.6 years
(3.9-16.8)
220 yes no no no
Aggarwal
2006 (33)
63 3.8 years
(1.1-17.5)
165
(45-520)
yes yes yes, p<0.008 no data
Erkus
2006 (34)
29 1 month 182
(56-374)
yes yes yes, p<0.05 yes
NT-pro-BNP
Ekstein
2005 (35)
23 directly after dose 25 no yes no yes, p<0.0001
Soker
2005 (5)
31 9 months
(1-42)
300
(30-600)
yes, 4/31 yes yes, p<0.008 no
Germanakis
2006 (36)
19 3.9 years
(0.6-8.3)
240
(22-1200)
yes yes yes, p=0.003 no
Troponin T
Kremer
2002 (37)
38 24 hours 255
SD ± 118.9
yes, 7/38 yes no no data
Fink
1995 (38) 22
< 72 hours
serial 
measurements
180
(60-460) no no no no data
Lipshultz
1997 (39)
15 9 months 60
(45-222)
yes yes yes, p=0.003 no data
Kismet
2004 (40)
24 12 months
(1-168)
480
(400-840)
yes, 9/24 yes no no data
Troponin I
Mathew                
2001 (41) 15
after each 
cumulative dose of 
25-50
no data        (11.72 
mg/kg-375 mg/m2) yes, 7/15 yes no no
Soker
2003 (5)
31 9 months
(1-42)
300
(30-600)
yes, 4/31 no no no data
Koseoglu
2005 (42)
22 31 months
(6-74)
450
(group 1, n=10)
yes, 3/22
all in group 1
no no no
245
(group 2, n=12)
no no no
Erkus
2006 (34)
29 1 month 182
(56-374)
yes yes no no
Chapter 2  -  The role of biomarkers in the early detection of 
anthracycline-induced cardiotoxicity in children. A review of the literature.
50
Table 2.2 Specific abnormalities found by echocardiography in studies with 
 elevated biomarkers 
First author, year (ref) Biomarker Cardiac dysfunction
Hayakawa, 2001 (30) BNP ↓ EF (p<0.01), ↓ FS (p<0.01)
↓ mVcf (p<0.01),  LVSTI (p<0.01)
Aggarwal, 2006 (33) BNP ↓FS (p=0.009), mVcf (p=0.004), SVI (p=0.04)
Erkus, 2007 (34) BNP ↓ EF, ↓FS (p<0.05)
Soker, 2003 (5) NT-pro-BNP ↓ EF, ↓FS
Germanakis, 2006 (34) NT-pro-BNP ↓ LVM (p=0.003)
Lipshultz, 1997 (37) cTnT ↑ LV end-diastolic dimension z score (p<0.003)
↓ LV end-diastolic posterior wall thickness z score (p<0.0437)
EF  Left ventricular ejection fraction, FS= left ventricular fractional shortening
mVcf  Mean velocity of circumferential fiber shortening
LVSTI  Left ventricle systolic time interval
SVI  Stress velocity index
LVM  Left ventricular myocardial mass
4 Discussion
Disease free survival has significantly improved during the last 30 years since the 
use of anthracyclines for the treatment of childhood cancer [1,2]. The overall 
cure rate for paediatric malignancies is now 75%, resulting is a growing number 
of childhood cancer survivors. Survivors of childhood cancer have a high rate 
of illness owing to chronic health conditions [43,44]. Simple and reproductive 
methods with a strong predictive value to identify patients at risk for anthracycline-
induced cardiotoxicity at an early stage would be of great value. There could be an 
important role for the additional value of biomarkers [12,13] next to the currently 
available techniques, such as conventional echocardiography and the newer 
echocardiographic techniques TDI and SRI [7-10]. 
BNP and NT-pro-BNP and their role in detection of cardiac dysfunction
BNP and NT-pro-BNP are more extensively used in adult cardiologic evaluation. 
They serve as markers as well as a prognostic factor parameter for congestive heart 
failure [45]. A limited but expanding knowledge exists in the pediatric age group 
[45,46]. Nir and colleagues reviewed the literature on the use of BNP and NT-
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pro-BNP in children and concluded that the limited data in this age group suggests 
that natriuretic peptides could improve the diagnostic accuracy in the assessment 
of heart disease. Normal values are assay and age specific [18]. 
In four of five studies elevated BNP levels were found [30,31,33,34]. BNP 
was related to cumulative anthracycline in one study [34]. Abnormalities on 
echocardiography were found in all five studies. However, a significant elevation 
of BNP related to these abnormalities was only seen in three studies [30,33,34]. 
In two of three studies a significant relation between NT-pro-BNP and cardiac 
dysfunction was found [5,36]. Ekstein and colleagues did not find signs of clinical 
or echocardiographic evidence for acute cardiac dysfunction after the first dose 
of anthracycline. However, in the group of patients receiving 25 mg/m2 or more 
doxorubicin in the first course, a significant increase of NT-pro-BNP was found 
compared to controls. It would be interesting to know the echocardiographic 
evaluation at late follow-up in this specific patient group, to find out whether 
elevation of NT-pro-BNP in the acute moment could be an early indicator of 
cardiac dysfunction at later follow-up. Both Soker and Germanakis found a 
significant relation of NT-pro-BNP and abnormalities on echocardiography 
[5,36]. However, median follow-up ranged from one month till almost 9 years.
On the basis of current pediatric studies BNP and NT-pro-BNP seem sensitive 
markers for detection of anthracycline-induced cardiotoxicity.
Troponins and its role in detection of cardiac dysfunction
Release of cardiac troponins reflects damage of myocytes and is indicative of 
myocardial necrosis. Sparano and colleagues reported that the time to the peak of 
cTnT and cTnI was, respectively, 12-48 and 10-24 hours after acute myocardial 
infarction [12]. This suggests that release of cardiac troponins reflects early damage 
of myocytes. However, hemodynamic changes occurring in a later stage can also 
lead to subclinical ischemia. Troponins could therefore also play a role in later 
cardiac dysfunction. Immer and colleagues compared the use of cTnI and cTnT 
in 48 children undergoing a cardiovascular operation. They found the diagnostic 
value of cTnI to be similar to cTnT. However, they showed an advantage of cTnI 
since it was not influenced by renal failure [19]. Swaanenburg and colleagues found 
an equal accuracy of cTnT and cTnI in adult patients who experienced myocardial 
contusion from blunt thoracic trauma [20].
Lipshultz and colleagues detected elevated cTnT levels in patients with only 
minor exposure to anthracyclines and demonstrated that cardiomyocyte damage 
begins early during therapy and can occur even with the initial anthracycline dose 
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[39]. In an adult study including 200 patients, a close relationship between early 
cTnI increment and the greatest left ventricular ejection fraction (LVEF) reduction 
was found (p<0.0001) [26]. Cardiac TnI as a marker for anthracycline-induced 
cardiotoxicity in children has not been indicative so far, since most levels were 
under the detection limit [5,34,41,42]. 
Acute versus chronic cardiotoxicity
The role of biomarkers in the detection of acute cardiotoxicity remains unclear. 
Subtle acute cardiotoxicity could not be detected with echocardiography and/
or clinical signs, but elevated NT-pro-BNP levels were found immediately after 
anthracycline administration in the study of Ekstein [35]. Kremer and colleagues 
[37] showed a low predictive value of cTnT for subsequent left ventricle dysfunction. 
Late echocardiographic follow-up in patients with elevated biomarkers in the acute 
phase is important to determine its predictive value. The role of biomarkers in the 
detection of early and late chronic progressive cardiomyopathy is not yet clear but 
might be promising on the basis of current pediatric studies. In six studies the 
biomarker was elevated in relation to abnormalities on echocardiography. In these 
studies a relatively low mean cumulative anthracycline dose was administered (60-
300 mg/m2). Thus, even at low cumulative anthracycline doses, biomarkers could 
be an indicator of early cardiotoxicity.
5 Limitations
A major limitation of all studies is that, besides the relatively low patient number, 
the time to last dose of anthracyclines showed a wide range in the different studies 
(immediately after the anthracycline dose till 17.5 years later). It is therefore hard 
to determine what the best timing for detection of cardiac dysfunction with both 
biomarker and echocardiography will be and which method is most sensitive at 
which time in the detection of subclinical cardiomyopathy. 
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6 Conclusions
Six of fourteen studies in children showed a significant relation between elevated 
biomarkers and cardiac dysfunction. These studies suggest that BNP, NT-pro-
BNP and cTnT might be useful markers in the early detection of anthracyline-
induced cardiotoxicity. It would be very interesting to know what the impact is 
of elevated biomarkers in the acute phase on the development of late progressive 
cardiomyopathy. The potential use of these biomarkers as a predictive tool remains 
to be investigated in larger prospective studies.
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 Abstract
Background
Anthracycline-induced cardiotoxicity can cause serious health problems for an 
increasing number of survivors of childhood malignancies. The aims of this study 
were to document plasma concentrations of cardiac Troponin T (cTnT) and NT-
pro-brain natriuretic peptide (NT-pro-BNP) in a large group of asymptomatic 
long-term survivors of childhood cancer treated with anthracyclines, and to 
study the relation of the abnormal biomarker levels with different risk factors 
for anthracycline-induced cardiotoxicity and conventional echocardiographic 
parameters.
Procedures
122 asymptomatic survivors of childhood cancer underwent a detailed echo-
cardiography. Blood samples were taken to determine the levels of NT-pro-BNP 
and cTnT.
Results
None of the survivors had abnormal cTnT levels. Thirteen percent of the survivors 
(n=16) had abnormal NT-pro-BNP levels. Abnormal NT-pro-BNP levels were 
significantly related to cumulative anthracycline dosage (p<0.003). Eleven of 31 
survivors (35%) treated with cumulative anthracycline dose of 300 mg/m2 or 
more, had abnormal NT-pro-BNP levels which were significantly related to end-
diastolic left ventricular internal diameter (LVIDd) indexed for body surface area 
(BSA) (p<0.01).
Conclusion
Cardiac TnT does not contribute to the early detection of late-onset anthracyline-
induced cardiotoxicity. Abnormal levels of NT-pro-BNP were detected in 13% of 
122 asymptomatic, long-term survivors of childhood cancer. Follow-up of these 
survivors is essential to answer the question whether NT-pro-BNP is an early 
marker for late-onset anthracycline-induced cardiotoxicity.
Anthracycline-induced cardiotoxicity
60
Chapter 3  -  Abnormal NT-pro-BNP Levels in Asymptomatic 
Long-term Survivors of Childhood Cancer Treated With Anthracyclines
61
1 Introduction
Anthracycline-induced cardiotoxicity can cause serious health problems for an 
increasing number of survivors of childhood malignancies. Acute changes can 
progress to early-onset and late-onset chronic progressive cardiomyopathy [1,2]. 
It can manifest itself in patients as clinical heart failure or asymptomatic left 
ventricular dysfunction, with an increased risk for sudden death. The incidence 
of severe cardiotoxicity is dose-related. However, low cumulative doses of 
anthracyclines can also lead to myocardial injury [1,2]. 
Noninvasive techniques are important for the assessment and management 
of anthracycline-induced cardiotoxicity. Of the methods currently available, 
the conventional echocardiography, electrocardiography (ECG), radionuclide 
ventriculography and tissue Doppler imaging (TDI) lack the sensitivity required to 
detect the early stages of cardiomyopathy [3]. The role of newer echocardiographic 
methods, such as TDI with strain rate imaging (SRI) is encouraging [4,5]. 
There is a growing interest in the use of biomarkers for the detection of 
anthracycline-induced cardiotoxicity. Release of cardiac troponins reflects damage 
of myocytes and is indicative for myocardial necrosis. Natriuretic peptides 
are released by the myocardium in response to volume and pressure overload. 
These biomarkers have shown to be sensitive in the detection of left ventricular 
dysfunction [6,7]. Several adult studies have reported a correlation between the 
levels of the various biomarkers (brain natriuretic peptide (BNP), N-terminal 
pro-brain natriuretic peptide (NT-pro-BNP) and cardiac Troponin T (cTnT) and 
cardiac Troponin I (cTnI) and abnormalities documented by echocardiography 
in patients treated with anthracyclines [8-11]. However, pediatric studies [12] 
have low patient numbers and do not differentiate between early and late-onset 
progressive cardiomyopathy. The aims of this study were 1) to document plasma 
concentrations of NT-pro-BNP and Troponin T in a large group of asymptomatic 
long-term survivors of childhood cancer treated with anthracyclines, 2) to study 
the relation of the abnormal biomarker levels with different risk factors for 
anthracycline-induced cardiotoxicity based on conventional echocardiographic 
parameters.
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2 Patients and methods
Study population
All consecutive survivors of childhood cancer, who visited the Late Effects Clinic 
from May 2006 till October 2007, who received anthracyclines as part of their 
therapy for various kinds of malignancies more than five years ago, were included 
in our study. Survivors were excluded if they had clinical heart failure, as defined by 
the New York Heart Association classification (NYHA, class II-IV) [13], a history 
of cardiovascular disease or chronic renal insufficiency. The study was approved by 
the local ethics committee.
Medical information was obtained by record view. All survivors underwent a 
complete physical examination (including measurement of blood pressure), ECG 
and a detailed echocardiography. 
Biochemical analysis
Blood samples were obtained by venous puncture. Routine blood chemistry was 
performed in all survivors. EDTA blood was stored on ice for determation of 
biomarkers. Cardiac Troponin T levels were assessed by the Elecsys Troponin T 
STAT Immunoassay. The electrochemiluminescence immunoassay was performed 
on a Modular E immunoassay analyzer (Roche Diagnostics, Mannheim, 
Germany) [14]. A level of <0.01 ng/ml was defined as normal. NT-pro-BNP 
was measured using an electrochemiluminescence immunoassay. It was performed 
with the Modular E, using the NT-pro-BNP kit (Roche Diagnostics, Mannheim, 
Germany). Normal values for adults were different for males (< 10 pmol/l) and 
females (<18 pmol/l) (cut-off 97.5th percentile) [15]. For normal values for 
children, we used the age-dependent reference values by Albers and colleagues 
(cut-off 97.5th percentile) [16].
Echocardiography
Transthoracic echocardiography in left lateral position was performed by 
experienced echocardiographic technicians and supervised by two (pediatric) 
cardiologists (LK, LB), who were unaware of the cumulative dose of chemotherapy 
and of the levels of cTnT and NT-pro-BNP. Each study was performed at rest, 
without sedation. Images were obtained with a 3.0-Mz and a 5.0-MHz transducer 
using a commercially available system, the Vivid 7 echographic scanner (GE, 
Vingmed Ultrasound, Horten, Norway). Quantification of cardiac chamber size, 
ventricular mass and systolic and diastolic left ventricular function were measured 
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in accordance with the recommendations for chamber quantification by the 
American Society of Echocardiography’s Guidelines and Standard Committee and 
the Chamber Quantification Writing Group [17]. An M-mode echocardiogram 
was performed in the parasternal long and short axis views to measure the internal 
dimensions of the left ventricle at end-systole and end-diastole (LVIDs, LVIDd), 
the posterior and the septal wall thickness at end-diastole (LVPWd, IVSd). 
Measurements of left ventricular dimensions and left ventricular mass (LVM) 
were indexed by body surface area (BSA). The left ventricle systolic function was 
indicated using fractional shortening (FS), ejection fraction (EF), rate corrected 
velocity of circumferential fiber shortening (VCFc) and end-systolic wall stress 
(ESWS). FS was obtained by dividing LVIDd minus the LVIDs through LVIDd 
times 100%. Ejection fraction (EF) was calculated using the modified Simpson’s 
rule. Left ventricular end-systolic wall stress (ESWS) was calculated using the 
modified formula of Rowland [18]. Velocity of circumferential fibre shortening 
(VCFc) was calculated via the formula obtained from Colan and colleagues [19]. 
Left ventricular diastolic function was indicated using the E/A ratio and the 
isovolumic relaxation time. The ratio of early (E) to late atrial (A) mitral Doppler 
peak flow velocity (E/A ratio) was obtained by pulse Doppler at the mitral valve 
inflow and compared to established normal values. The isovolumic relaxation time 
(IVRT), was identified as the interval between the closure of the aortic valve and 
the opening of the mitral valve [20]. Left ventricular mass was calculated with 
the formula for estimation of left ventricular mass according to the formula of 
Devereux [21]. The echocardiographic study and the blood sampling for biomarker 
estimation were performed at the same time.
Statistical analysis
Characteristics of the study population as age at diagnosis, follow-up duration, 
age at follow-up, BSA, systolic and diastolic blood pressure and heart rate were 
summarized by using median and range. The relation between abnormal NT-
pro-BNP levels and different risk factors and conventional echocardiographic 
parameters was studied using the Kruskall Wallis test. The relation between 
abnormal NT-pro-BNP levels and cumulative anthracycline dosage was further 
analysed by dividing the study population into three cumulative anthracycline 
dosage groups. Group 1 consisted of survivors with a cumulative anthracycline 
dosage of 120 mg/m2 or less, group 2 with a cumulative anthracycline dosage 
between 120-300 mg/m2 and group 3 with a cumulative anthracycline dosage of 
300 mg/m2 or more. Abnormal NT-pro-BNP levels were related to abnormal FS 
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and EF using the Fisher Exact test. 
The results of the conventional echocardiographic parameters were expressed 
as mean and standard deviation. The echocardiographic data were studied in the 
above mentioned subgroups using the One Way Analysis of Variance (ANOVA) 
and using trend tests.
Statistical analyses were performed using the Statistical Package for Social 
Sciences (SPSS) for Windows, version 14.0. A p-value less than 0.05 was 
considered to indicate significance. 
3 Results
Subject characteristics
One hundred and twenty two asymptomatic survivors of childhood cancer were 
included in our study. Two other survivors were excluded because of mild clinical 
heart failure (NYHA class II). None of the survivors had a history of acute 
cardiotoxicity immediately following an anthracycline dosage. Table 3.1 shows the 
characteristics of the study population. 
Biomarkers and cumulative anthracycline dosage
None of the survivors showed elevated cTnT levels. Sixteen of the 122 survivors 
(13%) had abnormal NT-pro-BNP levels compared to sex and age appropriate 
norms. There was no significant relation between abnormal NT-pro-BNP levels 
and age at diagnosis, gender, follow-up duration, age at follow-up, BSA, systolic 
and diastolic blood pressure and heart rate (data not shown). However, abnormal 
NT-pro-BNP levels did significantly relate to cumulative anthracycline dosage 
as a continuous variable (p<0.003) (figure 3.1). We therefore further divided the 
survivors into three cumulative anthracycline subgroups (group 1 (≤120 mg/m2), 
group 2 (120-300 mg/m2) and group 3 (≥ 300 mg/m2).
We then analyzed how often abnormal abnormal NT-pro-BNP levels were 
seen within the three groups. None (0%) of the survivors in group 1 had abnormal 
NT-pro-BNP levels. Five of the 74 survivors (7%) in group 2 and 11 of the 31 
survivors (36%) in group 3 had abnormal NT-pro-BNP levels (p<0.001). 
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Table 3.1 Characteristics of 122 long-term survivors of childhood cancer
Number of patients (n)    122
Male gender (%)     62 (51%)
Median age at study, years (range)  21 (5.8-39.4)
Median follow-up, years (range)   13.8 (5.0-28.7)
Median age at diagnosis, years (range)  5.7 (0.03-14.4)
Median CAD, mg/m2 (range)   180 (50-542)
CAD ≤ 120 mg/m2 (n)    17
CAD 120-300 mg/m2 (n)    74
CAD ≥ 300 mg/m2 (n)    31
Diagnosis
 ALL     38
 AML     8
 Ependymoma    1
 Ewing Sarcoma    6
 Hepatoblastoma    3
 Hodgkin's disease   13
 Neuroblastoma    6
 NHL     30
 Rhabdomyosarcoma   4
 Osteosarcoma    3
Wilms´ tumour    10
Mediastinal radiation (n)    7
CAD Cumulative anthracycline dosage
AML Acute Myeloid Leukemia
ALL Acute Lymphoblastic Leukemia
NHL Non-Hodgkin Lymphoma
Figure 3.1 Relation of abnormal NT-pro-BNP and cumulative anthracycline dosage
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Echocardiographic parameters and biomarkers
Echocardiographic parameters were obtained from all 122 survivors. Four survivors 
(3%) had a FS lower than 29% (range 27-28%, none in group 1). Nine survivors 
(7%) had an EF lower than 55% (range 48-54%, none in group 1). Only two of these 
nine survivors with reduced EF, had abnormal NT-pro-BNP levels. Abnormal left 
ventricular systolic function was not significantly related to abnormal NT-pro-
BNP levels. No abnormal NT-pro-BNP levels and no abnormal echocardiographic 
parameters were observed in the survivors who received a cumulative anthracycline 
dosage of 120 mg/m2 or less (group 1). A significant relation between increased 
LVIDd indexed for BSA and abnormal NT-pro-BNP levels was found (p<0.01), 
only in group 3 (table 3.2).
Table 3.2 Echocardiographic results of 31 childhood cancer survivors 
 treated with >300 mg/m2
NT-pro-BNP abnormal NT-pro-BNP normal P value *
n=11 n=20
Left ventricular dimensions
IVSd/BSA (cm/m2) 0.38 ± 0.1 0.36 ± 0.1 0.5
LVPWd/BSA (cm/m2) 0.41 ± 0.09 0.3 ± 0.09 0.5
LVIDd/BSA (cm/m2) 3.3 ± 0.76 3.1 ± 0.50 0.01
LVIDs/BSA (cm/m2) 2.2 ± 0.6 2.0 ± 0.3 0.5
Left Ventricular Systolic Function
FS (%) 35 ± 4 33 ± 0.3 0.3
EF (Simpson) (%) 61 ± 6.1 60 ± 6.7 0.8
Vcfc (circ/s) 1.14 ± 0.19 1.13 ± 0.14 0.7
ESWS (g/m2) 0.35 ± 0.07 0.35 ± 0.07 0.8
Left Ventricular Diastolic Function
E/A ratio 2.0 ± 1.2 1.7 ± 0.5 0.1
Left Ventricular Mass/BSA (g/m2) 51.3 ± 15.9 51.3 ± 11.0 0.9
Isovolumic Relaxation Time (ms) 70 ± 14 69 ± 18 0.8
Values are expressed as mean and standard deviation.
* One-Way Analysis of Variance (ANOVA)
Echocardiographic parameters and cumulative anthracycline dosage
Table 3.3 shows the echocardiografic results of the 122 survivors when divided into 
the three cumulative anthracyclines dosage groups. The LVM indexed by BSA was 
significantly decreased with increased cumulative anthracyline dosage (p<0.005) 
and showed a significant trend (p<0.002). A reduced left ventricular systolic 
function, expressed by a decrease in EF and FS, was not significantly related to 
increased cumulative anthracycline dosage, but showed a statistically significant 
trend (p<0.01 resp p<0.03). Excluding the survivors with mediastinal radiation 
did not alter the results significantly (data not shown).
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Table 3.3 Echocardiographic results of 122 childhood cancer survivors
CAD ≤ 120 mg/m2 CAD 120-300 mg/m2 CAD ≥ 300 mg/m2 P value * P value **
n=17 n=74 n=31
Left ventricular dimensions
IVSd/BSA (cm/m2) 0.35 ± 0.07 0.34 ± 0.09 0.36 ± 0.1 0.4 0.5
LVPWd/BSA (cm/m2) 0.39 ± 0.08 0.39 ± 0.08 0.39 ± 0.08 0.6 0.8
LVIDd/BSA (cm/m2) 3.1 ± 0.8 3.0 ± 0.5 3.1 ± 0.6 0.7 0.7
LVIDs/BSA (cm/m2) 1.9 ± 0.5 1.9 ± 0.4 2.1 ± 0.4 0.3 0.2
Left Ventricular Systolic Function
FS (%) 36.4 ± 3.7 35.7 ± 4.0 34.0 ± 3.7 0.07 0.03
EF (Simpson) (%) 67.0 ± 5.9 60.6 ± 6.5 60 ± 6.3 0.05 0.01
Vcfc (circ/s) 1.20 ± 0.10 1.18 ± 0.15 1.12 ± 0.16 0.3 0.1
ESWS (g/m2) 75.3 ± 31.4 73.3 ± 23.8 73.4 ± 20.9 0.9 0.9
Left Ventricular Diastolic Function
E/A ratio 1.7 ± 0.48 1.8 ± 0.53 1.8 ± 0.80 0.6 0.4
Left Ventricular Mass/BSA (g/m2) 65.7 ± 17.2 56.0 ± 13.5 51.3 ± 12.7 0.005 0.002
Isovolumic Relaxation Time (ms) 75 ± 12.6 68 ± 13.7 73 ± 15.9 0.1 0.9
Values are expressed as mean and standard deviation.
*   One-Way Analysis of Variance (ANOVA)
**  Linear regression
4 Discussion
Early detection of anthracycline cardiotoxicity is important to find ways to 
prevent heart failure in childhood cancer survivors. The role of biomarkers in the 
early detection on anthracycline-induced cardiotoxicity in children was recently 
reviewed [22]. In this study, the role of biomarkers in relation to anthracycline-
induced cardiotoxicity was investigated in a large group of asymptomatic long-term 
survivors of childhood cancer, with a relatively homogenous follow-up duration. 
In many studies follow-up duration varies from months to years, which combines 
early-onset as well as late-onset anthracycline-induced cardiotoxicity. 
None of the survivors in our study had elevated cTnT levels. Cardiac Troponins 
reflect myocardial injury and are related to acute anthracycline-induced cardiotoxic 
changes. Three pediatric studies showed elevated levels of cTnT in anthracycline 
treated survivors, all with a short follow-up duration [13]. The absence of abnormal 
cTnT in our long-term survivors (5-28 years) suggests that cTnT does not play any 
role in the detection of late-onset anthracyline-induced cardiotoxicity. 
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Natriuretic peptides are released by the myocardium in response to volume and 
pressure overload, but is also stimulated by cytokines and growth factors, suggestive 
of a remodeling mechanism [6, 23]. We showed that abnormal NT-pro-BNP levels 
were detected in 13% of our asymptomatic survivors. Abnormal levels of NT-pro-
BNP were significantly related to increasing cumulative anthracycline dosage. 
We divided our survivors in three cumulative anthracycline dosage subgroups. A 
cumulative anthracycline dosage of 120 mg/m2 or less is considered to be a low risk 
dose [24] and our data confirmed this result. A cumulative anthracycline dose of 
300 mg/m2 and more is considered to be of high risk for developing anthracycline-
induced cardiotoxicity [25]. An increased left ventricular dimension is a common 
abnormal echocardiographic finding in anthracycline-induced cardiomyopathy 
[24]. In the high cumulative anthracycline dosage group (group 3) we could 
show a statistically significant relation between abnormal NT-pro-BNP levels 
and increased LIVDd indexed by BSA. Reduced left ventricular systolic function 
was not significantly related to abnormal NT-pro-BNP levels. Only two of the 
nine survivors with reduced EF had abnormal NT-pro-BNP levels. This negative 
finding complicates the clinical usefulness of abnormal NT-pro-BNP levels. NT-
pro-BNP should always be used in addition to echocardiographic parameters. It 
will be very interesting to know whether lower cut-off values of NT-pro-BNP 
can discriminate between the group with and without reduced EF. However, since 
the NT-pro-BNP levels of children vary quite significantly from those of adults, 
especially in adolescents, it is not feasible in this cohort of patients. We used normal 
versus abnormal levels of NT-pro-BNP as defined by published reference values 
[15,16]. This definition makes it useful for clinical practice.
Normal NT-pro-BNP levels were found in 87% of our asymptomatic survivors. 
In the currently used guidelines of the European Society of Cardiology (ESC) 
and the American Heart Association (AHA), normal NT-pro-BNP levels are 
used as a test to rule out heart failure, in the setting of patients presenting with 
symptoms suggestive of heart failure. In our population, it is interesting to know if 
it is possible to use NT-pro-BNP levels to identify asymptomatic survivors at risk 
for developing heart failure [26,27]. 
Two pediatric studies using NT-pro-BNP in relation to anthracycline-induced 
cardiotoxicity [12] showed a significant relation of elevated NT-pro-BNP levels 
with cardiac dysfunction. These studies did not use cut-off values defining normal 
versus abnormal, but compared levels of NT-pro-BNP which were elevated in the 
study group compared to the control group in relation to antracycline-induced 
cardiac dysfunction. 
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Analysis of echocardiographic parameters in relation to cumulative anthracycline 
dosage showed that the LVM indexed for BSA significantly decreased with increase 
of cumulative anthracyline dose, but not with abnormal NT-pro-BNP levels. 
Thinning of the walls of the left ventricle is a known phenomenon in anthracycline-
induced cardiotoxicity [25]. Indexing of LVM to BSA is used in a population with 
children of different ages, although it is known that dividing the LVM by height 
increased to a power of 2.7 (which is generally used) best correlates to indexing 
LVM to lean body mass [17]. 
Analysis of echocardiographic parameters also showed a significant trend in 
reduced left ventricular systolic function in relation to increased dosage of cumulative 
anthracyclines. EF and FS are often used in treatment protocols for follow-up of 
anthracycline-induced cardiotoxicity in patients on treatment. Abnormal EF and/
or FS can be a reason to adjust the dosage of anthracyclines. Decreased systolic 
left ventricular function, LVM indexed by BSA and abnormal levels of NT-pro-
BNP were all significantly related to increased cumulative anthracyline dosage. 
Cumulative anthracycline dosage is the most significant predictor of abnormal 
cardiac function [28-31]. Our data confirm this relation. Survivors who receive 
low dose cumulative anthracycline might also develop anthracycline-induced 
cardiotoxicity [28-31]. In the present study, we did not detect abnormal NT-pro-
BNP levels nor abnormal EF and FS in our low dosage cumulative anthracycline 
dosage group. 
We hypothesize, that abnormal NT-pro-BNP levels in patients without 
abnormalities on conventional echocardiography could be a predictor for heart 
failure. Follow-up of these patients is essential to get an answer to this hypothesis. 
The relation of abnormal levels of NT-pro-BNP with newer echocardiographic 
techniques, such as myocardial strain rate imaging (SRI), will also be a very 
interesting area for further study.
5 Limitations
Although we could include a relatively large group of survivors of childhood cancer, 
analysis of differences between the groups with different cumulative anthracycline 
dosages as well as other risk factors, was limited. A larger study group is needed 
to further analyse the characteristics of asymptomatic survivors with abnormal 
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NT-pro-BNP levels without abnormal echocardiographic findings. We have one 
biomarker sample of our survivors. Consequently, we were not able to show an 
increase of biomarker values, which is known to be a predictor of heart failure, 
even if the values are within the normal range. Furthermore, biomarker estimates 
were based on reference values from literature and not on age-matched controls, 
evaluated by the same laboratory.
6 Conclusion
We showed that cardiac TnT does not contribute to the early detection of late-
onset anthracyline-induced cardiotoxicity. Abnormal levels of NT-pro-BNP 
were frequently detected in asymptomatic, long-term survivors of childhood 
cancer, especially in survivors who received a cumulative anthracycline dosage 
of 300 mg/m2 or more and related to an increased LVIDd. Follow-up of these 
survivors is essential to answer the question whether NT-pro-BNP is an early 
marker for late-onset anthracycline-induced cardiotoxicity. 
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 Abstract
Myocardial strain imaging with 2-dimensional (2D) echocardiography is a 
relatively new non-invasive method to assess myocardial deformation. To determine 
the interobserver, intraobserver and intrapatient reliability scores, we evaluated 
myocardial strain measurements of ten asymptomatic survivors of childhood 
cancer. Ten patients were randomly selected out of a follow-up cohort of childhood 
cancer survivors. All ten patients underwent a transthoracic echocardiographic 
examination. Two-dimensional gray scale images were made in parasternal apical 
4-chamber, apical 2-chamber, mid-cavity short-axis and basal short-axis views. Off-
line analysis was performed using software for echocardiographic quantification 
(Echopac 6.1.0, GE Medical Systems, Horten, Norway). All echocardiographic 
studies were analyzed off line by three observers, separately (AM, GW, MP). A 
custom made software package was designed for averaging the strain curves of 
three consecutive cardiac cycles. Values of peak systolic strain, time-to-peak strain 
and time-to-end-systole of the different segments of the left ventricle were used 
for statistical analysis. Interobserver, intraobserver and intrapatient reliability were 
expressed as intraclass correlation coefficients (ICCs). Interobserver intraclass 
correlation coefficients (ICC’s) of peak strain, time to peak strain and time to aorta 
valve closure were generally good to very good in all views and segments, except 
for the 2 chamber view. Intraobserver ICC’s were rated as very good for almost 
all segments, except for the longitudinal peak strain values of the 2 chamber view. 
Intrapatient ICC’s were generally good for the 2 chamber, 4 chamber and mid-
cavity short axis views, but fair to moderate for the segments of the basal short axis 
view (SaxMV). 
We recommend to use the 4 chamber view for longitudinal peak strain values, 
and the basal and mid-cavity short axis views for radial and circumferential peak 
strain values. Furthermore, we strongly recommend to use the average of three 
cardiac cycles for peak strain values in clinical studies.
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1 Introduction
Myocardial strain imaging with 2-dimensional (2D) echocardiography is a 
relatively new non-invasive method to assess myocardial deformation [1]. It is 
considered to be less affected by tethering, translational artefacts and traction 
than Doppler measurements of myocardial velocities [2,3]. Tissue movement is 
estimated using frame-by frame image tracking. Ultrasound tissue images contain 
many small picture elements (speckles), natural acoustic markers, which move 
together with the tissue and do not change their pattern significantly in the time 
between the successive frames. In this way, displacement of tissue can be assessed 
in two dimensions for the whole image. Each speckle can be followed accurately 
during several consecutive frames. A different displacement between regions 
reflects deformation of the tissue by contraction or relaxation [3]. Strain is the 
change in size relative to its original size, i.e., the relative deformation. Regional 
deformation of the myocardium occurs in the three orthogonal directions: 
longitudinally, radially and circumferentially. Using 2D strain imaging, two of these 
components can be determined, depending on the used image plane. Myocardial 
Strain Imaging is still used only in an experimental setting and has not yet gained 
extensive clinical use. The first studies on reproducibility of this technique have 
been published [4-7]. We are currently evaluating the use of strain rate imaging 
(SRI) for the early detection of anthracycline-induced cardiotoxicity in a large 
study. To determine the interobserver, intraobserver and intrapatient reliability 
scores, we evaluated myocardial strain measurements of ten asymptomatic 
survivors of childhood cancer.
2 Methods
Study population
Ten patients were randomly selected out of a follow-up cohort of childhood 
cancer survivors. The criterion for selection was a successful and complete 
echocardiographic study without the presence of a structural heart disease or 
clinical heart failure. All ten patients were treated with anthracyclines (cumulative 
dose ranging from 50-450 mg/m2, median: 160 mg/m2) more than five years 
before the present study. The group included 5 males and 5 females. The age of the 
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patients ranged from 8 to 35 years (median: 23 years). This study was approved by 
the local Medical Ethical Committee and all patients gave their informed consent.
Echocardiographic study
All ten patients underwent a transthoracic echocardiographic examination in the 
left lateral position. Each examination was performed at rest, without sedation. 
Images were obtained with a 3.0-MHz and a 5.0-MHz transducer using a 
commercially available system, the Vivid 7 echographic scanner (GE, Vingmed 
Ultrasound, Horten, Norway) for all ten patients. Two-dimensional gray scale 
images were made in parasternal apical 4-chamber, apical 2-chamber, mid-cavity 
short-axis (at the level of the papillary muscle) and basal short-axis views. An 
sector scan angle of 30-60 degrees was chosen and frame rates of 70 Hz or more 
were used. Cine loops of three cardiac cycles triggered by the R wave of the QRS 
complex were digitally saved. Off-line analysis was performed using software for 
echocardiographic quantification (Echopac 6.1.0, GE Medical Systems, Horten, 
Norway). Separately, timing of aortic valve closure (AVC) and mitral valve opening 
(MVO) with respect to peak strain and peak systolic strain were obtained, using 
single gated pulsed Doppler or continuous wave (CW-) Doppler images. For these 
measurements, special care was taken to keep the heart rate in the same range as the 
2D strain gray-scale images. Time measurements were expressed as a percentage of 
the duration of the complete cardiac cycle. 
Myocardial segments were named and localized according to the statement 
of the Cardiac Imaging Committee of the Council on Clinical Cardiology of the 
American Heart Association [8]. Manual tracking of the endomyocardial borders 
was performed at the end-systolic frame. An automatic generation of the second 
epicardial tracing was created by the software. The software automatically divided 
the image into six segments. Quality of the tracking was verified of each segment 
and adjusted when needed. The three consecutive cardiac cycles were analyzed for 
each segment. Myocardial longitudinal, radial en circumferential strain values were 
obtained and peak strain values were measured. Strain values are dimensionless and 
are expressed in percentage. Examples of a longitudinal, radial and circumferential 
strain curve are shown in figure 4.1, 4.2 and 4.3, respectively. Strain curves of the 
three consecutive cardiac cycles and values of the manual timing were imported into 
a custom made software package for further analysis. Q-Q interval was selected on 
the ECG signal to obtain cardiac cycle length. It is known that the systolic phase 
of the cardiac cycle does not change much with the change in heart rate, in contrast 
to the diastolic phase [9]. Therefore, the diastolic phase of the three cardiac cycles
Anthracycline-induced cardiotoxicity
79
Figure 4.1 Longitudinal strain
(color version of this figure on page 193)
Figure 4.2 Radial strain
(color version of this figure on page 195)
Figure 4.3 Circumferential strain
(color version of this figure on page 197)
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was automatically extended and adjusted by the software package to the longest 
of the three cardiac cycles. This intervention prevents the shift of the peak systolic 
strain with normalizing of the three consecutive cardiac cycles. Cardiac cycles with 
a length more than ten percent different from the mean length of the three cardiac 
cycles were excluded for further analysis. Figure 4.4 shows an example of three 
imported strain curves (dotted lines) with the calculated average curve (straight 
line).
Figure 4.4 4CH, longitudinal strain
(color version of this figure on page 199)
Statistical analysis
The echocardiographic studies of all ten patients were analyzed off line by three 
observers (AM, GW, MP). The analysis was done individually and the observers 
were unaware of each other’s results. Interobserver reliability was calculated using 
the average values of three consecutive cardiac cycles. Intraobserver reliability was 
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obtained by analyzing the same ten patients again at a different time by one of 
the observers, again using the average values of three consecutive cycles (MP). 
Intrapatient reliability scores were obtained by one of the observers (AM), 
analyzing values of three consecutive cardiac cycles. All analyses were performed 
on absolute cycle times. The time of the systolic part of the heart cycle was assessed 
using the Q to AVC timing. The diastolic phase was adjusted when necessary.
Values of peak systolic strain, time-to-peak strain and time-to-end-systole of 
the different segments of the left ventricle were used for statistical analysis. The 
segments analyzed were the apical, mid and basal segments of the inferior (ApInf, 
MidInf and BasInf, respectively) and anterior wall (ApAnt, MidAnt and BasAnt, 
respectively) of the 2CH view, the apical, mid and basal segments of the septal 
(ApSept, MidSept and BasSept, respectively) and lateral wall (ApLat, MidLat 
and BasLat, respectively) of the 4CH view, the anterioseptal (AntSept) , anterior 
(Ant), lateral (Lat), posterior (Post), inferior (Inf ) and septal (Sept) segments 
of the basal and mid-cavity short axis views (SaxMV and SaxPM respectively). 
Interobserver, intraobserver and intrapatient reliability were expressed as intraclass 
correlation coefficients (ICCs) [10]. An ICC less than 0.20 is considered as poor 
agreement, between 0.21-0.40 as fair agreement, between 0.41-0.60 as moderate 
agreement, between 0.61-0.80 as good agreement and between 0.81-1.00 as very 
good agreement [11]. We decided to consider a myocardial segment with an ICC 
of more than 0.60 as acceptable for using it in further study.
In the interobserver reliability study, three sources of variation can be identified: 
variation between observers, variation between subjects and variation due to 
residual measurement error. These three sources of variability can be assumed to 
act independently from each other and can be quantified using so called variance 
components. With respect to the peak values of each view, we calculated, across the 
six segments, the percentage of variance explained by interobserver variability as 
100 times the between-observer variance divided the sum of the between-observer, 
between-subject and residual measurement variance. 
In the same manner we estimated in the intraobserver reliability study, across 
six segments and for each view, the percentage of variance in the peak value 
measurements explained by the intra-observer variance. Finally we did the same 
procedure with respect to intrapatient reliability study. These calculations were 
carried out using SAS (version 8.2), procedure PROC MIXED in which the 
segments were treated as fixed factors and the indicated sources of variability as 
random factors. 
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3 Results
Interobserver reliability
Interobserver reliability coefficients of peak strain, time to peak strain and time 
to AVC were generally good to very good in all views and segments, except for 
the 2 chamber view (table 4.1). Agreement between the three observers in the 2 
chamber view was moderate for the longitudinal peak strain values of the segments 
of the anterior wall and poor for the longitudinal peak strain values of the inferior 
wall. ICCs of all measured parameters of the 4 chamber view were good, except 
for the longitudinal peak strain values in the apex. In the short axis views, the 
agreement for circumferential peak strain values was better than for the radial peak 
strain values. ICC’s for peak strain values were moderate in some segments of the 
mid-cavity short axis view. ICC’s on timing were generally good to very good in all 
segments of all views. For the peak values, the percentages of variance explained by 
the inter-observer variability ranged from 0 to 5%.
Intraobserver reliability
Table 4.2 shows the ICC’s of the intraobserver reliability. The peak strain values are 
rated as very good for almost all segments, except for the longitudinal peak strain 
values of the 2 chamber view. Agreement on time-to-peak strain was very good for 
almost all segments in all views. Agreement on time-to-end-systole was moderate 
for the short axis views, and good for the 2CH and 4CH views. For the peak values, 
the percentages of variance explained by the intra-observer variability ranged from 
0 to 1.3%.
Intrapatient reliability
Intrapatient reliability scores are shown in table 4.3. Reliability of three consecutive 
cycles was generally good for the 2 chamber, 4 chamber and mid-cavity short axis 
views. Agreement was generally fair to moderate for the peak strain values, time 
to peak strain and time to end-systole of the segments of the basal short axis view 
(SaxMV). For the peak values, the percentages of variance explained by the intra-
patient variability ranged from 0 to 0.7%.
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Table 4.1 Interobserver reliability
2CH
ApAnt ApInf MidAnt MidInf BasAnt BasInf % of variance b
Peak SL (%) 0.49 a 0.56 0.47 0.17 0.17 0.14 4.4
Time to peak strain (%) 0.87 0.9 0.88 0.9 0.86 0.86
Time to end-systole (%) 0.94 0.95 0.94 0.94 0.94 0.94
4CH
ApLat ApSept MidLat MidSept BasLat BasSept
Peak SL (%) 0.69 0.58 0.75 0.76 0.72 0.87 0
Time to peak strain (%) 0.95 0.82 0.96 0.86 0.89 0.73
Time to end-systole (%) 0.93 0.8 0.85 0.81 0.85 0.81
SaxMV
AntSept Ant Lat Post Inf Sept
Peak SR (%) 0.82 0.68 0.77 0.77 0.69 0.75 3.3
Time to peak strain (%) 0.39 0.74 0.94 0.93 0.52 0.65
Time to end-systole (%) 0.9 0.9 0.9 0.92 0.9 0.9
Peak SC (%) 0.88 0.79 0.71 0.9 0.98 0.95 0
Time to peak strain (%) 0.85 0.91 0.64 0.48 0.59 0.94
Time to end-systole (%) 0.88 0.89 0.87 0.89 0.88 0.88
SaxPM
AntSept Ant Lat Post Inf Sept
Peak SR (%) 0.84 0.57 0.53 0.53 0.76 0.86 5.0
Time to peak strain (%) 0.85 0.76 0.97 0.93 0.97 0.73
Time to end-systole (%) 0.8 0.8 0.8 0.8 0.8 0.8
Peak SC (%) 0.83 0.81 0.79 0.83 0.96 0.87 0
Time to peak strain (%) 0.84 0.74 0.59 0.74 0.85 0.89
Time to end-systole (%) 0.8 0.8 0.8 0.8 0.8 0.8
a ICC’s were calculated using the average of three cycles.
b % of variance in measurements accounted for by interobserver variability. A value of zero can be interpreted as interobserver variability 
 that is negligible as compared with variability between subjects plus random measurement error. The theoretical maximum value is 100%.
Chapter 4  -  Interobserver, Intraobserver and Intrapatient reliability scores 
of myocardial strain imaging with 2-dimensional echocardiography in patients 
treated with anthracyclines
84
Table 4.2 Intraobserver reliability
2CH
ApAnt ApInf MidAnt MidInf BasAnt BasInf % of variance b
Peak SL (%) 0.65 a 0.79 0.22 0.36 0,00 0.46 0
Time to peak strain (%) 0.88 0.97 0.92 0.95 0.94 0.69
Time to end-systole (%) 0.67 0.72 0.67 0.67 0.67 0.67
4CH
ApLat ApSept MidLat MidSept BasLat BasSept
Peak SL (%) 0.81 0.88 0.95 0.94 0.79 0.89 0
Time to peak strain (%) 0.95 0.91 0.99 0.99 0.99 0.82
Time to end-systole (%) 0.76 0.76 0.76 0.76 0.76 0.76
SaxMV
AntSept Ant Lat Post Inf Sept
Peak SR (%) 0.92 0.87 0.78 0.86 0.63 0.79 0
Time to peak strain (%) 0.52 0.46 0.88 0.99 0.63 0.71
Time to end-systole (%) 0.36 0.4 0.4 0.35 0.4 0.4
Peak SC (%) 0.9 0.87 0.99 0.99 0.99 0.91 0
Time to peak strain (%) 0.99 0.92 0.84 0.99 0.79 0.97
Time to end-systole (%) 0.33 0.33 0.4 0.35 0.33 0.33
SaxPM
AntSept Ant Lat Post Inf Sept
Peak SR (%) 0.81 0.82 0.87 0.9 0.8 0.7 1,30
Time to peak strain (%) 0.99 0.99 0.99 0.91 0.97 0.99
Time to end-systole (%) 0.51 0.5 0.5 0.5 0.5 0.7
Peak SC (%) 0.93 0.97 0.92 0.96 0.93 0.93 0
Time to peak strain (%) 0.8 0.97 0.84 0.72 0.65 0.94
Time to end-systole (%) 0.57 0.57 0.57 0.57 0.57 0.57
a ICC’s were calculated using the average of three cycles.
b % of variance in measurements accounted for by intraobserver variability. A value of zero can be interpreted as intraobserver variability 
 that is negligible as compared with variability between subjects plus random measurement error. The theoretical maximum value is 100%.
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Table 4.3 Intrapatient reliability
2CH
ApAnt ApInf MidAnt MidInf BasAnt BasInf % of variance b
Peak SL (%) 0.84 a 0.94 0.75 0.76 0.46 0.68 0.2
Time to peak strain (%) 0.75 0.92 0.81 0.9 0.85 0.9
Time to end-systole (%) 0.88 0.95 0.89 0.95 0.88 0.94
4CH
ApLat ApSept MidLat MidSept BasLat BasSept
Peak SL (%) 0.89 0.94 0.56 0.73 0.42 0.87 0
Time to peak strain (%) 0.69 0.7 0.82 0.75 0.5 0.67
Time to end-systole (%) 0.91 0.82 0.9 0.82 0.9 0.82
SaxMV
AntSept Ant Lat Post Inf Sept
Peak SR (%) 0.82 0.49 0.63 0.55 0.69 0.77 0.6
Time to peak strain (%) 0.46 0.34 0.54 0.43 0.14 0.42
Time to end-systole (%) 0.25 0.25 0.25 0.24 0.27 0.28
Peak SC (%) 0.67 0.43 0.55 0.7 0.72 0.81 0
Time to peak strain (%) 0.64 0.57 0.26 0.35 0.26 0.2
Time to end-systole (%) 0.21 0.2 0.2 0.21 0.22 0.23
SaxPM
AntSept Ant Lat Post Inf Sept
Peak SR (%) 0.71 0.7 0.75 0.63 0.64 0.76 0.7
Time to peak strain (%) 0.21 0.93 0.93 0.89 0.84 0.9
Time to end-systole (%) 0.76 0.76 0.76 0.76 0.76 0.75
Peak SC (%) 0.99 0.97 0.91 0.78 0.92 0.98 0.3
Time to peak strain (%) 0.96 0.72 0.25 0.51 0.16 0.54
Time to end-systole (%) 0.76 0.76 0.76 0.76 0.76 0.75
a ICC’s were calculated using the average of three cycles.
b % of variance in measurements accounted for by intrapatient variability. A value of zero can be interpreted as intrapatient variability 
 that is negligible as compared with variability between subjects plus random measurement error. The theoretical maximum value is 100%.
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4 Discussion
Myocardial strain imaging using 2D tissue tracking is a promising method for 
automatic wall deformation assessment. In spite of its limitations (such as its 
sensitivity to signal noise), it has the advantage over conventional Tissue Doppler 
based strain imaging that a lower frame rate is required, that the strain estimates are 
not angle dependent and that strain in 2 dimensions is obtained. Myocardial strain 
imaging has been extensively validated with sonomicrometry [12] and magnetic 
resonance imaging [13]. The place of myocardial strain imaging in standard clinical 
practice remains to be defined [14]. However, there is a growing interest in using this 
new method in clinical studies concerning myocardial function in different patient 
groups. Results of myocardial strain imaging in patients treated with anthracyclines 
have recently been published by Ganame and colleagues [15-17]. They used the 
software package for echocardiographic quantification, Speqle 4 (Catholic University 
of Leuven, Belgium). To assess interobserver and intraobserver agreement, Ganame 
and colleagues used the 95% limit of repeatability. This measure quantifies the 
random error between two observers and does not estimate reliability. Other authors 
have used inter and intraobserver variabilities, determined by the mean of differences 
between paired strain measurements. The inter and intraobserver variabilities were 
substantial (10-13%) [4,5,7]. When we recalculated our data accordingly, we showed 
mean differences of 0-5% (data not shown).
Intraclass correlation coefficients (ICC’s) are designed to assess consistency or 
conformity between two or more quantitative measurements. It is a way to explain 
the random error in the context of the population in which the instrument is used. 
The randomly selected patients are a proper representative of our study population. 
A possible limitation is the relatively low number of patients included in the study.
Interobserver, intraobserver and intrapatient ICC’s for all segments of the 
standard 4-chamber, 2-chamber and short axis views have, to our knowledge, 
never been published before in healthy subjects or in anthracycline treated 
patients. Describing reliability scores for the different segments allows us to use 
them separately, only when the agreement is good. This, in turn, allows us to use 
the separate segments in studies looking for local myocardial damage, as might be 
expected in anthracycline-induced cardiotoxicity [18]. 
In our study, we have shown that myocardial strain imaging with 2D 
echocardiography can produce high interobserver and intraobserver reliability scores 
for almost all parameters, in almost all segments, in almost all views. We showed that 
interobserver and intraobserver reliability was poor to moderate in the 2-chamber 
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view. We do not have a definite explanation for this finding. Intrapatient reliability 
scores, obtained by calculating the agreement between three consecutive cardiac 
cycles, were generally good, but not for most items of the basal short axis view. This 
might be caused by the influence of the movement of the mitral valve to the image 
quality and the effect of breathing on the recordings, especially in children. 
We, therefore, recommend using the 4 chamber view for longitudinal peak strain 
values, and the basal and mid-cavity short axis views for radial and circumferential 
peak strain values. Furthermore, we strongly recommend using the average of three 
cardiac cycles for peak strain values in clinical studies. In this study, we showed 
that this method is reliable in the group of patients of our interest. Further study 
is warranted to assess the role of myocardial strain measurements in the early 
detection of anthracycline-induced cardiotoxicity.
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 Abstract
Background
The accurate evaluation of intrinsic myocardial contractility in children with or 
without congenital heart disease (CHD) has turned out to be a challenge. Two-
dimensional strain echocardiography or speckle tracking (2DSTE) appears to hold 
significant promise as a tool to improve the assessment of ventricular myocardial 
function. 
Aims
We aimed to estimate left ventricular myocardial systolic function with 2DSTE in 
a large cohort consisting of healthy children and young adults to establish reference 
strain values. 
Methods
Transthoracic echocardiograms were acquired in 195 healthy subjects (139 
children and 56 young adults) and were retrospectively analysed. Longitudinal, 
circumferential and radial peak systolic strain values were determined by means of 
speckle tracking. Non-linear regression analysis was performed to assess the effect 
of aging on these 2DSTE parameters. 
Results
There was a strong, statistically significant second order polynomial relation 
(P<0.001) between global peak systolic strain parameters and age. Global peak 
systolic strain values were lowest in the youngest and oldest age groups. 
Conclusion
This is the first report that establishes age dependent reference values per cardiac 
segment for myocardial strain in all three directions assessed with 2DSTE in 
a large pediatric and young adult cohort. We emphasize the need for using age 
specific reference values for the adequate interpretation of 2DSTE measurements.
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1 Background
Despite impressive developments in echocardiographic technology during the past 
fifty years, there are still important challenges which new techniques try to meet. One 
important, yet partially unresolved, challenge that remains is the quantification of 
ventricular myocardial function in children with congenital heart disease (CHD). 
Traditional methods, such as the one-dimensional M-mode technique (e.g., 
fractional shortening) and two-dimensional imaging (e.g., ejection fraction), are 
used to evaluate left ventricular function. However, these methods are not always 
applicable to pediatric hearts with complex congenital malformations. The cardinal 
reason for this is that they are based on geometric assumptions and overlook the 
complex characteristics of CHD [1]. Moreover, those current indices provide no 
information about regional alterations in ventricular myocardial contraction [2]. 
These disadvantages complicate the assessment of systolic and diastolic function in 
children with CHD and underscore the need for better quantitative techniques to 
assess ventricular function in this subset of patients.
New modalities, such as strain imaging, have been developed to address 
the previously mentioned shortcomings. Myocardial strain is a dimensionless 
assessment of regional ventricular deformation (i.e., a percentage of deformation), 
whereas myocardial strain rate (SR), which is a time derivate of strain, indicates 
the rate of deformation of a defined myocardial segment. Multiple studies have 
proven the accuracy and reliability of strain (rate) techniques in the assessment 
of (regional) ventricular myocardial function [3,4]. Moreover, these techniques 
appear to be able to detect sub-clinical myocardial dysfunction at an earlier stage 
when compared to conventional imaging modalities [5-7]. Several diagnostic 
imaging modalities to assess myocardial strain and strain rate have been developed 
in recent years. In addition to tagged magnetic resonance imaging (tagged MRI) 
and tissue Doppler imaging (TDI), a third method to determine myocardial strain 
was introduced some years ago. This relatively novel technique is based on two-
dimensional echocardiographic images, hence the name: two-dimensional strain 
echocardiography (2DSTE). It determines myocardial deformation by means 
of frame-by-frame tracking and motion analysis of speckles within the B-mode 
images using optical flow algorithms. Validation studies with tagged MRI and 
sonomicrometry in the adult population have provided the evidence that 2DSTE 
is a reliable method to determine ventricular myocardial function [3,4]. In spite 
of its limitations, such as sensitivity to noise, it has the advantage over TDI based 
strain imaging that the strain estimates are not angle-dependent and that strain is 
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obtained in two dimensions [4,8-11]. Intra- and inter-observer reliability scores 
have been established previously and are high for almost all parameters [12]. Since 
this novel technique could be easily accessible and applicable, and moreover is not 
based on geometric assumptions, it may serve as an important tool in the future 
evaluation of regional and global ventricular function in pediatric subjects with or 
without CHD. The establishment of normal values in a healthy pediatric cohort is a 
mandatory prerequisite for its use in evaluating (pathologic) changes in ventricular 
function. Data in this area are scarce and include only peak systolic strain in one or 
two directions [13,14]. For these reasons, we aimed at evaluating left ventricular 
myocardial strain in all three directions (longitudinal, circumferential and radial) 
assessed by means of 2DSTE in a large, healthy pediatric and young adult cohort 
to establish the 2DSTE reference values and to determine the influence of age and 
growth on these values.
2 Material and methods
Study population
Subjects that were routinely referred for echocardiographic evaluation of an 
asymptomatic, innocent heart murmur between 01-05-2005 and 01-11-2009 
were retrospectively analysed for their eligibility for inclusion in the study. All 
consecutive healthy subjects aged from birth to 40 years were identified from our 
echocardiographic database from the outpatient clinic at both the Children’s Heart 
Centre and the Adult Heart Centre, Nijmegen, the Netherlands. Patients with 
structural (congenital) heart disease or abnormal cardiac rhythm were excluded. 
Other exclusion criteria consisted of hypertension and/or chronic or recent acute 
illness. Demographic characteristics, including age and gender were collected at the 
time the echocardiographic study was performed. Informed consent was obtained 
from each participant. This study was approved by the local Medical Ethical 
Committee.
2DSTE Data acquisition:
A complete physical examination was performed, including weight, height and 
blood pressure measurements (see table 5.1). Subsequently, all subjects underwent 
a detailed transthoracic echocardiographic examination in the left lateral position 
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according to the recommendations of the American Society of Echocardiography 
[15]. Every examination was performed at rest, without using sedation. Images 
were obtained with a 3.0 MHz (S3) or a 5.0 MHz (S5) phased-array transducer 
using a commercially available system, the Vivid 7 echocardiographic scanner (GE, 
Vingmed Ultrasound, Horten, Norway). The choice for a S3 or a S5 transducer 
depended on the age and posture of the child. Two-dimensional multi-frame B-mode 
(grey scale) images were obtained in the apical 4-chamber (4C), and parasternal 
mid-cavity short-axis view (at the level of the papillary muscle: SaxPM) and 
parasternal basal short-axis view (at the level of the mitral valve: SaxMV). A sector 
scan angle of 30-60 degrees was chosen and frame rates of 70 – 90 Hz were used, 
since these rates are considered to be optimal for 2D speckle tracking [4,11,16]. 
Data were stored at the same frame rate as the acquisition frame rate. Preferably 
images from three cardiac cycles triggered by the R wave of the QRS complex were 
digitally saved in cineloop format. Off-line speckle tracking analysis was performed 
using software for echocardiographic quantification (EchoPAC 6.1.0, GE Medical 
Systems, Horten, Norway). Timing of aortic valve closure (AVC) and mitral valve 
opening (MVO) with respect to peak systolic strain were manually obtained, using 
single gated pulsed wave (PW-)Doppler or continuous wave (CW-) Doppler 
images of the left ventricle outflow tract. For these measurements, special care was 
taken to keep the heart rate in the same range as during the 2D grey-scale imaging 
used for 2D strain calculations. Endomyocardial borders of the left ventricle were 
manually traced within the end-systolic frame. The second, epicardial tracing was 
automatically generated by the computer algorithm, and when necessary, manually 
adjusted to cover the whole myocardial wall. The tracking algorithm then followed 
the myocardial speckles during the cardiac cycle. Tracking was only accepted if both 
visual inspection as well as the EchoPAC software indicated adequate tracking. This 
means that tracking of any given segment was only accepted when it was indicated 
with a green box. The software automatically divided the cross sectional image into 
six segments, which were named and identified according to the statement of the 
Cardiac Imaging Committee of the Council on Clinical Cardiology of the American 
Heart Association [17]. The left ventricle segments to be analyzed were the apical, 
mid and basal segments of the septal (ApSept, MidSept, BasSept, respectively) 
and the lateral wall (ApLat, MidLat, BasLat, respectively) of the 4C view, as well 
as the anterioseptal (AntSept), anterior (Ant), lateral (Lat), posterior (Post), 
inferior (Inf ) and septal (Sept) segments of the basal and mid-cavity short axis 
views. Strain curves of the three consecutive cardiac cycles and values of the manual 
timing were imported into a custom made software package for further analysis. 
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Q-Q interval was estimated from the ECG signal to obtain cardiac cycle length. 
It is known that the systolic phase of the cardiac cycle does not change much with 
small changes in heart rate, in contrast to the diastolic phase [18]. Therefore, the 
diastolic phase of the three cardiac cycles was automatically extended and adjusted 
by the software package to the longest of the three cardiac cycles. This intervention 
prevents a shift of the peak systolic strain while averaging the three consecutive 
cardiac cycles. Cardiac cycles with a length more than ten percent difference 
from the mean length of the three cardiac cycles were excluded from averaging 
and thus for further analysis. Myocardial longitudinal, radial and circumferential 
strain values were obtained. To determine global strain, the strain values of the six 
segments were averaged for the four chamber as well as the short axis views. Strain 
values are dimensionless and are expressed in percentage. Negative strain values 
reflect shortening, while positive strain values reflect lengthening/thickening. All 
offline measurements with EchoPAC were performed by a single observer (K.M.). 
Inter-observer and intra-observer variability was determined by measurement of 
left ventricular myocardial strain in 40 randomly selected subjects (5 in each age 
group). To assess intra-observer variability, the same observer (K.M.) measured 
the left ventricular segments again with an interval greater than two months to 
avoid recall bias. To assess inter-observer variability, strain measurements were 
performed by a second observer (M.B.) who was blinded to the results of the first 
observer (K.M.). Figure 5.1and 5.2 show an illustration of 2D strain imaging.
Table 5.1 Demographic and anthropometric characteristics (mean ± standard 
 deviation) of study subjects (n=195) categorized by age group
BSA Body surface area
BMI Body mass index
HR Heart rate
SysBP Systolic blood pressure
DiaBP Diastolic blood pressure
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Figure 5.1 Short-axis imaging at the level of the papillary muscle with segmentation 
 used for two-dimensional strain echocardiography (color version in chapter 11)
RV Right ventricle
LV Left ventricle
Sep Septal wall
Antsep Anterior septal wall
Ant Anterior wall
Lat Lateral wall
Post Posterior wall
Inf Inferior wall
Figure 5.2 Radial and circumferential strain and strain rate curves of the septal wall 
 at the level of the papillary muscle
(color version of this figure on page 201)
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Conventional echocardiographic parameters
Quantification of cardiac chamber size, ventricular mass and systolic and diastolic 
left ventricular function were measured in accordance with the recommendations 
for chamber quantification by the American Society of Echocardiography’s 
Guidelines and Standard Committee and the Chamber Quantification Writing 
Group [15]. The left ventricular systolic function was indicated using fractional 
shortening (FS), ejection fraction (EF), left ventricular myocardial performance 
index, or Tei index, end-systolic wall stress (ESWS) and rate corrected velocity 
of circumferential fiber shortening (VCFc). Ejection fraction (EF) was calculated 
using the modified Simpson’s rule. The PWD-derived myocardial performance 
index was calculated by adding the iso-volumetric contraction time (ICT) and the 
iso-volumetric relaxation time (IVRT) and dividing the sum by the ejection time 
(ET) [19]. Left ventricular end-systolic wall stress (ESWS) was calculated using 
the modified formula of Rowland [20]. Velocity of circumferential fiber shortening 
(VCFc) was calculated with the formula obtained from Colan and colleagues 
[21]. Left ventricular mass was calculated with the formula for estimation of left 
ventricular mass according to Devereux and was subsequently indexed by the body 
surface area (BSA) [22].
Statistical analysis
Patients were divided in eight different age groups (see table 5.1) for further 
analysis. All demographic, conventional echocardiographic and 2D strain values 
are expressed as mean ± standard deviation (SD). The relation between age and 
global strain parameters was reported using scatter plots, One Way Analysis of 
Variance (ANOVA) and second order polynomial regression analysis. Multiple 
linear regression analysis was performed to determine the additional effect of 
anthropometrics (including heart rate, weight and height) and conventional 
echocardiographic parameters on the myocardial global strain variables. 
Intra- and inter-observer agreement was calculated using Bland-Altman 
approach, including the calculation of mean bias (average difference between 
measurements), the statistical significance of the mean bias on paired t tests (the 
null hypothesis was zero bias), and the lower and upper limits of agreement (95% 
limit of agreement of mean bias). In addition, the coefficient of variation was 
determined (i.e., the standard deviation of the difference of paired samples divided 
by the average of the paired samples). A P-value less than 0.05 was considered 
to indicate significance. Statistical analyses were performed using the Statistical 
Package for Social Sciences for Windows, version 16.0 (SPSS Inc, Chicago, IL).
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3 Results
A total of 226 subjects were evaluated for inclusion in the study. Of those subjects, 
31 (13.7%) were subsequently excluded in light of incomplete echocardiographic 
data or suboptimal imaging quality. In total 195 healthy subjects (139 children and 
56 young adults) were enrolled in the study. Subject characteristics and anthropo-
metric parameters are described in table 5.1. Conventional echocardiographic 
parameters of the study subjects are presented in table 5.2. All standard 
echocardiographic findings were within previously described normal values. 
Myocardial strain parameters are presented in table 5.3 – 5.5 and figures 5.3 – 5.5. 
Tracking was feasible in 91% of all segments of the 4 chamber view, in 96% of all 
segments in the short axis view at the level of the papillary muscle and in 91% of all 
segments in the short axis view at the level of the mitral valve. 
The most striking observation was a quadratic relationship (P<0.001) between 
global peak systolic parameters and age. This means that global peak systolic strain 
values are lowest in the youngest and oldest age groups. In contrast to teens, which 
show the highest global peak systolic values. There were statistically significant 
differences (P<0.05) between most of the age groups for all global peak systolic 
parameters as assessed by means of the One Way Analysis of Variance with 
Bonferroni correction for multiple comparisons (table 5.3–5.5). A second order 
polynomial regression analysis revealed that age (together with (age)2) accounted 
for 37% of variation in global longitudinal peak systolic strain (R2=0.368; P<0.05). 
Age (and (age)2) accounted for 22% and 29% of variation in global circumferential 
peak systolic strain at the level of the papillary muscle (R2=0.222; P<0.05) and 
mitral valve (R2=0.293; P<0.05) respectively. In the radial direction, age (together 
with (age)2) accounted for 12% and 14% of variation in global radial peak systolic 
strain at the level of the papillary muscle (R2=0.117; P<0.05) and mitral valve 
(R2=0.142; P<0.05) respectively. 
The intra-observer and inter-observer variability results are shown in table 5.6. 
There were no important differences in variability scores between the various age 
groups or various segments. 
Multiple linear regression analyses among the anthropometric and standard 
echocardiographic parameters were performed to determine the additional effect 
of these parameters on the myocardial global strain variables (table 5.7). Of 
these parameters, only VCFc and LVETc appear to be significantly associated 
with global strain values after adjustment for age. VCFc was associated with 
global circumferential strain (P<0.05). One unit (i.e., circ/sec) increase of 
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VCFc goes along with 1.5 units (i.e., percent) decrease of global circumferential 
peak systolic strain at the level of the papillary muscle (95% CI: 0.3 - 2.8) and 
1.7 units (i.e., percent) decrease of global circumferential peak systolic strain at 
the level of the mitral valve (95% CI 0.5 – 2.9). LVETc was associated with both 
global circumferential and global longitudinal peak systolic strain (P<0.05). One 
millisecond increase of LVETc goes along with 0.015 units (i.e., percent) decrease 
of global longitudinal peak systolic strain (95% CI: 0.006 - 0.023). As with global 
peak systolic circumferential strain, one millisecond increase of LVETc goes along 
with 0.05 percent decrease of global peak systolic circumferential strain at the level 
of the papillary muscle (95% CI: 0.034 - 0.067) and 0.024 percent decrease at the 
level of the mitral valve (95% CI: 0.009 - 0.039). No gender-based differences were 
present. Figure 6a and 6b illustrate peak systolic strain in longitudinal direction 
versus some of the key morphometric variables.
Table 5.2 Conventional echocardiographic parameters (mean ± standard deviation) 
 of study subjects (n=195) categorized by age group
LVET Left ventricular ejection time
LVETc LVET corrected for heart rate
VCFc Heart-rate corrected velocity of circumferential fiber shortening
FS Fractional shortening
EF biplane Ejection fraction measured by modified Simpson’s method
ESWS End-systolic wall stress
LV mass/BSA Left ventricular mass corrected for body surface area
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Table 5.6 Intraobserver and interobserver variability of global peak systolic strain
Variable Bias LLA ULA CV
Intra-observer
Global S-L 0.03 -2.89 2.95 7.15
Global S-CP -0.39 -3.51 2.74 7.22
Global S-CM -0.02 -3.19 3.14 7.89
Global S-RP -0.32 -10.01 9.36 8.91
Global-S-RM -0.23 -9.19 8.73 8.52
Inter-observer
Global S-L -0.04 -3.35 3.27 8.12
Global S-CP 0.46 -3.61 4.54 9.44
Global S-CM -0.09 -4.52 4.34 11.04
Global S-RP -0.39 -14.78 14.01 13.22
Global-S-RM 0.28 -13.21 13.78 12.83
Global S-L Global peak systolic longitudinal strain
Global-S-CP Global peak systolic circumferential strain at the level of the papillary muscle
Global-S-CM Global peak systolic circumferential strain at the level of the mitral valve
Global-S-RP Global peak systolic radial strain at the level of the papillary muscle
Global-S-RM Global peak systolic radial strain at the level of the mitral valve
Bias Mean difference between paired measurements
LLA 95% lower limit of agreement
ULA 95% upper limit of agreement
CV Coefficient of variation
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Table 5.7 Coefficient of determination R2
Outcome variable
Predictors GlobalSL GlobalSCP GlobalSCM GlobalSRP GlobalSRM
Age//Age2   0.37 e   0.22 e   0.29 e   0.12 e   0.14 e
Age//Age2 // LVETc   0.41 b   0.25 b   0.34 c 0.12 0.14
Age//Age2 // VCFc 0.37   0.24 b   0.31 b 0.12 0.14
Age//Age2 // Tei index 0.37 0.23 0.29 0.12 0.14
Age//Age2 // FS 0.38 0.22 0.29 0.12 0.14
Age//Age2 // EF biplane 0.37 0.22 0.29 0.13 0.14
Age//Age2 // ESWS 0.38 0.23 0.29 0.12 0.14
Age//Age2 // LVIDs 0.37 0.22 0.29 0.12 0.14
Age//Age2 // LVIDd 0.37 0.22 0.30 0.12 0.14
Age//Age2 // LVEDV 0.38 0.23 0.29 0.12 0.15
Age//Age2 // HR 0.37 0.22 0.30 0.12 0.14
Age//Age2 // weight 0.38 0.22 0.29 0.12 0.15
Age//Age2 // height 0.38 0.22 0.29 0.12 0.14
Age//Age2 // BMI 0.37 0.22 0.29 0.12 0.14
Age//Age2 // BSA 0.37 0.22 0.30 0.12 0.15
Final Model g   0.41 b   0.28 d   0.37 d   0.12 e   0.14 e
Predictors used in
Final Model f
Age//Age2    
(P<0.0001)
LVETc
(P=0.001)
Age//Age2
(P<0.0001)
LVETc
(P<0.001)
VCFc
(P=0.025)
Age//Age2
(P<0.0001)
LVETc
(P<0.001)
VCFc
(P=0.031)
Age//Age2
(P<0.0001)
Age//Age2
(P<0.0001)
Each R2 is based on the linear model that uses all subjects with known values for all predictors used in that particular model. 
a P<0.05; b: P<0.01; c: P<0.001; d: P<0.0001; e: P < 0.0001
a, b, c, d P-value based on partial F-test comparing model with indicated predictors to model using only age and age2 as predictors
e P-value based on global F-test for linear model using age and age2 as predictors
f P-values based on partial F-test comparing the Final Model to the model based on all variables in Final Model minus the 
 variable of concern
g The Final Model uses as predictors age and age2 and the variables that contribute significantly over age and age2, as shown 
 in the upper part  of the table, and remained significant in multivariable analysis. 
Predictors:
LVETc LV ejection time corrected for heart rate
VCFc heart-rate corrected velocity of circumferential fiber shortening
FS fractional shortening
EF biplane Ejection fraction measured by modified Simpson’s method
ESWS End-systolic wall stress
LVIDs LV internal diameter during systole
LVIDd LV internal diameter during  diastole
LVEDV LV end diastolic volume
HR Heart rate
BMI Body mass index
BSA Body surface area
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Figure 5.3 Global peak systolic longitudinal strain versus age among study subjects
 (scatter plot)
GlobalSL Global longitudinal peak systolic strain (%)
Age (years) lines indicate: regression line (mean) in the middle and 95% individual prediction interval
Figure 5.4 Midventricular global peak systolic circumferential strain versus age 
 among study subjects (scatter plot)
GlobalScP Global peak systolic circumferential strain at the level of the papillary muscle (%)
Age (years) lines indicate: regression line (mean) in the middle and 95% individual prediction interval
Figure 5.5 Midventricular global peak systolic radial strain versus age 
 among study subjects (scatter plot)
GlobalSRP Global peak systolic radial strain at the level of the papillary muscle (%)
Age (years) lines indicate: regression line (mean) in the middle and 95% individual prediction interval
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Figure 5.6a Global peak systolic longitudinal strain versus various morphometric variables 
 among study subjects (scatter plot)
Figure 5.6b Global peak systolic longitudinal strain versus various morphometric variables 
 among study subjects (scatter plot)
Scatterplots with locally-weighted line smoothers (loess regression lines) to indicate curved linear relationships
GlobalSL Global longitudinal peak systolic strain (%)
LV_mass Left ventricular mass (g)
LV_mass_BSA Left ventricular mass corrected for body surface area (g/m2)
LVEDV Left ventricular end diastolic volume (ml)
LVESV Left ventricular end systolic volume (ml); height (m)
BSA Body surface area (m2)
HR Heart rate (bpm)
EF_biplane Left ventricular ejection fraction (%).
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4 Discussion
 
Reference values for 2D strain echocardiography measurements in the pediatric 
and young adult population are scarce. Two previously published reports have 
focused on this subject. Lorch et al. investigated 2D strain echocardiography in 
a large healthy pediatric population [14]. This study provided us reference values 
for 2D longitudinal strain outcomes, however circumferential and radial strain 
measurements were not included. Bussadori et al. described reference values for 
circumferential and longitudinal strain and strain rate measurements in a small 
pediatric (n=15) and adult (n=30) population [13]. Data on circumferential 
and radial 2D strain measurements in a large healthy pediatric and young adult 
population, to establish their reference values and investigate the influence of age 
on them, were still lacking. The present study collected 2D strain echocardiography 
data in different left ventricular wall segments and in all three directions, 
longitudinal, radial and circumferential, in a large healthy cohort consisting of 
children and young adults. Our findings are in disagreement with the previous 
study performed by Lorch et al. that showed a relative invariability of longitudinal 
peak systolic strain with age [14]. Regression analysis performed on our data 
showed a strong, statistically significant relationship between age and global peak 
systolic strain values in all directions. Subjects on both ends of the age spectrum 
display the lowest peak systolic strain values in contrast to teenagers, whose strain 
values are significantly higher. In several previous studies the growth and function 
of the human heart was analyzed by means of echocardiography and ergometry, 
which gave evidence for an increase in cardiac contractility during puberty [23,24]. 
Increased cardiac contractility is probably one of the most important factors that 
enable a substantial increase in physical working capacity during puberty [25]. The 
systolic thickness of ventricular walls increases disproportionally when related to 
the rise in afterload during pubertal development. With this observation, it seems 
that cardiac systolic function prepares a reserve, probably for future increase in 
myocardial energy expenditure due to an increase in functional working capacity. 
The same relationship between age on one hand and left ventricular mass (LVM) on 
the other has been reported in healthy, normotensive humans. A study performed 
by Cain et al. identified age as the major determinant of LVM in healthy subjects 
[26]. LVM strongly increased when children reached pubertal age and subsequently 
declined during adult life to a level that is approximately 80% of early adulthood 
despite increasing blood pressure and exercise activity with increasing age in their 
study population. The underlying biological trigger which causes the sudden surge 
Anthracycline-induced cardiotoxicity
109
in cardiac contractility and LVM has not been identified. A possible explanation 
could be a physiological response as an adaptation process to an increased oxygen 
demand due to an increasing body mass and functional working tasks. Other factors, 
such as genetic and hormonal factors should also be considered. There is evidence 
that hormones, such as growth hormone and sex hormones, whose concentrations 
surge during puberty, influence cardiac growth and systolic function [27-35]. A 
remarkable result of our study was the observation of low global peak systolic 
strain values in infants. Previous reports have not reached consensus on the cardiac 
contractile state in this age group when compared to older children. Some conclude 
that newborn infants have a higher basal contractile state that cannot be accounted 
for completely by a lower afterload [36-38]. Pena et al., for instance, found higher 
peak systolic radial and longitudinal strain assessed by means of TDI in healthy 
neonates during their first day of life when compared to a second measurement at 
the age of one month [39]. Others have reported lower TDI velocities in infants 
when compared with older children, which is in accordance with the results of 
invasive animal studies [40]. These studies describe a lower myocardial contractile 
state in the newborn age group [41]. Besides lower global systolic strain results, 
we also found a greater range of variation in the youngest age group in comparison 
with older subjects. This variation could be explained by a previously reported 
greater sensitivity of myocardial performance to changes in afterload [38]. Indeed 
several important hemodynamic changes occur during early neonatal life. Preload 
increases due to the closure of the ductus arteriosus with subsequent increase of 
pulmonary blood flow. A postnatal increment in afterload is related to the removal 
of the low-resistance placental circulation and increased systemic arterial blood 
pressure. When taking these alterations in loading conditions into account it seems 
likely that they exert at least some influence on myocardial deformation. Therefore 
it is important to note that our study population did not include infants below the 
age of 1 month. Besides hemodynamic and other biological factors, it is possible 
that (part) of the large variations in myocardial strain in neonates reflect a technical 
shortcoming of 2DSTE analysis. Thin LV walls of infants with small absolute 
deformation distances could be more susceptible to error. 
After adjustment for age, of the anthropometric and conventional echo-
cardiographic parameters tested in this study only VCFc and LVETc appear to 
be significantly associated with global strain values. Unlike the study by Lorch et 
al., we did not find a strong relation between cardiac size (e.g., left ventricular end 
diastolic volume) and peak systolic strain parameters [14]. Although our findings 
did not indicate one specific antropometric or hemodynamic variable that explains 
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the observed differences in myocardial deformation between the various age groups, 
it is likely that each individual morphometric variable (and their alterations during 
growth and development) contributes to the overall changes in peak systolic strain 
which we have observed. 
Our results indicate a significant gradient of deformation from base to apex for 
longitudinal strain in the left ventricular septum and lateral free walls. In addition, 
circumferential and radial strain increased from base to mid-ventricle as well. These 
findings are in agreement with those of Bussadori et al. [13]. However, considering 
that in this latter study a different 2D strain method was used that analyzed only 
the left side of the septum for longitudinal strain and only the subendocardial layer 
for circumferential strain, it is interesting to observe that in our study population 
this base to apex gradient is significant even using speckle tracking that uses kernels 
distributed throughout the whole thickness of the myocardial wall and septum. In 
previous studies, different imaging techniques have given variable results regarding 
the uniformity of left ventricular strain from base to apex. Tagged MRI and 2DSTE 
studies reported higher strain in the apex, in contrast to tissue velocity imaging 
reports which did not show significant variation from base to apex [42-45]. The 
latter could be a reflection of the implications of the angle of insonation on apical 
measurements when using TDI. In addition to technical factors contributing to 
the base to apex gradient of deformation, we consider it is possible that there exists 
a physiological substrate in which the base to apex gradient is the result of the 
torsional mechanism of the left ventricular system and the direction of contraction 
of the descending fibers in the internal loop of helical ventricular myocardial band. 
5 Limitations
This study is limited by its retrospective nature. Our study population did not 
include infants below the age of 1 month. Furthermore, the dependence of 2DSTE 
on frame-by-frame tracking of the myocardial pattern makes it dependent on 
image factors including reverberation artifacts and attenuation. Indeed, technical 
proficiency remains important in image processing. Also, we did not investigate 
radial and circumferential strain at the apical level of the left ventricle. Comparison 
with an independent external technique, such as tagged MRI, was not performed 
in the current study, primarily because the validation of speckle-tracking software 
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has already been compared with MRI previously [46,47]. Overall, the variability 
of radial peak systolic strain measurement was higher when compared to 
circumferential and longitudinal measurement, which is in accordance with another 
study [48]. However, the reproducibility of peak systolic strain measurements in 
all three directions of deformation (expressed by intra-observer and inter-observer 
variability scores) was somewhat higher when compared to this previous report. 
In addition, we used custom made software which is not commercially available. 
The custom made software was specially developed to improve the estimation of 
timing of peak systolic strain measurements while averaging strain curves, as well 
as to include peak systolic strain measurements which occur (shortly) before aortic 
valve closure. Although the custom made software is not commercially available, 
this method can be implemented in generally available software such as Matlab.  
6 Conclusion 
With this study, we present age specific reference values for 2D strain 
echocardiography parameters which are essential for its use in evaluating 
(pathologic) changes in ventricular myocardial function. This study shows that age 
is a major determinant of peak systolic strain values in healthy subjects and therefore 
emphasizes the need for age specific reference values for adequate interpretation of 
2DSTE measurements. 
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 Abstract
We studied the role of global myocardial strain and strain rate in monitoring 
subclinical heart failure in a large group of asymptomatic long-term survivors of 
childhood cancer. Global strain (rate) parameters of survivors were compared 
to those in healthy controls and were related to conventional echocardiographic 
parameters, N-terminal-pro-natriuretic peptide (NT-pro-BNP) levels and clinical 
parameters. 2D-echocardiography was performed in 111 survivors and 107 
healthy controls. Blood samples were taken from survivors to determine NT-pro-
BNP levels. We showed that global myocardial strain, strain rate and time to peak 
systolic strain in asymptomatic survivors of childhood cancer were significantly 
lower compared to healthy controls (p-values <0.0001) and were significantly 
related to several systolic and diastolic left ventricular parameters. Whether 
myocardial strain and strain rate are superior to conventional echocardiography 
in the early detection of subclinical heart failure needs to be explored in further 
longitudinal prospective studies.
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1 Introduction
Late-onset anthracycline-induced cardiotoxicity is a well known late effect of 
treatment of childhood cancer. Subclinical heart failure occurs in up to 65% of 
asymptomatic survivors of childhood cancer [1]. Newer techniques, such as 
myocardial strain imaging and biomarkers still have to prove their prognostic value 
in the early detection of anthracycline-induced cardiotoxicity [2, 3]. 
Myocardial strain imaging with 2D echocardiography is a relatively new non-
invasive method to assess myocardial deformation [4]. Strain is the change in size 
relative to its original size, i.e. the relative deformation. Myocardial strain imaging is 
now increasingly used in clinical studies [5-9]. Recently, we showed that in a group 
of asymptomatic survivors of childhood cancer, myocardial strain imaging with 2D 
echocardiography can produce scores with high interobserver, intraobserver and 
intrapatient reliability [10]. Two studies so far have demonstrated that myocardial 
longitudinal strain and strain rate are decreased directly after anthracycline therapy 
for childhood malignancies and in asymptomatic survivors of childhood cancer 
[11, 12]. Two studies in adults showed reduction in myocardial strain and strain 
rate directly after anthracyline therapy and after a short follow-up of 18 months [7, 
13]. However, the long-term effect of anthracycline-induced cardiotoxicity was not 
investigated using myocardial strain (rate) imaging.
The role of biomarkers in the early detection of anthracycline-induced 
cardiotoxicity in children was recently reviewed, showing that brain natriuretic 
peptide (BNP), NT-pro-BNP and cardiac troponin T (cTnT) might be useful 
markers in the early detection of anthracyline-induced cardiotoxicity [14,15]. In a 
large cohort study, we showed that cTnT did not contribute to the early detection 
of late-onset anthracyline-induced cardiotoxicity in asymptomatic survivors of 
childhood cancer. On the other hand, abnormal levels of NT-pro-BNP were 
detected in 13% of 122 asymptomatic long-term survivors of childhood cancer and 
were related to left ventricular internal diameter in end-diastole indexed by body 
surface area (LIVDd/BSA) [16]. 
In this present study, we aim to determine the role of global myocardial 
strain and strain rate in monitoring subclinical heart failure in a large group of 
asymptomatic long-term survivors of childhood cancer. Myocardial global strain 
and strain rate parameters of survivors are compared to healthy controls and 
related to conventional echocardiographic parameters, N-terminal-pro-natriuretic 
peptide (NT-pro-BNP) levels and clinical parameters in the survivors.
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2 Patients and methods
Study population
All consecutive survivors of childhood cancer, who visited the Late Effects Clinic 
from May 2006 till October 2008 and who received anthracyclines as part of 
their therapy for various kinds of malignancies more than five years earlier, were 
included in our study if adequate gray scale images were available from their 
echocardiographic study. We considered the sum of doxorubicin and daunorubicin 
as cumulative anthracycline dosage. Survivors were excluded if they had clinical 
heart failure, as defined by the New York Heart Association classification (NYHA, 
class II-IV) [17], a history of cardiovascular disease or chronic renal insufficiency. 
The survivors gave informed consent and the study was approved by the local ethics 
committee. Medical information was obtained by record view. As a control group, 
we included 107 healthy controls that were routinely referred for echocardiographic 
evaluation of an asymptomatic, innocent heart murmur or for screening purposes 
between May 2005 and November 2009. All consecutive healthy subjects aged 
from birth to 40 years were identified from our echocardiographic database from 
the outpatient clinic at the Children’s Heart Centre and the Adult Heart Centre, 
Nijmegen, the Netherlands. Patients with structural (congenital) heart disease 
or abnormal cardiac rhythm were excluded. None of the healthy controls used 
any sort of medication. All were free from (a past history of ) chronic or acute 
(potentially) serious illness. History, electrocardiogram, and echocardiogram were 
not indicative of cardiac disease. 
All survivors and controls underwent a complete physical examination, 
electrocardiography (ECG) and a detailed echocardiography. 
Echocardiographic study
All study survivors and controls underwent a transthoracic echocardiography in 
left lateral position. The echocardiograpic study was performed by experienced 
echocardiographic technicians and supervised by (pediatric) cardiologists, who 
were unaware of the cumulative anthracycline dosage and the levels of NT-pro-
BNP in the survivors group. Each study was performed at rest, without sedation. 
Images were obtained with a 3.0-Mz and a 5.0-MHz transducer, depending on 
the age and weight of the study subjects, using a commercially available system, the 
Vivid 7 echographic scanner (GE, Vingmed Ultrasound, Horten, Norway). Special 
attention was given to make sure that the frame rate was between 70 and 100 
frames per second (fps). Quantification of cardiac chamber size, ventricular mass 
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and systolic and diastolic left ventricular function were measured in accordance 
with the recommendations for chamber quantification by the American Society 
of Echocardiography’s Guidelines and Standard Committee and the Chamber 
Quantification Writing Group [18]. An M-mode echocardiogram was performed 
in the parasternal long and short axis views to measure the internal dimensions of 
the left ventricle at end-systole and end-diastole (LVIDs, LVIDd), the posterior 
and the septal wall thickness at end-diastole (LVPWd, IVSd). Measurements of 
left ventricular dimensions and left ventricular mass (LVM) were indexed by body 
surface area (BSA). The left ventricle systolic function was indicated using fractional 
shortening (FS), ejection fraction (EF), rate corrected velocity of circumferential 
fiber shortening (VCFc) and end-systolic wall stress (ESWS). FS was obtained by 
dividing LVIDd minus the LVIDs through LVIDd times 100%. Ejection fraction 
was calculated using the modified Simpson’s rule. Left ventricular end-systolic 
wall stress (ESWS) was calculated using the modified formula of Rowland [19]. 
Velocity of circumferential fiber shortening (VCFc) was calculated via the formula 
obtained from Colan and colleagues [20]. Left ventricular diastolic function was 
indicated using E/A ratio, isovolumic relaxation time and E/E’ ratio. The ratio 
of early (E) to late atrial (A) mitral Doppler peak flow velocity (E/A ratio) was 
obtained by pulse Doppler at the mitral valve inflow. The isovolumic relaxation 
time (IVRT) was identified as the interval between the closure of the aortic valve 
and the opening of the mitral valve [21]. Peak early diastolic myocardial velocity 
(E’) was measured at the basal segment of the lateral left ventricular wall [22]. Left 
ventricular mass was calculated with the formula for estimation of left ventricular 
mass according to the formula of Devereux [23]. 
Two-dimensional gray scale images were made in parasternal apical 4-chamber, 
apical 2-chamber, mid-cavity short-axis (at the level of the papillary muscle) and 
basal short-axis views. A sector scan angle of 30-60 degrees was chosen and frame 
rates of 70 Hz or more were used. Cine loops of three cardiac cycles triggered 
by the R wave of the QRS complex were digitally saved. Off-line analysis was 
performed using software for echocardiographic quantification (Echopac 6.1.0, 
GE Medical Systems, Horten, Norway). Separately, timing of aortic valve closure 
(AVC) and mitral valve opening (MVO) with respect to peak strain and peak 
systolic strain were obtained, using single gated pulsed Doppler or continuous 
wave (CW-) Doppler images. These images were acquired just after the 2D strain 
gray-scale images and special care was taken to keep the heart rate in the same 
range. Time measurements were expressed as a percentage of the duration of the 
complete cardiac cycle.
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Myocardial segments were named and localized according to the statement 
of the Cardiac Imaging Committee of the Council on Clinical Cardiology of the 
American Heart Association [24]. Manual tracking of the endomyocardial borders 
was performed at the end-systolic frame. An automatic generation of the second 
epicardial tracing was created by the software. The software automatically divided 
the image into six segments. Quality of the tracking was verified for each segment 
and adjusted when needed. The three consecutive cardiac cycles were analyzed 
for each segment. Figure 6.1 shows a composite figure with the region of interest 
(left side) and graphic depiction of longitudinal strain in 4-chamber long axis view. 
Strain values are dimensionless and are expressed in percentage. Strain rate is the 
temporal derivative of strain and is expressed as 1/s. Strain curves of the three 
consecutive cardiac cycles and values of the manual timing were imported into 
a custom made software package for further analysis. Q-Q interval was selected 
on the ECG signal to obtain cardiac cycle length. It is known that the systolic 
phase of the cardiac cycle is relatively constant if heart rate changes less than ten 
percent, in contrast to the diastolic phase [25]. Therefore, the diastolic phase of 
the three cardiac cycles was automatically extended and adjusted by the software 
package to the longest of the three cardiac cycles. This intervention prevents the 
shift of the peak systolic strain with normalizing of the three consecutive cardiac 
cycles. Cardiac cycles with a length more than ten percent different from the mean 
length of the three cardiac cycles were excluded for further analysis. The average 
values of peak systolic longitudinal, radial and circumferential strain and strain 
rate of the three imported curves were calculated by the custom made software. 
Global longitudinal myocardial strain (globalSL) and strain rate (globalSrL) were 
calculated by averaging the six segments of the 4-chamber long-axis view. Global 
radial and circumferential myocardial strain (global SR, global SC) and strain rate 
(globalSrR, globalSrC) were calculated by averaging the six segments of the mid-
cavity short-axis view. We recently showed that myocardial strain imaging with 
2D echocardiography can produce scores with high interobserver, intraobserver 
and intrapatient reliability in a group of asymptomatic long-term survivors of 
childhood cancer [10].
Biochemical analysis
Blood samples from the survivors were obtained by venous puncture. Routine 
blood chemistry was performed in all survivors. Ethylenediaminetetraacetic acid 
(EDTA) blood was stored on ice for determination of NT-pro-BNP. NT-pro-
BNP was measured using an electrochemiluminescence immunoassay. It was 
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performed with the Modular E, using the NT-pro-BNP kit (Roche Diagnostics, 
Mannheim, Germany). Normal values for adults were different for males (< 10 
pmol/l) and females (<18 pmol/l) (cut-off 97.5th percentile) [26]. For normal 
values of children, we used the age-dependent reference values by Albers and 
colleagues (cut-off 97.5th percentile) [27]. The echocardiographic study and the 
blood sampling for biomarker estimation were performed at the same time.
Figure 6.1
(color version of this figure on page 203)
Statistical analysis
Characteristics of the study population as age at study, BSA, systolic and diastolic 
blood pressure, follow-up duration, age at diagnosis and cumulative anthracycline 
dosage were summarized by using median and range. 
Conventional echocardiographic and strain (rate) parameters were expressed 
by using mean and standard deviation. Differences between survivors and controls 
were studied using the t-test with Satterthwaite correction. We applied Bonferroni 
correction in order to correct for multiple testing.
The relation between global SL, global SR, global SC, global SrL, global SrR, 
global SrC, time to peak global SL, time to peak global SR and time to peak global 
SC measurements and conventional echocardiographic parameters of the survivors 
was studied using Spearman’s rank correlation. The relation between global SL, 
global SR, global SrL and global SrR and the different clinical parameters was 
studied using the independent t-test and linear regression. 
Statistical analyses were performed using the Statistical Package for Social 
Sciences (SPSS) for Windows, version 16.0. A p-value less than 0.05 was 
considered to indicate significance. 
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3 Results
Characteristics of the study population
One hundred and eleven asymptomatic survivors of childhood cancer met our 
inclusion criteria and were included in this study. None of the survivors had a 
history of acute cardiotoxicity immediately following an anthracycline dosage. 
One hundred and seven healthy controls were included. Table 6.1 shows the 
characteristics of the study population. Both survivors and healthy controls are 
comparable regarding demographic parameters.
Feasibility
In the survivors group, we were able to measure global SL and SrL in 83%, global 
SR and SrR in 80% and global SC and SrC in 75%. In 96% of global SL and 
SrL, 98% of global SR and SrR and 99% of global SC and SrC, all segments were 
adequate prior to analysis. In the control group, we were able to measure global 
SL and SrL in 98%, global SR and SrR in 96% and global SC and SrC in 96%. In 
respectively 93% of global SL and SrL, 100% of SR and SrR and 100% of SC and 
SrC, all segments were adequate prior to analysis. 
Asymptomatic survivors of childhood cancer compared to healthy controls
Table 6.2 shows the conventional echocardiographic and strain (rate) parameters 
of the asymptomatic survivors of childhood cancer and the healthy controls. 
Conventional echocardiographic parameters of the group of long-term 
asymptomatic survivors of childhood cancer were all, except LIVDd/BSA, 
VCFc, E/A ratio and E/E’ratio, lower compared to healthy controls (p-values 
<0.0001). Myocardial global strain and strain rate and time to peak systolic strain 
of asymptomatic survivors were also significantly lower than those of the healthy 
controls (p-values <0.0001). 
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Table 6.1 Characteristics of the study population
     Survivors   Controls
Number (N)    111   107
Male gender (%)    57 (51%)   61 (57%)
Median age at study, years (range)  20 (5.6-37.4)  18 (5.2-39.8)
Median BSA (m2)    1.65 (0.76-2.45)  1.75 (0.72-2.38)
Median systolic blood pressure (mmHg)  117 (80-174)  120 (90-154)
Median diastolic blood pressure (mmHg) 67 (40-95)  60 (45-90)
Median follow-up, years (range)  13.2 (5.0-29.2)  –
Median age at diagnosis, years (range)  4.8 (0.03-16.9)  –
Median cumulative anthracycline dosage, 180 (50-600)  –
 mg/m2 (range)    
 < 120 mg/m2 (N)   20
  120-300 mg/m2 (N)   51
  > 300 mg/m2 (N)   40
Diagnosis (N)
 ALL    30
 AML    9
 Ependymoma   1
 Ewing Sarcoma   4
 Hepatoblastoma   5
 Hodgkin’s disease   12
Nasopharyngeal carcinoma  1
Neuroblastoma   8
 NHL    19
Osteosarcoma   3
Rhabdomyosarcoma  7
 Wilm’s tumour   12
 
Mediastinal radiation (n)   7
BSA Body Surface Area
ALL Acute Lymphoblastic Leukemia
AML Acute Myeloid Leukemia
NHL Non-Hodgkin Lymphoma
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Table 6.2 Conventional echocardiographic and strain (rate) parameters
    Survivors  Controls  p-value 
    N=111  N=107
Echocardiographic parameters (mean ± SD)
EF (%)    61 ± 6  71 ± 6  <0.0001
FS (%)    35 ± 4  38 ± 5  <0.0001
LIVDd/BSA (cm/m2)  3.2 ± 0.6  3.1 ± 0.7  0.49
IVSd/BSA (cm/m2)   0.37 ± 0.10 0.42 ± 0.08 <0.0001
LVPWd/BSA (cm/m2)  0.40 ± 0.09 0.47 ± 0.10 <0.0001
LVM/BSA (g/m2)   56 ± 14  69 ± 18  <0.0001
VCFc (circ/s)   1.16 ±0.15  1.23 ± 0.32 0.07
ESWS (g/m2)   72 ± 22  44 ± 12  <0.0001
IVRT (ms)   72 ± 14  62 ± 10  <0.0001
E/A ratio    1.9 ± 0.6  2.0 ± 0.5  0.06
E/E’ ratio    - 9.5 ± 4.2  - 9.8 ± 3.7  0.60
Strain (rate) parameters (mean ± SD)
Global SL (%)   -19.8 ± 2.6 -21.2 ± 1.6 <0.0001
Global SrL (1/s)   -1.22 ± 0.19 -1.40 ± 0.08 <0.0001
Global SR (%)   49 ± 12  57 ± 5  <0.0001
Global SrR (1/s)   1.75 ± 0.35 3.43 ± 0.36 <0.0001
Global SC (%)   -15.9 ± 6.7 -22.6 ± 2.1 <0.0001
Global SrC (1/s)   -1.48 ± 0.42 -1.83 ± 0.17 <0.0001
Time to Peak Global SL (%)  44 ± 7  39 ± 3  <0.0001
Time to Peak Global SR (%)  46 ± 8  38 ± 4  <0.0001
Time to Peak Global SC (%)  43 ± 7  37 ± 3  <0.0001
P-values not corrected for multiple (22) testing.
After Bonferroni correction all p-values <0.0001 remained to indicate significance at the 0.05 level.
Strain (rate) measurements of asymptomatic survivors of childhood cancer compared to 
conventional echocardiographic parameters
Table 6.3 shows the results of the relation between strain (rate) measurements 
and conventional echocardiographic parameters of asymptomatic survivors of 
childhood cancer, expressed as Spearman’s rho, p-value and the number of available 
subjects. A lower global SL was significantly related to a lower FS, EF , and LVPWd/
BSA. Global SR was not significantly related to conventional echocardiographic 
parameters. A lower global SC was related to a lower EF, a lower FS, a lower VCFc, 
a higher ESWS and a higher IVRT.
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A lower global SrL was significantly related to a lower EF, LVIDd/BSA, 
LVPWd/BSA, and IVSd/BSA. Global SrL was significantly lower with a longer 
IVRT. A lower global SrR was related to a lower E/A ratio. A lower global SrC 
was significantly related to a lower FS, a lower LVPWd/BSA and a higher IVRT. 
The percentage of time of one heart cycle to reach the peak global SL was 
significantly longer with a lower LVM/BSA a higher LVIDd/BSA, higher IVSd/
BSA, a lower VCFc and a lower ESWS. The percentage of time of one heart cycle 
to reach the peak global SR was longer whith a lower ESWS and a lower E/A 
ratio. The percentage of time of one heart cycle to reach the peak global SC was 
longer with a lower LVM/BSA and a lower ESWS.
Strain (rate) measurements of asymptomatic survivors of childhood cancer compared to 
clinical parameters and NT-pro-BNP levels
There was no significant relation between global SL and global SR (mid-cavity) 
measurements and gender, age at diagnosis, follow-up duration, age at follow-up 
and cumulative anthracycline dosage (data not shown). The mean NT-pro-BNP 
level in our group of survivors was 6 pmol/l (range: 1-55 pmol/l). NT-pro-BNP 
levels were available in 96 of the 111 survivors. Sixteen of 96 (17%) had abnormal 
NT-pro-BNP levels. Abnormal NT-pro-BNP levels were not related to lower 
global SL and global SR measurements nor to the time to reach the peak global SL 
(data not shown).
Figure 6.2 shows that decreased global SrL was related to older age at diagnosis 
(Spearman’s r=0.346, (p<0.01), older age at follow-up (Spearman’s r=0.497, 
(p<0.001)) and follow-up duration (Spearman’s r=0.370, (p<0.01)), but not to 
cumulative anthracycline dosage and abnormal NT-pro-BNP levels (data not 
shown). Global SrR was not related to clinical parameters and NT-pro-BNP levels 
(data not shown).
Figure 6.2a
Figure 6.2b
Figure 6.2c
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4 Discussion
This is the first study of monitoring late-onset subclinical heart failure by strain 
and strain rate in a large group of asymptomatic long-term survivors of childhood 
cancer, approximately 15 years after the last anthracycline therapy. This study 
shows that both conventional echocardiographic parameters and global myocardial 
strain, strain rate and time to peak systolic strain in asymptomatic survivors of 
childhood cancer were significantly lower as compared to healthy controls (p-values 
<0.0001). In addition to this, global myocardial strain and strain rate and time to 
peak systolic strain were significantly related to several systolic and diastolic left 
ventricular parameters. P-values expressing the relation between conventional 
and strain parameters are not Bonferroni corrected. However, table 6.3 shows 
that 26 of 99 p-values are <0.05. When there would have been no true relation 
between conventional and strain parameters, one would expect that, on the 
basis of coincidence, 5 p-values (5% of 99) would be <0.05. Since there are 26 
p-values <0.05, it is very likely that a true relation between conventional and strain 
parameters does exist.
Long-term follow-up of survivors of childhood cancer showed an increased risk 
of several severe conditions including congestive heart failure [28]). The standardized 
mortality ratio for cardiac causes is eight times higher than in the normal population 
[29]. Serial monitoring of cardiac function is essential and new techniques such as 
myocardial strain and strain rate imaging and biomarkers are warranted to detect 
anthracycline-induced cardiotoxicity in an earlier stage. Conventional parameters 
are load dependent and influenced by changes in preload and afterload. Strain 
and strain rate parameters are often seen as less load dependent [2]. However, a 
recent study in humans showed that strain and strain rate parameters are sensitive 
to changes in loading conditions [30]. Regional abnormalities can be identified by 
strain and strain rate imaging. However, the use of strain imaging is not yet standard 
in the clinical setting [2,31]. In about 20% of our survivors we were not able to 
obtain strain and strain rate data. This is a known phenomenon in studies of others 
as well [32,33]. Failure to get appropriate strain data is related to decreased image 
quality and not related to a deviating motion pattern.
Anthracycline-induced cardiotoxicity is characterized by myocardial cell necrosis, 
apoptosis and mitochondrial dysfunction. It can ultimately lead to severe dilated 
cardiomyopathy [1]. When and if it occurs is not easy to predict and early detection 
methods might be of benefit to the survivors if it gives opportunities to stop further 
cardiac deterioration. Left ventricular ejection fraction and fractional shortening 
(in children) are now the standard bed-side measurements by which anthracycline-
induced cardiotoxicity is assessed. However, they both reflect a relatively late stage of 
systolic impairment [34]. Strain and strain rate have been helpful to detect subclinical 
disease in a number of disease settings and it could also be useful in the early detection 
of subclinical heart failure in anthracycline treated patients [2]. 
Ganame and colleagues were the first to report on strain and strain rate in 
monitoring of myocardial dysfunction after anthracycline therapy in children 
[11,12]. They showed in a small group of patients (n=13) that subsequent low to 
moderate doses of anthracyclines could lead to acute cardiotoxicity, expressed by 
decreased longitudinal and radial peak strain and strain rate after three doses of 
anthracyclines [11]. The long-term significance of these findings on predicting late-
onset anthracycline-induced cardiotoxicity needs to be explored by prospective 
follow-up studies. In another study, the same authors found subtle myocardial 
abnormalities in approximately five years after anthracycline therapy with a 
cumulative dose less than 300 mg/m2 [12]. Subtle abnormalities were seen in both 
systolic and diastolic myocardial function. Reduction of myocardial longitudinal 
and radial strain was seen compared to a control group. Two other studies in adult 
patients showed similar findings directly after anthracycline therapy and after a 
follow-up period of 18 months [7,13]. Compared to the above mentioned studies, 
our study has a long follow-up duration with a median of 13 years and a range of 
5-29 years. 
None of the previous authors reported on the time to reach peak systolic 
strain. The asymptomatic survivors had a significantly longer time to reach peak 
systolic strain compared to healthy controls. It was hypothesised that in a heart, 
affected by anthracyclines, the time to reach the peak systolic strain is longer due to 
fibrosis and stiffness of the heart and by the dilation of the heart when myocardial 
necrosis occurs. Our data confirmed this hypothesis, especially in longitudinal en 
circumferential time to peak systolic strain, where it was significantly related to 
the left ventricular wall thickness, left ventricular internal diameter, left ventricular 
mass and end-systolic wall stress. In other words, the thinner the myocardial wall 
and the wider the left ventricular dimension, the more time is needed to reach the 
peak systolic strain. 
The relation between global myocardial strain and strain rate and known 
risk factors for anthracycline-induced cardiotoxicity was studied. Although the 
cumulative anthracycline dosage is known as the most powerful predictor of 
anthracycline-induced cardiotoxicity, we could not show a significant relation 
between strain parameters with cumulative anthracycline dosage. The median 
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cumulative anthracycline dosage of our study population was relatively low. 
Prospective follow-up studies are needed to indicate patients at risk with decreased 
abnormal strain or strain rate values, irrespective of the cumulative anthracycline 
dosage they received. 
We also studied the relation of strain parameters with the biomarker NT-
pro-BNP. In one of our previous studies we showed that 13% of asymptomatic 
survivors of childhood cancer had abnormal NT-pro-BNP levels [16]. Abnormal 
NT-pro-BNP levels were related to higher cumulative anthracycline dosage and to 
increased LVIDd/BSA in the group of survivors who had received a cumulative 
anthracycline dosage of 300 mg/m2 or more which was still observed in the present 
study. Survivors with abnormal NT-pro-BNP levels in this study (17%) did not 
have significantly lower values strain parameters. 
This study shows that both conventional and strain (rate) parameters in a large 
group of long-term asymptomatic survivors of childhood cancer are significantly 
lower than in healthy controls. Longer follow-up of this group is needed to 
identify those survivors who will get symptoms of heart failure over the following 
years. From our study, it is not clear whether strain and strain rate are superior to 
conventional echocardiography in the early detection subclinical heart failure or not. 
Although more time consuming, it is not unlikely that lower strain and strain rate 
values might precede abnormalities in conventional echocardiographic parameters, 
because of its ability to study the myocardium in more detail. They only way to 
determine the additional role of myocardial strain and strain rate in monitoring 
subclinical heart failure in asymptomatic long-term survivors of childhood cancer is 
long-term follow-up with strain (rate) measurements. Since anthracycline-induced 
cardiotoxicity is a growing health concern with life threatening consequences, 
follow-up with strain (rate) parameters, as a complementary method, might be 
promising in monitoring subclinical heart failure in asymptomatic survivors of 
childhood cancer. 
5 Conclusion
This study showed that global myocardial strain, strain rate and time to peak 
systolic strain in asymptomatic survivors of childhood cancer were significantly 
lower compared to healthy controls and were significantly related to several systolic 
and diastolic left ventricular parameters. Whether myocardial strain and strain rate 
are superior to conventional echocardiography in the early detection of subclinical 
heart failure needs to be explored in further longitudinal prospective studies. 
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 Abstract
Objectives
The aim of this study was to investigate cardiac biomarkers and myocardial 2D 
strain echocardiography in the assessment of cardiac function in children with 
Acute Lymphoblastic Leukemia (ALL) during and shortly after treatment with 
anthracyclines.
Background
Anthracycline-induced cardiotoxicity can lead to severe heart failure and is a 
growing problem in survivors of childhood cancer.
Methods
Cardiac function of 60 children with ALL was prospectively studied with 
measurements of cardiac  Troponin T (cTnT) and N-Terminal-pro-brain 
natriuretic peptide (NT-pro-BNP) and conventional and myocardial 2D strain 
echocardiography before start (T=0), after three months (T=1) and after one year 
(T=2), and were compared to 60 healthy age-matched controls.
Results
None of the patients showed clinical signs of cardiac failure. The fractional 
shortening (FS) remained normal. Cardiac function decreased significantly during 
treatment and was significantly decreased compared to normal controls. cTnT 
levels were abnormal in 11% of the patients at T=1 and were significantly related 
to increased time to global peak systolic longitudinal strain at T=2 (p=0.003). 
NT-pro-BNP levels were abnormal in 13% of patients at T=1 and in 20% at T=2. 
Absolute values of NT-pro-BNP increased throughout treatment in 59% of the 
patients. Predictors for abnormal cardiac biomarkers and myocardial 2D strain 
parameters at T=2 were cumulative anthracycline dose, z-score of the diastolic left 
ventricular internal diameter and FS at baseline, abnormal NT-pro-BNP at T=0 
and T=1, and global longitudinal strain and strain rate at T=1. 
Conclusion
Cardiac biomarkers en myocardial 2D strain echocardiography are useful in the 
detection of early anthracycline-induced cardiotoxicity. 
Anthracycline-induced cardiotoxicity
138
Chapter 7  -  Cardiac biomarkers and myocardial 2D strain echocardiography in 
children during and shortly after anthracycline therapy for 
Acute Lymphoblastic Leukemia (ALL). A prospective study.
139
1 Introduction
Cardiotoxicity is a well known side effect of anthracycline therapy. Early-onset 
anthracycline-induced cardiotoxicity occurs during or within the first year after 
anthracycline treatment. It is a risk factor for the development of late-onset 
anthracycline-induced cardiotoxicity, which is known to cause serious cardiac 
health problems in a growing number of cancer survivors [1-6]. 
Cardiac biomarkers are increasingly used for the detection of anthracycline-
induced cardiotoxicity [7-17]. Release of cardiac troponins is indicative for 
myocardial necrosis. Natriuretic peptides are released by the myocardium in 
response to volume and pressure overload and have shown to be sensitive markers 
of left ventricular dysfunction [7,8]. 
The use of myocardial 2D strain echocardiography in early-onset anthracycline-
induced cardiotoxicity has been studied by tissue Doppler strain analysis [15] and 
by 2D speckle tracking strain analysis [16-18]. These studies showed decreased 
myocardial strain and strain rate during anthracycline therapy [15] and years after 
anthracycline therapy [16-18], with relatively preserved fractional shortening [19].
In this prospective study, we aim 1) to document cTnT and NT-pro-BNP levels 
and conventional and myocardial 2D strain echocardiographic parameters before, 
during and shortly after treatment with anthracyclines in children with newly 
diagnosed ALL, 2) to find predictors for abnormal cardiac function at one year after 
anthracycline treatment and 3) to compare cardiac function of children with ALL 
after one year of anthracycline treatment to cardiac function of healthy controls. 
2 Methods
Study population
Newly diagnosed patients with childhood ALL and their parents were asked 
informed consent for our study. Exclusion criteria were cardiac disease prior 
to therapy and renal failure.  As a control group, we included 60 healthy age-
matched controls that were routinely referred for echocardiographic evaluation 
of an asymptomatic, innocent heart murmur or for screening purposes. History, 
electrocardiogram, and echocardiogram were not indicative of cardiac disease and 
no medication was used. 
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Cardiac function was assessed by echocardiography for obtaining conventional 
and myocardial 2D strain parameters. Cardiac TnT and NT-pro-BNP were 
measured in the patient group. The first cardiac evaluation was done in the first 
week of ALL treatment, i.e. before the first anthracycline dose (T=0). The second 
cardiac evaluation was performed at the end of the induction phase of the ALL 
treatment, which is ten weeks after start of treatment and five weeks after the latest 
anthracycline dose (T=1). The third cardiac evaluation was performed one year 
after start of ALL treatment which is at least two weeks after the last anthracycline 
dose (T=2). The study was approved by the local ethics committee.
Anthracycline treatment as part of the antileukemic therapy
Treatment according to the DCOG-ALL-10 protocol is based the DCOG-
ALL-8 protocol. Patients are stratified in three treatment groups; standard risk 
(SR), medium risk (MR) and high risk (HR) patients largely based on response 
to treatment [20]. The total duration of treatment is 2 years, but shorter for 
HR patients who are eligible for stem cell transplantation (SCT). At T=1, the 
cumulative anthracycline dose of all patients is 120 mg/m2. At T=2, SR patients 
have received a cumulative anthracycline dose of 120 mg/m2, MR patients 300 mg/
m2 and HR patients a maximum cumulative anthracycline dose of 240 mg/m2 and 
an additional 52,5 mg/m2 of mitoxantrone and 18 mg/m2 of idarubicin, depending 
on (timing of ) SCT. All SCT patients received total body irradiation (TBI).
Cardiac biomarkers
Blood samples were obtained at T=0, T=1 and T=2 from a central venous line in 
patients with ALL. Cardiac TnT levels were assessed by the Elecsys Troponin T 
STAT Immunoassay, performed on a Modular E immunoassay analyzer (Roche 
Diagnostics, Mannheim, Germany) [21]. A level of ≤ 0.01 ng/ml was defined 
as normal. NT-pro-BNP was measured using an electrochemiluminescence 
immunoassay, using the NT-pro-BNP kit (Roche Diagnostics, Mannheim, 
Germany). Normal values for children were based on age-dependent reference 
values (97.5th percentile) [22].  
Echocardiography
Transthoracic echocardiography in left lateral position was performed at rest, 
without sedation. Images were obtained with a 3.0-MHz and a 5.0-MHz 
transducer, depending on the age and weight of the study subjects, using a Vivid 7 
echocardiographic scanner (GE, Vingmed Ultrasound, Horten, Norway). Frame 
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rate was kept between 70 and 100 frames per second (fps)[23,24]. Quantification 
of cardiac chamber size, left ventricular mass (LVM) and systolic and diastolic left 
ventricular function were measured in accordance with the recommendations for 
chamber quantification by the American Society of Echocardiography’s Guidelines 
and Standard Committee and the Chamber Quantification Writing Group [25]. 
Z-scores of left ventricular dimensions and LVM were calculated based on normal 
values of M mode measurements [26,27]. The left ventricular systolic function was 
indicated using fractional shortening (FS). Left ventricular diastolic function was 
indicated using the E/A ratio, E/E’ ratio [28] and the isovolumic relaxation time 
[29]. Left ventricular mass was calculated according to the formula of Devereux [30]. 
Two-dimensional gray scale images were made in parasternal apical 4-chamber 
and mid-cavity short-axis (at the level of the papillary muscle) views. A sector scan 
angle of 30-60 degrees was chosen to obtain frame rates of 70-100 Hz. Cine loops 
of three cardiac cycles triggered by the R wave of the QRS complex were digitally 
saved. Off-line analysis was performed using software for echocardiographic 
quantification (EchoPAC 6.1.0, GE Medical Systems, Horten, Norway). 
Separately, timing of aortic valve closure (AVC) and mitral valve opening (MVO) 
were obtained, using single gated pulsed Doppler or continuous wave (CW-) 
Doppler images. These images were acquired just after the 2D strain gray-scale 
images and special care was taken that the heart rate was in the same range.  Time 
measurements were expressed as a percentage of the duration of the complete 
cardiac cycle.
Myocardial segments were named and localized according to the statement 
of the Cardiac Imaging Committee of the Council on Clinical Cardiology of the 
American Heart Association [31]. Manual tracking of the endomyocardial borders 
was performed at the end-systolic frame. An automatic generation of the second 
epicardial tracing was created by the software. The software automatically divided 
the image into six segments. Quality of the tracking was verified for each segment 
and adjusted when needed. Strain curves of three consecutive cardiac cycles and 
values of the manual timing were imported into a custom made software package for 
further analysis. Cardiac cycles with a length more than ten percent different from 
the mean length of the three cardiac cycles were excluded for further analysis. The 
average values of peak systolic longitudinal (SL), radial (SR) and circumferential 
(SC) strain and strain rate of the three imported curves were calculated by the 
custom made software. Global strain and strain rate were calculated by averaging 
the six segments. 
We recently showed that myocardial strain imaging with 2D echocardiography 
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can produce scores with high interobserver, intraobserver and intrapatient reliability 
[32]. Abnormal global SL, SR and SC were defined as values lower than the 5th 
percentile of the normal pediatric population [33].
Statistical analysis
Characteristics of the study population and biomarker levels were summarized 
using median and range. Conventional echocardiographic and 2D strain parameters 
were summarized by using mean and standard deviation (SD). The biomarker 
levels were studied at T=1 and T=2 for available paired observations using the 
McNemar test for abnormal biomarkers levels and the Wilcoxon signed ranks 
test for the absolute biomarker levels. The echocardiographic data in the patient 
group were studied using Linear Mixed Models and Generalized Estimating 
Equations (GEE) to account for correlations between different points in time. 
Echocardiographic parameters of patients and controls were compared using the 
independent t-test. 
Using logistic regression analysis we searched for possible predictors at baseline 
and T=1 for abnormal cardiac biomarkers and 2D myocardial global SL, SR and 
SC. We refrained from multiple regression analysis because of the small number 
of subjects. 
Statistical analyses were performed using the Statistical Package for Social 
Sciences (SPSS) for Windows, version 16.0 and SAS, version 8.2. A p-value less 
than 0.05 was considered to indicate significance.  
3 Results
Subject characteristics
Seventy children and their parents were asked to give informed consent for this 
study. Parents of four patients refused informed consent. One patient was excluded 
because of congenital heart disease (atrial septal defect). Consequently, 65 
patients were included in the study. Before T=1, three patients altered treatment 
because of treatment related toxicity and two patients died (progressive disease 
and sepsis, respectively). Further analysis was done in the remaining 60 patients. 
Three patients died after T=1 (one sepsis and two relapses, respectively) and one 
patient was lost to follow-up by moving abroad. Parents of one SR patient refused 
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echocardiography and biomarker sampling at T=2. In six patients, follow-up was 
not available at T=2. Six patients in the HR-group completed T=2. Four of them 
received the full dose of anthracyclines, two were eligible for SCT; one received a 
cumulative anthracycline dose of 120 mg/m2, one a cumulative anthracycline dose 
of 120 mg/m2 plus 18 mg/m2 of idarubicin and 26.25 mg/m2 of mitoxantrone. 
None of the patients showed clinical symptoms (e.g rhythm disorders, acute heart 
failure) of acute anthracycline-induced cardiotoxicity and none of them used 
cardiac medication.
 Hyperhydration - i.e. the infusion of 3000 ml/m2/d of glucose 2.5%/NaCl 
0.45% - as part of the supportive care to prevent tumor lysis syndrome was given 
in 95% of the patients at T=0, but in none  at T=1 and T=2. Echocardiographic 
parameters of the patients were compared to 60 healthy controls. The characteristics 
of the study population are shown in table 7.1.
Biomarkers
Table 7.2 shows the results of the biomarker levels at T=0, T=1 and T=2. Levels 
of cTnT were normal in all patients before start of anthracycline treatment (T=0). 
At T=1, cTnT levels were abnormal in 11% of the patients (5/45) and normalized 
in all at T=2. In one MR-patient, cTnT became abnormal at T=2 (i.e. after a 
cumulative anthracycline dose of 300 mg/m2). 
NT-pro-BNP levels were abnormal in 26% of the patients (12/46) at T=0. 
Ninety-five percent of the patients received hyperhydration at T=0, when plasma 
samples of NT-pro-BNP and cTnT were obtained. The median NT-pro-BNP 
level at T=0 was 13 pmol/l (range 2-185). Abnormal NT-pro-BNP levels were 
not significantly related to, but showed a tendency towards lower hemoglobin 
(Hb) levels, higher total leucocyte counts (TLC) and hyperhydration (data not 
shown). NT-pro-BNP levels were abnormal in 13% 6/45) at T=1 and in 20% 
of the patients (8/41) at T=2. Absolute NT-pro-BNP levels increased during 
treatment in 59% of the patients. 
Echocardiographic parameters
The echocardiographic parameters during treatment are shown in table 7.3. None 
of the patients had a FS below 28%. FS decreased significantly after the first 120 
mg/m2 of anthracyclines (p<0.0001). In 23% of the patients a decreased FS of 
more than 10% was observed. Z-scores of left ventricular dimensions and LVM 
all changed significantly over time. All myocardial 2D strain parameters decreased 
during anthracycline treatment; a statistically significant decrease was observed for
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Table 7.1 Characteristics of the study population
     Patients   Controls  p-value‡
Number (N)    60    60
Male gender (N)    37 (62%)   40 (67%)
Age at diagnosis, (yr),   6 (2.2-15.4)   5.8 (2.2-14.7)  0.09
BSA     0.87 (0.54-1.93)   0.81 (0.50-1.84)  0.07
HR     79 (53-122)   90 (53-122)  0.04
Hb* level at diagnosis, (mmol/l)  5.5 (2.2-9.5)
TLC†  at diagnosis, (*109/l),  10.4 (0.7-348)
Hyperhydration at T=0,
(N (percentage))   57(95%)
Risk stratification
 SR (n)     20
 MR (n)     30
 HR (n)     10
Cumulative anthracycline dose at the diﬀerent time points
 T=0    all patients:   0 mg/m2
 T=1    all patients:   120 mg/m2
 T=2    SR-patients:   120 mg/m2
     MR-patients:   300 mg/m2
     HR-patients (n=4), no SCT 240 mg/m2+ 18 mg/m2 idarubicin 
         + 52.5 mg/m2 mitoxantrone
     HR-patient (n=1), SCT:  120 mg/m2
     HR-patient (n=1), SCT:  120 mg/m2 +18 mg/m2 idarubicin 
         + 26.25 mg/m2 mitoxantrone
Values are expressed as median and range.
* Hemoglobin
† Total Leucocyte Count
‡ Mann-Whitney-U analysis
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Table 7.2 Cardiac biomarkers in ALL patients during treatment with anthracyclines
      T=0  T=1  T=2  p-value
Number of patients (N)    60  60  49
Number of biomarker samples (N)  46  45  41
Abnormal cTnT (%) [N]    0 [0]  11 [5]  2.5 [1]   0.2*
cTnT (ng/ml), median (range)   0.01   0.01 (0.01-0.04) 0.01 (0.01-0.02) 0.08†
Abnormal NT-pro-BNP (%) [N]   26 [12]   13 [6]  20 [8]   0.5*
NT-pro-BNP (pmol/l), median (range)  13 (2-185) 10 (1-45) 11 (1-68) 0.5†
Values are expressed as median and range.
*McNemar test based on 37 paired available observations at T=1 and T=2
† Wilcoxon signed ranks test on 37 paired available observations at T=1 and T=2
global SrL, global SR and global SC (p=0.03, 0.004 and 0.01 respectively) and all 
time to peak systolic strain parameters (p<0.001). Global SL, SrL and SR were 
inversely related to cumulative anthracycline dose (p=0.004, p=0.03 and p=0.006 
respectively). Patients with abnormal cTnT level at T=1 had a significant longer 
time to peak global SL at T=2 (p=0.003). 
Table 7.4 shows the echocardiographic data of patients at T=2 compared to 
that of healthy controls.  Conventional echocardiographic parameters of patients 
showed significant decreased FS, and increased IVRT compared to healthy 
controls. Z-scores of left ventricular dimensions and LVM were not significantly 
different from healthy controls. In contrast, all myocardial strain parameters were 
significantly decreased in patients compared to healthy controls, except for global 
SR.  Time to peak global SL, SR and SC was significantly increased in patients 
compared to healthy controls (p<0.0001).
Predictors for abnormal biomarkers and strain parameters
Cardiac biomarkers and 2D myocardial global SL, SR and SC were defined as 
normal and abnormal based on age-dependent reference values at T=2. Predictors 
for abnormal global SL were cumulative anthracycline dose (p<0.05, OR 
associated with an increase of 100 mg/m2 = 2.25, 95%CI[1.02-4.93]), LVIDd 
z-score at baseline (p=0.03, OR=1.95, 95%CI[1.05-3.62]) and FS at baseline 
(p<0.05, OR=1.17, 95%CI[1.00-1.36]). Predictors for abnormal global SC at 
the level of the papillary muscle were global SL (p=0.02, OR=1.33, 95%CI[1.05-
1.68]) and global SrL (p=0.04, OR=24.96, 95%CI[1.22-510]) at T=1. Predictors 
for abnormal NT-pro-BNP were an abnormal NT-pro-BNP at T=0 and T=1 
(p=0.01, OR=11.0, 95%CI[1.6-73.5]). Predictors for a decreased FS of more than 
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10% at T=2 were FS (p=0.01, OR=1.5, 95%CI[1.1-2.0]), LVM z-score (p=0.01, 
OR=3.8, 95%CI[1.3-10.7] and z-scores of the diastolic left ventricular septum 
(p<0.01, OR=4.2 95%CI[1.6-11.1]) and z-score of LVPWd (p=0.004, OR=4.1, 
95%CI[1.6-10.9] at T=1.  
Table 7.3 Echocardiographic parameters in ALL patients during treatment 
 with anthracyclines
     T=0  T=1  T=2  P value*
     N=60  N=60  N=49
Conventional parameters (mean ± SD)
FS (%), mean (±SD)   40 ± 5  36 ± 3  35 ± 3  <0.0001
z-score LIVDd (±SD)   0.14 ± 1.15 0.63 ± 0.82 0.48 ± 0.88  0.005
z-score LVPWd (±SD)   -0.07 ± 1.14 -0.36 ±0.88 -0.59 ± 1.28 0.04
z-score IVSd (±SD)   -0.80 ± 1.05 -0.59 ± 0.98 -1.09 ± 1.05 0.02
z-score LVM (±SD)   -2.23 ± 1.58 -1.61 ± 1.12 -2.20 ± 1.62 0.007
IVRT (msec)    72 ± 12  67 ± 9  71 ± 10   0.01
E/A ratio    1.8 ± 0.6 1.8 ± 0.5 1.8 ± 0.6  0.8
E/E’ ratio    10.1 ± 4.8 12.4 ± 3.9 11.6 ± 5.7  0.11
   
Strain (rate) parameters (mean ± SD)
Global SL (%)    -18.2 ± 3.1 -17.3 ± 3.6 -16.7 ± 5.2 0.5
Global SrL (1/s)    -1.44 ± 0.3 -1.32 ± 0.3 -1.20 ± 0.4 0.03
Global SR (%)    66.8 ± 12 53.5 ± 13 55.2 ± 16 0.004
Global SrR (1/s)    2.6 ± 0.5 2.4 ± 0.5 2.3 ± 0.6 0.1
Global SC (%)    -19.4 ± 4.3 -17.1 ± 3.7 -16.9 ± 3.1 0.01
Global SrC (1/s)    -1.7 ± 0.3 -1.6 ± 0.3 -1.5 ± 0.2 0.08
Time to Peak Global SL (%)  43 ± 8  51 ± 6  48 ± 8  <0.0001
Time to Peak Global SR (%)  45 ± 8  53 ± 8  52 ± 8  <0.0001
Time to Peak Global SC (%)  43 ± 8  50 ± 7  48 ± 7  <0.0001
Abnormal Global SL (%)   45%  52%  42%  0.51 (GEE)
Abnormal Global SR (%)   3%  15%  15%  0.01 (GEE)
Abnormal Global SC (%)   15%  35%  35%  0.002 (GEE)
Values are expressed as mean and standard deviation.
* P values with respect to differences between time points are based on linear mixed model analyses 
or GEE analysis as indicated
FS fractional shortening
LIVDd diastolic left ventricular internal diameter
LVPWd diastolic left ventricular posterior wall thickness
IVSd diastolic intraventricular septum
LVM left ventricular mass
IVRT isovolumic relaxation time
SL longitudinal strain
SrL longitudinal strain rate
SR radial strain
SrR radial strain rate
SC circumferential strain
SrC circumferential strain rate
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Table 7.4 Echocardiographic conventional and myocardial 2D parameters 
 in ALL patients at T=2 compared to healthy controls
      Controls  Patients
         T=2   P value
      N=60   N=49
Conventional parameters (mean ± SD)
FS (%), mean (±SD)    38 ± 4   35 ± 3   0.002
z-score LVIDd, mean (±SD)   0.51 ± 1.00  0.48 ± 0.88  0.86
z-score LVPWd, mean (±SD)   -0.34 ± 1.42  -0.59 ± 1.28  0.40
z-score IVSd, mean (±SD)    -0.92 ± 1.14  -1.1 ± 1.05  0.42
z-score LVM, mean (±SD)   -2.03 ± 1.38  -2.20 ± 1.62     0.56
IVRT (msec)     47 ± 5       71 ± 10  <0.0001
E/A ratio     2.0 ± 0.5  1.8 ± 0.6  0.03
E/E’ ratio     12.0 ± 5.0  11.6 ± 5.7  0.6
Strain (rate) parameters (mean ± SD)
Global SL (%)     -20.9 ± 1.3  -16.7 ± 5.2  <0.0001
Global SrL (1/s)     -1.3 ± 0.1  -1.20 ± 0.4  0.01
Global SR (%)     54.3 ± 6  55.2 ± 16  0.6
Global SrR (1/s)     3.4 ± 0.4  2.3 ± 0.6  <0.0001
Global SC (%)     -22.5 ± 2.1  -16.9 ± 3.1  <0.0001
Global SrC (1/s)     1.9 ± 0.2  -1.5 ± 0.2  <0.0001
Time to Peak Global SL (%)   43 ± 3   48 ± 8   <0.0001
Time to Peak Global SR (%)   42 ± 4   52 ± 8   <0.0001
Time to Peak Global SC (%)   43 ± 4   48 ± 7   <0.0001
Values are expressed as mean and standard deviation.
Abbreviations as in Table 3.
4 Discussion
Summary of study findings
Cardiac function of children with ALL, during treatment with a relatively low 
dose of cumulative anthracyclines, deteriorated over time as measured by cardiac 
biomarkers and conventional and myocardial 2D strain echocardiography. 
Comparison of echocardiographic parameters of the patients at one year after 
anthracycline therapy with healthy controls showed that mainly strain parameters 
were affected. 
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Biomarkers
Cardiac TnT levels were all normal before start of treatment (T=0) and became 
abnormal in 11% of patients after a cumulative anthracycline dose of 120 mg/m2 (at 
T=1). Release of cTnT during therapy or directly after might reflect direct damage 
to cardiomyocytes. This study shows that even after a cumulative anthracycline 
dose of 120 mg/m2, which is considered to be a relatively safe dose [34,35], damage 
of the cardiomyocytes occurs as indicated by the cTnT levels. The fact that most of 
the patients had their last anthracycline dose 6 months before T=2, might explain 
the absence of abnormal cTnT levels in all but one patient at that moment. The 
absolute levels of the abnormal cTnT measurements in our patients were in the 
lower ranges. Measurement of high sensitive cTnT is a newer method to detect 
troponin release at even lower concentrations than that is detectable now [36]. 
This might be an interesting future method to evaluate in our patients.  We showed 
that abnormal cTnT levels at T=1 were significantly related to increased time to 
reach the global peak systolic longitudinal strain at T=2 (p=0.003). The recent 
study of Sawaya and colleagues showed a similar relation between cardiac troponin 
I (cTnI) and longitudinal strain. They concluded that abnormal cTnI levels and 
longitudinal strain were predictive of cardiotoxicity in patients with breast cancer 
treated with anthracyclines and trastuzumab [37]. 
In our study, an interesting finding was the unexpected high percentage of 
abnormal NT-pro-BNP levels in patients (26%) before receiving anthracyclins. 
Our hypothesis is that in children with ALL, release of NT-pro-BNP might be 
addressed to commonly occurring symptoms as severe anemia , leucocytosis and 
to hyperhydration to prevent tumor lysis syndrome. A tendency towards lower 
Hb levels, higher leucocyte counts and hyperhydration was seen in our patients; 
however this relation was not statistically significant. 
The number of patients with abnormal NT-pro-BNP levels increased 
throughout treatment from 13% at T=1 to 20% at T=2. Absolute values of NT-
pro-BNP increased throughout treatment in 59% of the patients. We recently 
showed that in a large group of asymptomatic long-term survivors of childhood 
cancer, none of them had abnormal cTnT levels 15 years after anthracycline 
treatment and concluded that assessment of cTnT levels does not contribute to 
the detection of subclinical late-onset anthracyline-induced cardiotoxicity. On 
the other hand, abnormal levels of NT-pro-BNP were detected in 13% of in this 
group and were related to cumulative anthracycline dose [38]. 
The predictive role of biomarkers in chemotherapy-induced cardiotoxicity 
has been reviewed before [39]. An increase of troponin levels is related to a high 
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probability of major cardiac events within the first year of follow-up. Patients with a 
persistent normal troponin value would most likely not have cardiac complications, 
with a predictive negative value of 99%. The role of natriuretic peptides in the 
prediction of anthracycline-induced cardiotoxicity seemed less clear [39]. Long-
term follow-up of our patients might clarify this topic. Biomarkers reflecting 
fibrosis of the myocardium, such as galectin-3, might be of additional use in the 
assessment of anthracycline-induced cardiotoxicity [40].
Myocardial 2D strain
None of the patients had clinical signs of acute and/or early-onset anthracycline-
induced cardiotoxicity; all cardiac changes in our patients were subclinical. 
Although FS decreased significantly after 120 mg/m2 of cumulative anthracycline 
dose, none of the patients had abnormal FS. FS decreased more than 10% in 
23% of the patients. Predictors for this decrease were decreased z-scores of left 
ventricular dimensions and LVM. The cumulative anthracycline dose correlated 
negatively with global longitudinal strain (p=0.004) and strain rate (p=0.03) and 
global radial strain (p=0.006), but not with the conventional echocardiographic 
parameters, including FS. 
Increasing data suggest that systolic strain and strain rate are strong indices 
of left ventricular contractility [41,42]. An increasing number of studies report 
on the usefulness of myocardial 2D strain echocardiography in monitoring 
anthracycline-induced cardiotoxicity [15-19]. In our previous study in long-term 
survivors of childhood cancer treated with anthracyclines, we also showed that 
strain parameters were lower as compared to healthy controls [43]. Similar findings 
were reported by Tsai and colleagues, who studied cardiac function in long-term 
survivors of Hodgkin’s lymphoma [17]. Interestingly, Cheung and colleagues 
reported impaired left ventricular myocardial deformation and mechanical 
dyssynchrony in ALL patients after more than one year of treatment as compared 
to healthy controls. They showed that synchronicity of myocardial deformation 
may provide additional insights on the alteration of left ventricular mechanics 
[19]. In our present study, we also assessed time to reach peak systolic longitudinal, 
radial and circumferential strain which was significantly longer as compared to 
healthy controls. The increase in time to peak systolic strain seems to occur during 
anthracycline treatment. Reduced strain parameters and increased time to peak 
systolic strain, in the presence of reduced wall dimensions, can be attributable to 
loss of myocytes and increased collagen deposit, which may result in myocardial 
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fibrosis. This phenomenon is already reported in adults with heart failure [44]. 
Study limitations. Due to disease related complications, a complete follow-up of 
all patients was not possible. Abnormal cardiac function before start of treatment 
for ALL might not reflect the patients’ normal cardiac function, due to disease 
related anemia and leucocytosis which might alter myocardial function.  
5 Conclusion
Children with newly diagnosed ALL showed decline of asymptomatic systolic and 
diastolic function during treatment with anthracyclines using cardiac biomarkers 
and myocardial 2D strain echocardiography. The combination of cardiac biomarkers 
in combination with myocardial 2D strain echocardiography are important in the 
assessment of cardiac function of children with ALL treated with anthracyclines.  
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18 Summary and future perspectives
1 Summary
Almost 80% of children and adolescents with cancer becomes a long-term survivor 
[1,2]. This is a result of improved treatment and supportive care. Currently, in the 
Netherlands, about one of every 250 young adults is a survivor of childhood cancer 
[3]. Unfortunately, improved survival is accompanied by the occurrence of late 
effects of treatment. It has become clear that these late effects of treatment may not 
be clinically evident for many years.  One of the serious late effects of treatment is 
cardiotoxicity, which is related to the use of anthracyclines and mediastinal irradiation. 
Cardiotoxicity leads to a significant increase in morbidity and mortality; the relative 
risk of severe and life-threatening cardiac dysfunction is 10-15 times higher than in 
siblings and being a survivor of childhood cancer, the risk to die of cardiac disease is 
eight times higher than in the normal population [1,2]. 
In this thesis we aimed to investigate new strategies for the early detection 
of anthracycline-induced cardiotoxicity. Early detection may prevent morbidity 
and mortality when preventive measures or treatment are effective. Therefore, we 
investigated the role of cardiac biomarkers and 2D myocardial strain imaging in the 
early detection of anthracycline-induced cardiotoxicity.
An update on the knowledge of anthracyclines is presented in chapter 1, which covers 
a general introduction about anthracyclines and gives an outline of the thesis. It 
describes the anti-tumour activity as well as the cardiotoxic effect of anthracyclines. 
Different types of anthracycline-induced cardiotoxicity are presented and risk 
factors for the development of anthracycline-induced cardiotoxicity are described. 
Besides, several methods for the detection of cardiotoxicity are pointed out and 
the need for early detection of anthracycline-induced cardiotoxicity is emphasized. 
Interventional strategies, such as the use of the cardioprotectant dexrazoxane and 
the use of ACE inhibitors and beta blockage are also discussed.
In Chapter 2, a review of the role of cardiac biomarkers in the early detection 
of anthracycline-induced cardiotoxicity in children is presented. Untill now, only 
small studies are available in the pediatric population. In these small studies, 
different cardiac biomarkers are evaluated in different phases of anthracycline 
treatment, ranging from during anthracycline treatment till long after the end of 
anthracycline treatment. However, in spite of the heterogeneity of the studies, it 
has been concluded that BNP, NT-pro-BNP and cTnT might be useful markers 
in the early detection of anthracyline-induced cardiotoxicity.  Larger prospective 
studies are warranted to study the potential use of these biomarkers as a predictive 
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tool for the occurrence of anthracycline-induced cardiotoxicity. 
With the knowledge of the above presented information, we were able to conduct 
a prospective study in patients being treated with anthracyclines for Acute 
Lymphoblastic Leukemia (ALL) and a cross-sectional study in asymptomatic 
survivors of childhood cancer for more than five years after the end of treatment. 
In this way, we were able to study the role of biomarkers and 2D myocardial 
strain in both early-onset cardiotoxicity (cardiotoxicity occurring within the first 
year after anthracycline treatment) and late-onset cardiotoxicity (cardiotoxicity 
occurring more than one year after anthracycline treatment). We decided to use 
the cardiac biomarkers cTnT, which reflects damage to myocytes and is indicative 
for myocardial necrosis, and NT-pro-BNP which is released by the myocardium 
in response to volume and pressure overload.
In Chapter 3, we present the results of the study where we aimed to investigate the 
role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in 
asymptomatic survivors of childhood cancer who were more than five years after 
anthracycline treatment. The focus of this study was to determine whether cardiac 
biomarkers could be used for the early detection of late-onset anthracycline-
induced cardiotoxicity. We documented plasma concentrations of cTnT and NT-
pro-BNP in 122 asymptomatic long-term survivors of childhood cancer treated 
with anthracyclines. We studied the relation of the abnormal biomarker levels with 
different risk factors for anthracycline-induced cardiotoxicity and with conventional 
echocardiographic parameters. Our study showed that none of the survivors had 
abnormal cTnT levels. Apparently, in asymptomatic long-term survivors (i.e. 
more than five years after anthracycline treatment), myocardial necrosis, reflected 
by release of troponins could not be detected by determination of cTnT levels 
(anymore). Thirteen percent of the asymptomatic survivors had abnormal NT-
pro-BNP levels. We showed that abnormal NT-pro-BNP levels were significantly 
related to cumulative anthracycline dosage. Survivors treated with cumulative 
anthracycline dose of 300 mg/m2 or more, had abnormal NT-pro-BNP levels that 
were significantly related to left ventricular dimension, indexed for body surface 
area. We concluded that analysis of cTnT levels does not contribute to the early 
detection of late-onset anthracyline-induced cardiotoxicity. However, NT-pro-
BNP might be a useful biomarker in the early detection of anthracycline-induced 
cardiotoxicity. Follow-up of asymptomatic survivors with abnormal NT-pro-BNP 
levels is essential to answer the question whether NT-pro-BNP is an early marker 
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for late-onset anthracycline-induced cardiotoxicity. 
The current standard for the evaluation of left ventricular function in children is 
conventional echocardiography. Tissue Doppler Imaging (TDI), a more recently 
developed echocardiographic technique, allows quantitative assessment of the 
myocardial velocities. In previous work of our group, we observed decreased 
transmyocardial velocity gradients years after anthracycline treatment.  Abnormal 
left ventricular wall movements were seen in 60% of children shortly after 
anthracycline treatment and in 20% with a follow-up of approximately ten years 
[4,5,6].  In this present thesis, we investigated myocardial deformation using the 
most recently developed Doppler derived techniques, namely 2D myocardial 
strain  and strain rate imaging, in the early detection of anthracycline-induced 
cardiotoxicity. 
In the study described in Chapter 4, we investigated the reliability of our second new 
strategy, the use of 2D myocardial strain imaging. Myocardial strain imaging with 
2D echocardiography is a non-invasive method to assess myocardial deformation. 
Strain is the change in size relative to its original size, i.e., the relative deformation. 
We evaluated myocardial strain measurements of ten asymptomatic survivors of 
childhood cancer and determined the interobserver, intraobserver and intrapatient 
reliability scores.  Based on this study, we concluded that myocardial strain imaging 
with 2D echocardiography could produce high interobserver and intraobserver 
reliability scores for almost all parameters, in almost all segments, and in almost all 
views. Intrapatient reliability scores, obtained by calculating the agreement between 
three consecutive cardiac cycles, were generally good, except for most items of the 
basal short axis view. The influence of the movement of the mitral valve to the 
image quality and the effect of breathing on the recordings (especially in children), 
might be a possible explanation. In this study we showed that 2D myocardial strain 
imaging is a reliable method in the group of patients of our interest.
To evaluate the use of 2D myocardial strain imaging in the early detection of 
anthracycline-induced cardiotoxicity, reference values of a healthy control group 
are inevitable. The establishment of normal values in a healthy paediatric cohort 
makes it possible to evaluate (pathologic) changes in the left ventricular function. 
Therefore, we determined these reference values in a cohort of almost 200 children 
and young adults (Chapter 5). A striking result of this study was that peak systolic 
strain values were age-dependent with the lowest values in the youngest and 
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oldest age groups, in contrast to the teenagers. This study showed that age is a 
major determinant of peak systolic strain values in healthy subjects and therefore 
emphasized the need for age specific reference values for adequate interpretation of 
2D myocardial strain measurements.  
In chapter 6, we describe the study considering the role of 2D myocardial 
strain and strain rate imaging in more than hundred long-term survivors of 
childhood cancer (with a median follow-up duration of 15 years after anthracycline 
treatment). Global strain (rate) parameters of survivors were compared to 
those in healthy controls and were related to conventional echocardiographic 
parameters, NT-pro-BNP levels and clinical parameters. This study showed that 
conventional echocardiographic parameters and global myocardial strain, strain 
rate were significantly lower and time to peak systolic strain was significantly 
longer in asymptomatic survivors of childhood cancer as compared to healthy 
controls. In addition to this, global myocardial strain and strain rate and time to 
peak systolic strain were significantly related to several systolic and diastolic left 
ventricular parameters.  Longer follow-up of this group is needed to identify those 
survivors who will get symptoms of heart failure over the following years. From 
our study it is not yet clear whether or not measurements of 2D myocardial strain 
and strain rate parameters are superior to parameters obtained by conventional 
echocardiography in the early detection of subclinical heart failure. It is not 
unlikely that lower strain and strain rate values might precede abnormalities 
in conventional echocardiographic parameters, because of its ability to study 
the myocardium in more detail. The only way to determine the additional role 
of myocardial strain and strain rate in monitoring subclinical heart failure in 
asymptomatic long-term survivors of childhood cancer is long-term follow-up 
with strain (rate) measurements. Since anthracycline-induced cardiotoxicity is a 
growing health concern with life-threatening consequences, follow-up with strain 
(rate) parameters, as a complementary method, might be promising in monitoring 
subclinical heart failure in asymptomatic survivors of childhood cancer. 
In chapter 7 we present the results of our prospective study considering cardiac 
function in children with Acute Lymphoblastic Leukemia (ALL) during and shortly 
after treatment with anthracyclines. In this study we could investigate the role of 
2D myocardial strain and strain rate and cardiac biomarkers in the early detection 
of early-onset anthracycline-induced cardiotoxicity. We showed that cardiac 
function decreased significantly during treatment with anthracyclines and was 
significantly decreased compared to normal controls as measured by conventional 
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and myocardial 2D strain echocardiography. FS decreased throughout treatment 
with anthracyclines, however stayed within the normal range in all patients. 
The cumulative anthracycline dose correlated negatively with the maximum 
longitudinal strain and strain rate and the maximum radial strain. In contrast to 
the study in long-term survivors, in this prospective study, abnormal cTnT levels 
were documented in 11% of the patients after three months (T=1) of treatment. 
Abnormal cTnT levels were significantly related to increased time to peak systolic 
longitudinal strain within one year (T=2) after anthracycline treatment. NT-pro-
BNP levels were abnormal in 13% of patients at T=1 and in 20% at T=2. Absolute 
values of NT-pro-BNP increased throughout treatment in 59% of the patients. 
Predictors for abnormal cardiac biomarkers and myocardial 2D strain parameters 
at T=2 were cumulative anthracycline dose, z-score of the diastolic left ventricular 
internal diameter and FS at baseline, abnormal NT-pro-BNP at T=0 and T=1, 
and global longitudinal strain and strain rate at T=1. 
The combination of 2D myocardial strain rate echocardiography and cardiac 
biomarkers can be used to identify patients with subclincal early-onset anthracycline-
induced cardiotoxicity. A long-term follow-up of this patient group would be of 
great interest as early-onset anthracycline-induced cardiotoxicity could be a risk 
factor for the development of late-onset cardiotoxicity. A longitudinal study might 
show the predictive role of myocardial 2D strain rate echocardiography and cardiac 
biomarkers in the early detection of anthracycline-induced cardiotoxicity. 
2 Conclusions
Based on the results of the studies described in this thesis, we can conclude that both 
the use of cardiac biomarkers and 2D myocardial strain measurements in the early 
detection of anthracycline-induced cardiotoxicity are promising. However, follow-
up studies are required to determine their predictive roles. Cardiac cTnT does not 
contribute to the early detection of late-onset anthracycline-induced cardiotoxicity 
in asymptomatic long-term survivors of childhood cancer. However, NT-pro-
BNP was abnormal in 13% of this population and was related to cumulative 
anthracycline dose.  In the group of patients treated for ALL with anthracyclines, 
we showed that cTnT could be a useful marker in the early detection of early-onset 
anthracycline-induced cardiotoxicity. In this group NT-pro-BNP was abnormal 
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in 20% of the patients after one year of treatment. Absolute NT-pro-BNP values 
increased in 59% of this group.  
2D myocardial strain parameters were significantly lower compared to 
healthy controls in both the anthracycline treated patients with ALL and in the 
asymptomatic survivors. The time to reach peak systolic strain was significantly 
longer in patients with ALL. In addition to this, in the patient group, strain 
parameters decreased during treatment with anthracyclines. 
Besides being useful in the early detection of cardiotoxicity, both biomarkers 
and 2D myocardial strain parameters might also be helpful in increasing our 
understanding the pathophysiology of anthracycline-induced cardiotoxicity. 
3 Future perspectives
As frequently seen, the results of our studies not only provide answers to various 
questions as summarized above, but also raise additional questions. Future studies 
will be needed to address these questions, which regard the following areas of 
‘cardiotoxicity after treatment in childhood cancers’:
In the first place, the duration and optimal time points for follow-up have to be 
determined. To assess the predictive value of both strategies, longer follow-up of 
the patients is essential. Only longer follow-up will answer the question whether 
the observed abnormal cardiac biomarkers and 2D myocardial strain measurements 
are potential predictors of anthracycline-induced cardiotoxicity in those long-term 
survivors who had normal conventional parameters at the time of this study, and 
whether they are the ones who develop cardiac deterioration in the future. Only a 
longitudinal study can establish whether one or both of the strategies are superior 
to the conventional echocardiographic parameters. We are currently conducting 
this follow-up study in the same study population and we intend to do the same 
cardiac evaluation five years later. 
Follow-up will also be interesting in the group of patients treated for ALL. We 
studied cardiac function in these patients throughout treatment with anthracyclines 
with the same strategies and investigated their role in the early detection of early-
onset anthracycline-induced cardiotoxicity. A longitudinal study will give us 
information about the potential predictive value of biomarkers elevated during 
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treatment and the predictive value of a decrease in 2D myocardial strain parameters. 
Will the cardiac biomarkers continue to increase and the 2D myocardial strain 
parameters continue to decrease over time? Or, will there be a recovery in cardiac 
function after the end of treatment? Future research will focus on assessing their 
cardiac function again when they have become long-term survivors.
Secondly, the relevance of dyssynchrony has to be determined. Coordinated 
contraction of the left ventricle is crucial for an efficient contractile function. 
Electromechanical dyssynchrony on the other hand might result in pathological 
ventricular remodeling and contribute independently to further impairment 
in global systolic function [7]. Cheung and colleagues showed in their study, 
that dyssynchrony of the left ventricle does also occur in patients treated with 
anthracyclines.  In 45 patients treated for ALL, they showed that 16% of them had 
mechanical dyssynchrony observed by 3D echocardiography with preserved FS 
[8]. Marcus and colleagues recently reported on the timing of systolic deformation 
in healthy pediatric and young adults with 2D myocardial strain echocardiography. 
They established reference values and showed that the extent of dyssynchronous 
deformation increased with age [9]. In our future research, we will determine the 
extent of dyssynchrony in our patient en survivor population and compare timing 
of systolic deformation of our patients and survivors with this healthy control 
group. This might be a step towards a better understanding of the pathophysiology 
of anthracycline-induced cardiotoxicity. 
Future research will also focus on the deformation of the different myocardial 
segments in our study subjects. In contrast to the conventional echocardiography, 
non-invasive 2D myocardial strain imaging, enables this research to answer the 
question whether certain segments of the myocardium are more vulnerable to 
the toxic effects of anthracyclines. Is the cardiotoxic effect of anthracyclines more 
distinct in certain segments of the left ventricle, or is it a more diffuse effect?
In the third place, novel cardiac biomarkers may be helpful for the identification of 
patients at risk for cardiac failure. Heart failure appears to be not only the result of 
myocardial injury or hemodynamic overload, but it is also the result of an interplay 
among genetic, neurohormonal, inflammatory and biochemical changes acting on 
cardiac myocytes, the cardiac interstitium, or both [10,11]. Some biomarkers are 
not only indicative of an increased risk but may also be risk factors themselves, 
making them potential targets of therapy [12].
Morrow and De Lemos have set out three criteria a biomarker should fulfill to 
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be useful clinically. Firstly, accurate, repeated measurements must be available to 
the clinician at reasonable costs and with short turnaround times. Secondly, the 
biomarker must provide information that is not already available from a careful 
clinical assessment. And finally, knowing the measured level should aid in medical 
decision making [13].  Few biomarkers satisfy all criteria; however, many provide 
important information regarding the pathogenesis of heart failure [11].
Novel biomarkers are the high sensitive troponin T [14], galectin-3, a protein 
produced by activated macrophages which is shown to be up-regulated in patients 
with acute and chronic heart failure [15, 16], chromogranin, a polypeptide hormone, 
osteoprotegerin, a member of the tumor necrosis factor receptor, adiponectin and 
growth differentiation factor (GDF-15) [11]. 
Besides the use of novel biomarkers, combining more than one biomarker might 
be of additional value. Some studies have shown that measurements of plasma 
BNP and troponin has greater prognostic value than either marker alone, in the 
classification of heart failure [11,12]. 
Finally, the identification of genetic markers may help in identifying patients at risk to 
develop cardiotoxicity. Known risk factors for anthracycline-induced cardiotoxicity, 
such as cumulative dosage, concomitant radiation therapy and young age, do not 
fully explain the individual variability in cardiotoxicity after anthracycline therapy. 
A role of the individual genetic background in the development of anthracycline-
induced cardiotoxicity has been observed in several animal studies [17]. Genetic 
studies may help to identify markers predictive of adverse effects or could help 
to elucidate more precise mechanisms of anthracycline-induced cardiotoxicity. 
Several candidate gene studies have been conducted in adults and children [18-
21]. The patients’ genetic information might, in combination with clinical risk 
factors, echocardiographic results and result of cardiac biomarkers, lead to a 
better discrimination of patients who are at higher or lower risk for developing 
anthracycline-induced cardiotoxicity. This might lead to a patient driven treatment 
and follow-up instead of a disease directed treatment, of course, without 
compromising the cancer survival.
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19 Samenvatting en aanbevelingen
1 Samenvatting
Bijna 80% van de kinderen en adolescenten met kanker geneest en wordt overlever 
[1,2]. Dit is het gevolg van verbeterde behandelingen en verbeterde ondersteunende 
maatregelen. In Nederland is tegenwoordig ongeveer een op de 250 jongvolwassenen 
een overlever van kinderkanker [3]. Helaas gaat deze toegenomen overlevingskans 
gepaard met late effecten van de behandeling. Het is inmiddels duidelijk geworden 
dat deze late effecten ook pas na vele jaren klinische symptomen kunnen geven. Een 
van de ernstige late effecten van behandeling is cardiotoxiciteit, die kan ontstaan 
ten gevolge van anthracyclines en bestraling van het hart als onderdeel van de 
behandeling. Cardiotoxiciteit leidt tot een toename van morbiditeit en mortaliteit; 
het relatieve risico op ernstig en levensbedreigend hartfalen is bij een overlever van 
kinderkanker 10-15 keer hoger dan bij een gezonde broer of zus. Het zijn van een 
overlever van kinderkanker maakt dat het risico om aan een cardiale oorzaak te 
overlijden 8 keer hoger is dan bij de gezonde populatie [1,2].
In dit proefschrift onderzochten we nieuwe strategieën voor de vroege detectie van 
anthracycline-geïnduceerde cardiotoxiciteit. Vroege detectie van anthracycline-
geïnduceerde cardiotoxiciteit kan mogelijk morbiditeit en mortaliteit voorkomen 
indien preventieve maatregelen of behandelingen effectief zijn. Daarom 
onderzochten we de rol van cardiale biomarkers en 2D myocardial strain imaging 
in de vroege detectie van anthracycline-geïnduceerde cardiotoxiciteit.
Een overzicht van de kennis van anthracyclines wordt weergegeven in hoofdstuk 
1. Het geeft een algemene introductie over anthracyclines en een overzicht van 
de inhoud van het proefschrift. Het beschrijft de antitumoractiviteit als ook het 
cardiotoxische effect van anthracyclines. De verschillende types van anthracycline-
geïnduceerde cardiotoxiciteit worden weergegeven en de risicofactoren voor het 
ontwikkelen van anthracycline-geïnduceerde cardiotoxiciteit worden beschreven. 
De verschillende methodes van detectie van cardiotoxiciteit worden uitgelegd en de 
noodzaak voor de vroege detectie van  anthracycline-geïnduceerde cardiotoxiciteit 
wordt benadrukt. Interventiestrategieën, zoals het gebruik van het beschermende 
middel dexrazoxane en het gebruik van ACE-remmers en bètablokkers worden 
bediscussiëerd.
In hoofdstuk 2 wordt een overzicht gegeven van de rol van cardiale biomarkers 
in de vroege detectie van anthracycline-geïnduceerde cardiotoxiciteit bij kinderen. 
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Tot dusver zijn alleen kleine studies beschreven in de populatie kinderen. Bij 
deze kleine studies worden verschillende cardiale biomarkers in verschillende 
fasen van behandeling met anthracyclines geëvalueerd van tijdens de behandeling 
met anthracyclines tot lang na het einde van de behandeling. Echter, ondanks de 
heterogeniciteit van de studies, wordt er geconcludeerd dat BNP, NT-pro-BNP 
en cTnT bruikbare cardiale biomarkers kunnen zijn in de vroege opsporing van 
anthracycline-geïnduceerde cardiotoxiciteit. Grotere prospectieve studies zijn 
nodig om het potentiële nut van deze biomakers als een voorspeller voor het 
optreden van anthracycline-geïnduceerde cardiotoxiciteit aan te tonen.
Met de kennis van de hierboven beschreven informatie konden we een prospectieve 
studie opzetten bij patiënten die werden behandeld voor Acute Lymfatische 
Leukemie (ALL) en een cross-sectionele studie bij asymptomatische overlevers van 
kinderkanker, die verder dan vijf jaar na einde van hun therapie waren. Op die 
manier werd het mogelijk om de rol van cardiale biomarkers en 2D myocardial 
strain te bestuderen in zowel early-onset cardiotoxiciteit (cardiotoxiciteit 
optredende binnen het eerste jaar na behandeling met anthracyclines) als late-onset 
cardiotoxiciteit (cardiotoxiciteit optredend na meer dan een jaar na behandeling met 
anthracyclines).  We besloten gebruik te maken van zowel de cardiale biomarker 
cTnT, die de schade aan de myocyt weergeeft en een uiting is van necrose van de 
myocyt, als NT-pro-BNP, dat wordt vrijgegeven uit het myocardium in respons op 
volume en drukoverload.
In hoofdstuk 3 presenteren we de resultaten van de studie waarin we als doel 
hadden het vaststellen van de rol van biomarkers in de vroege opsporing van 
anthracycline-geïnduceerde cardiotoxiciteit in asymptomatische overlevers 
van kinderkanker die verder dan vijf jaar na het einde van hun therapie waren. 
Het doel van deze studie was om vast te stellen of cardiale biomarkers kunnen 
worden gebruikt in de vroege opsporing van late-onset anthracycline-geïnduceerde 
cardiotoxiciteit. We bepaalden plasmaconcentraties van cTnT en NT-pro-BNP 
in 122 asymptomatische overlevers van kinderkanker die behandeld waren met 
antracyclines. We bestudeerden de relatie van de abnormale waarden van de 
biomarkers met de verschillende risicofactoren voor anthracycline-geïnduceerde 
cardiotoxiciteit en met de conventionele echocardiografische parameters. Onze 
studie liet zien dat bij geen enkele overlever abnormale waarden van cTnT werden 
gevonden. Blijkbaar kan necrose van de myocyt, zich uitende in het vrijkomen 
van troponines, niet (meer) worden gedetecteerd met het bepalen van cTnT 
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plasmawaarden in overlevers van kinderkanker verder dan vijf jaar na het einde 
van hun behandeling. Dertien procent van de asymptomatische overlevers had 
abnormale waarden van NT-pro-BNP. We toonden aan dat abnormale NT-
pro-BNP waarden significant gerelateerd waren aan de cumulatieve dosis van 
anthracyclines. Overlevers, die waren behandeld met een cumulatieve anthracycline 
dosering van meer dan 300 mg/m2, hadden NT-pro-BNP waarden die significant 
gerelateerd waren aan de diameters van de linker ventrikel, geïndexeerd voor 
lichaamsoppervlak. We concludeerden dat analyse van cTnT waarden niet 
bijdraagt aan de vroege opsporing van late-onset anthracycline-geïnduceerde 
cardiotoxiciteit. Echter, NT-pro-BNP kan een bruikbare biomarker zijn in de 
vroege opsporing van anthracycline-geïnduceerde cardiotoxiciteit. Follow-up van 
asymptomatische overlevers met afwijkende NT-pro-BNP waarden is essentiëel 
om de vraag te beantwoorden of NT-pro-BNP een vroege marker is voor late-
onset anthracycline-geïnduceerde cardiotoxiciteit.
De hedendaagse standaard voor de evaluatie van de linker ventrikelfunctie in kinderen 
is de  conventionele echocardiografie. Tissue Doppler Imaging (TDI), een meer 
recente echocardiografische techniek, maakt het mogelijk om kwantitatief myocardiale 
snelheden vast te stellen. In eerder onderzoek van onze groep hebben we aangetoond, 
dat afgenomen transmyocardiale snelheden werden waargenomen jaren na 
behandeling met anthracyclines. Abnormale bewegingen van de linker ventrikelwand 
werden gezien in 60% van de kinderen kort na behandeling met anthracyclines en in 
20% van de kinderen na een follow-up van ongeveer tien jaar [4,5,6]. 
In dit proefschrift onderzochten we de myocardiale functie door gebruik te 
maken van de meest recente Doppler gebaseerde echocardiografische technieken, 
namelijk 2D myocardial strain and strain rate imaging in de vroege detectie van 
anthracycline-geïnduceerde cardiotoxiciteit.
In de studie die we beschrijven in hoofdstuk 4, onderzochten we de betrouw-
baarheid van onze tweede nieuwe strategie, het gebruik van 2D myocardial 
strain imaging. Myocardial strain imaging met 2D echocardiografie is een non-
invasieve methode om deformatie van het myocard vast te stellen. Strain is 
de verandering in lengte relatief tot zijn originele lengte, oftewel de relatieve 
deformatie. We evalueerden myocardial strainparameters in tien asymptomatische 
overlevers van kinderkanker en bepaalden de interobserver, intraobserver en 
intrapatiënt betrouwbaarheidsscores. Gebaseerd op deze studie concludeerden 
we dat myocardial strain imaging met 2D echocardiografie in staat was om hoge 
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interobserver en intraobserver betrouwbaarheidsscores te behalen voor bijna alle 
strainparameters in bijna alle segmenten en in bijna alle richtingen. Intrapatiënt 
betrouwbaarheidsscores, verkregen door de overeenkomst te berekenen tussen 
de drie opeenvolgende hartcycli, waren over het algemeen goed, behalve voor de 
meeste items van de basale korte as opname. De invloed van de beweging van de 
mitraalklep op de beeldkwaliteit en het effect van de ademhaling op de opnames 
(met name in kinderen) kan een mogelijke verklaring zijn. In deze studie lieten 
we zien dat 2D myocardial strain imaging een betrouwbare methode was  in de 
patiëntengroep waarin wij geïnteresseerd waren.
Om het gebruik van 2D myocardial strain imaging in de vroege opsporing van 
anthracycline-geïnduceerde cardiotoxiciteit te evalueren, zijn normaalwaarden, 
verkregen via een gezonde controlegroep, onmisbaar. Het vaststellen van 
normaalwaarden in een gezonde controlegroep bij kinderen en jongvolwassenen 
maakt het mogelijk om (pathologische) veranderingen in de linker ventrikel vast 
te stellen. Daarom bepaalden we deze normaalwaarden in een groep van bijna 
200 kinderen en jongvolwassenen (hoofdstuk 5). Een interessant resultaat van 
deze studie was dat piek systolische strainwaarden leeftijdafhankelijk waren, met 
de laagste waarden in de jongste en in de oudste leeftijdsgroep, in tegenstelling 
tot de waarden bij de tieners. Deze studie toonde aan dat leeftijd een belangrijke 
determinant is van piek systolische strain waarden in gezonde controles en 
benadrukt daarmee het belang van leeftijdsspecifieke normaalwaarden voor een 
adequate interpretatie van 2D myocardial strain metingen.
In hoofstuk 6 beschrijven we de studie die de rol van 2D myocardial strain en strain 
rate imaging onderzoekt in meer dan honderd overlevers van kinderkanker (met 
een mediane follow-up duur van 15 jaar na anthracycline therapie). Global strain 
(rate) parameters van overlevers werden vergeleken met die van gezonde controles 
en werden gerelateerd aan conventionele echocardiografische parameters, NT-pro-
BNP waarden en klinische parameters. Deze studie liet zien dat conventionele 
echocardiografische parameters en global myocardial strain en strain rate significant 
lager waren en dat de tijd tot de piek systolische strain significant hoger was in 
asymptomatische overlevers van kinderkanker vergeleken met die van gezonde 
controles. Daarnaast waren global myocardial strain,  strain rate en tijd tot de piek 
sytolische strain significant gerelateerd aan verschillende systolische en diastolische 
linker ventrikel parameters. Langere follow-up van deze groep is belangrijk om 
die overlevers te identificeren die de komende jaren symptomen zullen krijgen 
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van hartfalen. Op basis van deze studie is het nog niet duidelijk of 2D myocardial 
strain en strain rate parameters superieur zijn aan parameters verkregen door 
middel van conventionele echocardiografie in de vroege opsporing van subklinisch 
hartfalen. Het is niet ondenkbaar dat lagere strain en strain rate waarden eerder 
zullen optreden dan afwijkingen in conventionele parameters, dit vanwege de 
mogelijkheid van 2D myocardial strain imaging om het myocardium meer in detail 
te bekijken. De enige manier om de toegevoegde waarde van 2D myocardial strain 
en strain rate in de vroege opsporing van subklinisch hartfalen in asymptomatische 
overlevers van kinderkanker vast te stellen is langdurige follow-up met strain (rate) 
parameters. Aangezien anthracycline-geïnduceerde cardiotoxiciteit een groeiend 
gezondheidsprobleem is met levensbedreigende consequenties, kan follow-up 
met strain (rate) parameters, als een complementaire methode, een waardevolle 
toevoeging zijn in het monitoren van subklinisch hartfalen in asymptomatische 
overlevers van kinderkanker.
In hoofdstuk 7 presenteren we de resultaten van onze prospectieve studie naar 
hartfunctie in kinderen met Acute Lymfatische Leukemie (ALL) gedurende en 
kort na behandeling met anthracyclines. In deze studie onderzochten we de rol van 
2D myocardial strain en strain rate imaging en cardiale biomarkers in de vroege 
opsporing van early-onset anthracycline-geïnduceerde cardiotoxiciteit. We toonden 
aan dat cardiale functie verslechterde tijdens de behandeling met anthracyclines 
en dat deze significant verlaagd was in vergelijking met gezonde controles, 
gemeten met zowel conventionele als 2D myocardial strain echocardiografie. De 
verkortingsfractie (FS) verminderde tijdens de behandeling met anthracyclines, 
maar bleef normaal bij alle patiënten. De cumulatieve anthracyclinedosering 
correleerde negatief met longitudinale strain en strain rate en radial strain. In 
tegenstelling tot de studie die we deden in overlevers van kinderkanker, werden 
in deze studie wel abnormale cTnT waarden vastgesteld bij 11% van de patiënten 
na drie maanden (T=1) behandeling. Abnormale cTnT waarden waren significant 
gerelateerd aan een toegenomen tijd tot de piek longitudinale strain op T=2, een 
jaar na behandeling met anthracyclines. NT-pro-BNP waarden waren abnormaal 
in 13% van de patiënten op T=1 en in 20% van de patiënten op T=2. Absolute NT-
pro-BNP waarden namen toe gedurende de behandeling in 59% van de patiënten. 
Voorspellers voor abnormale cardiale biomarkers en myocardial 2D strain op T=2 
waren de cumulatieve anthracyclinedosis, de z-score van de diameter van de linker 
ventrikel in de diastolische fase en de FS op T=0, een abnormaal NT-pro-BNP op 
T=0 en T=1, en de global longitudinale strain en strain rate op T=1. 
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De combinatie van 2D myocardial echocardiografie en cardiale biomarkers 
kan gebruikt worden om patiënten te identificeren met subklinische early-
onset anthracycline-geïnduceerde cardiotoxiciteit. Een lange follow-up van deze 
patiëntengroep zou van grote waarde zijn, aangezien early-onset anthracycline-
geïnduceerde cardiotoxiciteit een risicofactor is voor het optreden van late-onset 
cardiotoxiciteit. Een longitudinale studie zou een voorspellende rol van 2D 
myocardial strain echocardiografie en cardiale biomarkers kunnen aantonen in de 
vroege opsporing van anthracycline-geïnduceerde cardiotoxiciteit. 
2 Conclusies
Gebaseerd op de resultaten van de studies die in dit proefschrift beschreven zijn, 
kunnen we concluderen dat zowel cardiale biomarkers als 2D myocardial strain 
metingen in de vroege opsporing van anthracycline-geïnduceerde cardiotoxiciteit 
veelbelovend zijn. Echter, follow-up studies zijn nodig om de voorspellende rol van 
beide strategieën te bepalen. Cardiale TnT draagt niet bij aan de vroege opsporing 
van late-onset anthracycline-geïnduceerde cardiotoxiciteit in asymptomatische 
overlevers van kinderkanker. Echter, NT-pro-BNP was abnormaal in 13% van 
deze onderzoeksgroep en was gerelateerd aan de cumulatieve anthracycline 
dosering. In de groep van patiënten, die werden behandeld met anthracyclines 
voor ALL, toonden we aan dat cTnT wel een bruikbare biomarker kan zijn in de 
vroege opsporing van early-onset anthracycline-geïnduceerde cardiotoxiciteit. In 
deze groep was het NT-pro-BNP afwijkend in 20% van de patiënten na een jaar 
behandeling. Absolute NT-pro-BNP waarden stegen in 59% van de patiënten met 
ALL tijdens de behandeling met anthracyclines.
2D myocardial strainparameters waren significant lager en de tijd tot de 
piek strain was significant langer in vergelijking met gezonde controles bij zowel 
de patiënten met ALL als de asymptomatische overlevers. Daarnaast zagen we 
dat strainparameters afnamen tijdens de behandeling met anthracyclines in de 
patiënten met ALL. 
Naast het feit dat cardiale biomarkers en 2D myocardial strain imaging 
bruikbaar kunnen zijn in de vroege opsporing van cardiotoxiciteit, kunnen beide 
strategieën ons mogelijk ook helpen in het begrijpen van de pathofysiologie van 
anthracycline-geïnduceerde cardiotoxiciteit.
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3 Aanbevelingen
Zoals vaak het geval is, geven de resultaten van onze studies niet alleen antwoorden 
op de verschillende vragen zoals hierboven beschreven, maar zorgen ze ook voor 
extra vragen waarvoor vervolgstudies nodig zijn. Deze studies kunnen gaan over de 
volgende gebieden van “cardiotoxiciteit na behandeling van kanker bij kinderen”:
In de eerste plaats zullen de lengte en optimale tijdstippen van follow-up moeten 
worden bepaald. Om de voorspellende waarde van de beide strategieën vast te stellen 
is langere follow-up van de patiënten met deze methodes essentiëel. Alleen langere 
follow-up zal de vraag beantwoorden of de nu geobserveerde abnormale cardiale 
biomarkers en 2D myocardial strain metingen bij de asymptomatische overlevers, 
die tijdens deze studie normale conventionele parameters hadden, voorspellers 
zijn van cardiale verslechtering in de toekomst. Alleen een longitudinale studie 
kan vaststellen of één of beide nieuwe strategieën superieur zijn aan conventionele 
echocardiografie. Momenteel zijn we bezig een follow-up studie op te zetten in 
dezelfde studiepopulatie waarin we dezelfde cardiale evaluatie zullen gebruiken vijf 
jaar na de laatste evaluatie.
Follow-up zal ook interessant zijn in de groep van patiënten die werd behandeld 
met anthracyclines voor ALL. We bestudeerden bij de patiënten de cardiale functie 
gedurende de behandeling met anthracyclines met dezelfde nieuwe strategieën en 
onderzochten de rol daarvan in de vroege opsporing van early-onset anthracycline-
geïnduceerde cardiotoxiciteit. Ook hier zal een longitudinale studie ons informatie 
geven over de mogelijke voorspellende waarde van cardiale biomarkers die tijdens 
de behandeling afwijkend waren en de voorspellende waarde van afgenomen 2D 
myocardial strainparameters. Zullen de cardiale biomarkers blijven toenemen 
in de tijd en de 2D myocardial strain parameters blijven afnemen? Of, zal er een 
herstel optreden van de cardiale functie na het einde van de behandeling? Verder 
onderzoek zal zich richten op het opnieuw vaststellen van de cardiale functie in 
deze onderzoeksgroep, wanneer ze overlevers zijn van kinderkanker.
In de tweede plaats kan toekomstig onderzoek zich richten op de relevantie van 
dyssynchroniciteit. Gecoördineerde contractie van de linker ventrikel is cruciaal 
voor een efficiënte contractiele functie. Electromechanische dyssynchroniciteit kan 
resulteren in pathologische ventriculaire “remodeling” en draagt onafhankelijk bij 
aan verdere achteruitgang van de systolische functie [7]. Chueng en zijn collegae 
toonden in hun studie aan dat dyssynchroniciteit van de linker ventrikel ook 
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aanwezig is in kinderen die werden behandeld met anthracyclines. In 45 patiënten, 
die werden behandeld voor ALL zagen zij met behulp van 3D echocardiografie 
dat 16% van hen mechanische dyssynchroniciteit had, terwijl de FS normaal 
was [8]. Marcus en haar collegae rapporteerden recentelijk over de timing van 
systolische deformatie in gezonde kinderen en jongvolwassenen met behulp 
van 2D myocardial strain echocardiografie. Zij stelden normaalwaarden vast en 
toonden aan dat de mate van dyssynchrone deformatie toeneemt met de leeftijd 
[9]. In ons toekomstige onderzoek zullen we de mate van dyssynchroniciteit in 
onze beide onderzoekspopulaties bepalen en zullen we de timing van systolische 
deformatie van onze beide onderzoeksgroepen vergelijken met die van gezonde 
controles.  Dit kan mogelijk ook een stap vooruit zijn naar het beter begrijpen van 
de pathofysiologie van anthracycline-geïnduceerde cardiotoxiciteit.
Vervolgonderzoek in onze beide onderzoeksgroepen zal zich ook richten op de 
deformatie van de verschillende segmenten van de linker ventrikel. In tegenstelling 
tot conventionele echocardiografie kan 2D myocardial strain imaging de vraag 
beantwoorden of bepaalde segmenten van de linker ventrikel meer kwetsbaar 
zijn voor de toxische effecten van anthracyclines dan andere segmenten. Is het 
cardiotoxische effect van anthracyclines meer uitgesproken in bepaalde segmenten 
van de linker ventrikel, of is het meer een diffuus effect?
In de derde plaats kunnen nieuwe biomarkers worden ingezet om die patiënten te 
identificeren die een verhoogd risico hebben op het ontwikkelen van anthracycline-
geïnduceerde cardiotoxiciteit. Hartfalen lijkt niet alleen het resultaat te zijn van 
myocardschade of hemodynamische overload, maar is ook het resultaat van een 
samenspel van genetische, neurohormonale, inflammatoire en biochemische 
veranderingen in de myocyt, het interstitium of beide [10,11]. Sommige 
biomarkers zijn niet alleen indicatief voor een verhoogd risico maar kunnen ook 
zelf een risicofactor zijn, wat ze als een potentiële target van therapie maakt [12].
Morrow en De Lemos hebben drie criteria opgesteld waaraan een biomarker 
moet voldoen om klinisch bruikbaar te zijn. Als eerste moet een accurate meting 
beschikbaar zijn die herhaald kan worden, met een redelijke kostprijs en met een korte 
bepaaltijd. Als tweede moet de biomarker informatie verschaffen die niet al aanwezig 
is door een nauwkeurig klinisch onderzoek. En als laatste moet de wetenschap van de 
uitslag van de biomarker behulpzaam zijn in het maken vam medische beslissingen 
[13]. Slechts enkele biomarkers behalen alle criteria. Echter, vele biomarkers geven 
belangrijke informatie over de pathogenese van hartfalen [11].
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 Nieuwe biomarkers zijn onder andere: high sensitive troponine T [14], 
galectine-3, een eiwit dat wordt geproduceerd door geactiveerde macrofagen 
waarvan het is aangetoond dat ze verhoogd aanwezig zijn in patiënten met acuut 
en chronisch hartfalen [15,16], chromogranine, een polypeptide hormoon, 
osteoprotegerine, uit de groep van de tumornecrosisfactor, adiponectine en growth 
differentiation factor (GDP-15) [11].
Naast het gebruik van nieuwe biomarkers, kan ook het combineren van meer 
dan een biomarker een toegevoegde waarde hebben. Sommige studies hebben 
aangetoond dat, in de classificatie van hartfalen, het bepalen van zowel plasma BNP 
als troponine een betere voorspellende waarde had dan één van beide afzonderlijk 
[11,12].
Tot slot kan het vaststellen van genetische markers ons mogelijk ook helpen om 
patiënten te identificeren die een verhoogde kans hebben op het ontwikkelen van 
cardiotoxiciteit.  Bekende risiciofactoren voor het optreden van anthracycline-
geïnduceerde cardiotoxiciteit, zoals cumulatieve dosering, bestraling op het hart 
en de jonge leeftijd, verklaren niet geheel de intervariabiliteit van cardiotoxiciteit 
na de behandeling met anthracyclines. Een rol van de individuele genetische 
achtergrond in de  ontwikkeling van anthracycline-geïnduceerde cardiotoxiciteit is 
waargenomen in verscheidene studies bij dieren [17]. Genetische studies kunnen 
helpen om markers te identificeren die voorspellend zijn voor de cardiotoxiciteit 
of kunnen helpen om de precieze mechanismen van anthracycline-geïnduceerde 
cardiotoxiciteit te verhelderen. Verscheidene studies met kandidaatgenen zijn 
verricht bij kinderen en volwassenen [18-21]. De genetische informatie van de 
patiënt kan, in combinatie met klinische risicofactoren, echocardiografische 
uitkomsten en de resultaten van de biomarkers, mogelijk leiden tot het beter 
kunnen onderscheiden van patiënten die meer of minder risico hebben op het 
ontwikkelen van anthracycline-geïnduceerde cardiotoxiciteit. Dit leidt mogelijk 
tot een behandeling meer op maat voor de individuele patiënt, zonder de kans op 
genezing negatief te beïnvloeden. 
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De totstandkoming van dit proefschrift is het resultaat van inspanningen van veel 
mensen. Juist de bijzondere samenwerking met velen, heeft mij de energie gegeven 
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voor je vertrouwen in mij als kinderoncoloog en als promovendus op dit onderzoek. 
Een sollicitatiegesprek was daarvoor niet nodig, vond je. Je hebt me geholpen 
de combinatie dokter en onderzoeker mogelijk te maken. Daarnaast heeft je 
helicopterview altijd belangrijke en zinvolle kritische opmerkingen opgeleverd, met 
de toevoeging van een goed gevoel voor humor.
Ik ben in de gelukkige omstandigheden geweest dat ik omringd werd door drie 
co-promotoren!
Dr. L. Kapusta, lieve Livia, jouw promotie-onderzoek is de basis geweest 
voor dit proefschrift. Jij hebt me heel veel geleerd over je vak en over het doen 
van onderzoek. Jouw passie en gedrevenheid voor het onderzoek en voor het leven 
zijn een voorbeeld voor me. Je bent een bijzonder mens, nooit ontbreekt er een 
persoonlijke ‘touch’. Ik heb onze samenwerking als heel waardevol ervaren, en hoop 
dat we deze nog lang zullen voortzetten.
Dr. ir. C.L. de Korte, beste Chris, dank voor jouw heldere kijk op het 2D strain 
onderzoek en je waardevolle input bij het beoordelen van onze artikelen. Ik heb 
genoten van jouw droge humor, ben jaloers op je scherpe blik, en heb geleerd van je 
grote relativeringsvermogen.
Dr. J. Loonen, beste Jacqueline,  jouw inspanningen, met name tijdens 
de beginperiode van mijn promotietraject, zijn belangrijk geweest voor de 
totstandkoming van dit proefschrift. Jouw heldere en overzichtelijke kijk op dit 
onderwerp heeft mij erg geholpen. Dank daarvoor.
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Graag wil ik de manuscriptcommissie, bestaande uit prof. dr. Winette van der Graaf, 
prof. dr. Luc Mertens en prof. dr. ir. Han Thijssen bedanken voor het beoordelen van 
het manuscript.
Er zijn nog meer mensen nauw betrokken bij en van onschatbare waarde geweest 
voor dit onderzoek. 
‘Mijn student’, Milanthy Pourier. Beste Milanthy, jouw harde werken, je snelle 
inzicht in het onderwerp, en de weekenddagen die we samen kwamen om alle data 
op een rijtje te zetten, hebben mij enorm geholpen om dit proefschrift voor elkaar te 
krijgen. Ik ben erg gelukkig met het feit dat je dit onderzoek gaat voortzetten en je 
binnenkort als AIOS Kindergeneeskunde  van start gaat.
Mijn steun en toeverlaat bij alle technische aspecten van het onderzoek, 
Gert Weijers. Beste Gert, dank voor je hulp bij al mijn vragen over computers, 
computerprogramma’s en 2D strain en dank voor al je geduld! 
De medewerkers van het echolab Bob, Imke, Romana, Marian en Maria. Dank 
voor alle mooie echo’s die jullie maakten, voor jullie interesse in dit onderzoek en 
voor jullie flexibiliteit als er weer eens een patiënt tussendoor ‘moest’.  
Drs. L. Bellersen, beste Louise, jij bent als cardioloog betrokken bij dit onderzoek. 
Dank voor wat je me leerde over je vak, je input bij de artikelen en de medebeoordeling 
van alle ECG’s van de volwassen overlevers van kinderkanker.
T. Feuth, best Ton, jij bent als statisticus en ook als mede-auteur betrokken bij 
dit onderzoek en hebt me veel geleerd over de statistiek. Dank voor je flexibiliteit en 
je geduld!  
Dr. J.P.M. Bokkerink, beste Jos, jij hebt alle overlevers van kinderkanker 
poliklinisch gezien. Ik nam jouw kinderoncologie poli’s over toen je je volledig ging 
richten op de zorg voor overlevers van kinderkanker. Naast jouw bijdrage aan dit 
onderzoek, ben je een belangrijke leermeester voor me geweest in mijn vorming tot 
kinderoncoloog. 
Dr(s). K.A. Marcus, beste Karen, jij zorgde voor de uitwerking van de 
strainwaarden van de gezonde controles, die we beide hebben gebruikt ter vergelijking 
met de verschillende patiëntengroepen. Ik bewonder je tomeloze energie en en het 
ogenschijnlijke gemak waarmee jij je promotietraject hebt volbracht. Ik wens je een 
geweldige promotiedag toe op 13 juni!
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Mijn overige collegae kinderoncologen, Paul Brons (humorvol, en nog altijd aan het 
nagenieten van het feit dat een van zijn patiënten hem ooit heeft vergeleken met 
George Clooney), Corrie Gidding (brede interesse in mens en cultuur), mijn maatjes 
Maroeksa te Loo en Jan Loeffen (van hetzelfde uur en enkele jaren op dezelfde 
kamer lief en leed gedeeld, nu ‘uit elkaar’ en ik mis het!) kinderpsycholoog Esther 
Meijer (creatieve geest en iPad-maatje), en verpleegkundig specialisten Janneke 
Evers, Viviane van de Crommert en Christel van Riel (betrouwbare duizendpoten), 
Monica Alon (zorgt ervoor dat we ons aan de regels houden). Dank voor de fijne 
samenwerking!  Jan, wij verstaan elkaar, dank dat je mijn paranimf wil zijn!
Mijn collegae (kinder)artsen, arts-assistenten Kindergeneeskunde, 
verpleegkundigen van Q2Zee, dagbehandeling en poli kinderoncologie en alle 
anderen met wie ik dagelijks werk, wil ik bedanken voor het feit dat ik mede 
dankzij hen elke dag fluitend naar mijn werk ga. Speciale dank voor Annemiek 
te Dorsthorst en Christel van Riel voor de geweldige samenwerking voor ‘onze’ 
patiënten.
Lieve vrienden en familie, dank dat jullie mijn leven zo mooi maken! Dank voor 
de interesse in mijn onderzoeksactiviteiten en voor de gezellige momenten samen.
Mijn schoonfamilie, dear Amma, Anna, Priya, Rajen, Aadit and Anika. Thanks 
for the warm welcome into your family. Two cultures means twice the pleasure! 
Mijn ouders, lieve papa en mama, wat is het een rijkdom om op te groeien in 
een warm en liefdevol gezin. Je altijd gesteund en gestimuleerd voelen, in goede en 
minder goede tijden, is een heel groot goed. Dank voor jullie vertrouwen in mij. 
Mijn zussen, Caroline en Marianne. Caroline, jij was mijn getuige op onze 
trouwdag, Marianne ( Janneman), bijzonder dat jij mijn paranimf bent op mijn 
promotie. Jullie zijn  belangrijk voor mij, net als Theo en Aart en mijn lieve neefjes 
Wouter en Pim.
Mijn liefste Amar, Emma en Alex. Bij jullie ben ik thuis, niets is belangrijker. 
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Figure 4.1     Longitdinal strain
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Figure 4.2     Radial strain
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Figure 4.3     Circumferential strain
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Figure 4.4     4CH, longitudinal strain
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Figure 5.2     Radial and circumferential strain and strain rate 
curves of the septal wall at the level of the papillary muscle
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